Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
By using carrier polymer-active agent ingredients and adjuvants in the gastric residency system, the problem of unstable release of therapeutic agents in the stomach is solved, stable sustained release and effective therapeutic agent release are achieved, and the therapeutic effect and safety are improved.
Patent Information
- Application Number
- CN202411064156.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-09-30
- Filing Date
- 2016-10-21
- Publication Date
- 2024-11-19
AI Technical Summary
The existing gastric residency system is difficult to achieve stable release of therapeutic agents in the stomach, especially hydrophilic therapeutic agents are prone to sudden release, resulting in sudden increase in plasma levels and difficulty in releasing hydrophobic therapeutic agents in gastric juice.
Using carrier polymer-active agent ingredients, through coupling polymer connection, combined with dispersant, release promoter and stabilizer, control the release rate of therapeutic agents, ensure stable release in the stomach, and maintain the respite of therapeutic agents in gastric juice. Release the effect.
The stable sustained release of therapeutic agents in the stomach is achieved, which reduces burst release, ensures the time limit for effective release of therapeutic agents in the stomach, and improves the treatment effect and patient safety.
Smart Images

Figure CN118975972A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application 201680075519.3. The application date of the original application is October 21, 2016, and the name is “Gastric Retention System for Sustained Release of Therapeutic Agents and Method of Use Thereof”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 245,789, filed October 23, 2015; U.S. Provisional Patent Application No. 62 / 245,797, filed October 23, 2015; U.S. Provisional Patent Application No. 62 / 264,795, filed December 8, 2015; U.S. Provisional Patent Application No. 62 / 264,799, filed December 8, 2015; U.S. Provisional Patent Application No. 62 / 264,806, filed December 8, 2015; and U.S. Provisional Patent Application No. 62 / 402,947, filed September 30, 2015. The entire contents of each of those patent applications are incorporated herein by reference. Field of the Invention
[0004] The present invention relates to a gastric retention system for sustained gastric release of a therapeutic agent and methods of using the same. Background of the Invention
[0006] Gastric resident systems are delivery systems for therapeutic agents that are maintained in the stomach for days to weeks or even longer periods of time, during which time the drug or other active agent can be eluted from the system for absorption in the gastrointestinal tract. Examples of such systems are described in International Patent Application No. PCT / US2015 / 035423 (WO2015 / 191920). Gastric resident systems are most conveniently administered to patients in compressed form via capsules. When the capsule dissolves in the stomach, the system expands to a size that prevents passage through the pyloric sphincter beyond the desired resident system. The system needs to release the therapeutic agent at a stable rate over an extended period of time in the gastric environment, which places particularly stringent requirements on the formulation of the system.
[0007] The present invention describes advances in gastric resident system formulations, including the use of dispersants to elute the therapeutic agent component during gastric residence and to grind the active agent to a desired size. The systems described herein provide improved system performance when administered to a patient. SUMMARY OF THE INVENTION
[0009] In some embodiments, the present invention provides a gastric resident system for administration to a patient, comprising a plurality of carrier polymer-active agent components, comprising i) a carrier polymer and ii) a therapeutic agent or a pharmaceutically acceptable salt thereof, wherein the carrier polymer-active agent components are connected to each other by one or more coupling polymer components, wherein at least one of the one or more coupling polymer components is an elastomer; wherein the gastric resident system is configured to have a compressed form in a container, which is suitable for oral administration or administration through a feeding tube; wherein the gastric resident system allows the resident system to remain in the stomach for at least about 24 hours to about 1 month; and wherein the system releases a therapeutically effective amount of the therapeutic agent within an effective release period; and the system releases less than about 20% of the therapeutic agent or a pharmaceutically acceptable salt thereof within a period of about 6 hours. In some embodiments, the effective release period is less than or equal to the residence period. In some embodiments, the effective release period is less than or equal to (residence period + about 24 hours). In some embodiments, the effective release period is less than or equal to (residence period + about 48 hours). In some embodiments, the effective release period is less than or equal to (residence period + about 72 hours). In some embodiments, the effective release period is about 3 days. In some embodiments, the effective release period is about 7 days. In some embodiments, the effective release period is about 10 days. In some embodiments, the effective release period is about 14 days. In some embodiments, the effective release period is about 20 days. In some embodiments, the effective release period is about 21 days. In some embodiments, the effective release period is about 28 days. In some embodiments, the effective release period is about 30 days. In some embodiments, the effective release period is about 1 month. In some embodiments, the effective release period can be about 3 days to about 1 month, about 3 days to about 4 weeks, about 3 days to about 2 weeks, about 3 days to about 14 days, about 3 days to about 7 days or about 3 days to about 5 days. In some embodiments, the effective release period can be about 7 days to about 1 month, about 7 days to about 4 weeks, about 7 days to about 2 weeks, about 7 days to about 14 days or about 7 days to about 10 days. In any of these embodiments, the residence period can be about 24 hours to about 2 weeks, about 24 hours to about 1 week, about 24 hours to 3 days, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, or about 1 month. In any of these embodiments, the residence period can be about 24 hours to about 2 weeks, about 24 hours to about 1 week, about 24 hours to 3 days, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, or about 10 days longer than the effective release period.
[0010] In some embodiments, the system releases about 30% to about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof within about 40% to 60% of the effective release period.
[0011] In some embodiments, the system releases about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof within about 90% of the effective release period.
[0012] The release of the therapeutic agent or a pharmaceutically acceptable salt thereof can be measured in an aqueous environment selected from the group consisting of 0.1N HCl aqueous solution, simulated gastric fluid, fasted simulated gastric fluid, fed simulated gastric fluid, animal stomach, pig stomach, dog stomach, and human stomach. The release of the therapeutic agent or a pharmaceutically acceptable salt thereof can be measured in 0.1N HCl aqueous solution. The release of the therapeutic agent or a pharmaceutically acceptable salt thereof can be measured in fasted simulated gastric fluid. The release of the therapeutic agent or a pharmaceutically acceptable salt thereof can be measured in fed simulated gastric fluid.
[0013] In some embodiments of the gastric resident system, the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is increased by no more than about 40% in a 40% ethanol / 60% 0.1N HCl aqueous solution compared to the release in 0.1N HCl over the same time period, or by no more than about 40% in 40% ethanol / 60% simulated gastric fluid compared to the release in simulated gastric fluid over the same time period, or by no more than about 40% in 40% ethanol / 60% fasted simulated gastric fluid compared to the release in fasted gastric fluid over the same time period, or by no more than 40% in 40% ethanol / 60% fed simulated gastric fluid compared to the release in fed simulated gastric fluid over the same time period. The time period may be about 15 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 90 minutes, or about 120 minutes.
[0014] In some embodiments of the gastric resident system, the gastric resident system can release no more than about 20% of the therapeutic agent in a 40% ethanol / 60% 0.1N HCl aqueous solution after a time period of about 15 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 90 minutes, or about 120 minutes. In some embodiments of the gastric resident system, the gastric resident system can release no more than about 20% of the therapeutic agent in a 40% ethanol / 60% 0.1N HCl aqueous solution after about 120 minutes.
[0015] In some embodiments of the gastric retention system, ii) the therapeutic agent or a pharmaceutically acceptable salt thereof comprises about 10% to about 35% of a carrier polymer-active agent component. The therapeutic agent or a pharmaceutically acceptable salt thereof may be selected from doxycycline, donepezil, ivermectin, risperidone, cetirizine and rosuvastatin and pharmaceutically acceptable salts thereof. In some embodiments, the therapeutic agent or a pharmaceutically acceptable salt thereof is doxycycline or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutic agent or a pharmaceutically acceptable salt thereof is donepezil or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutic agent or a pharmaceutically acceptable salt thereof is ivermectin or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutic agent or a pharmaceutically acceptable salt thereof is risperidone or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutic agent or a pharmaceutically acceptable salt thereof is cetirizine or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutic agent or a pharmaceutically acceptable salt thereof is rosuvastatin or a pharmaceutically acceptable salt thereof. In some embodiments of the gastric resident system, the therapeutic agent may include an adamantane, such as memantine; amantadine; adapromine; nitromemantine; rimantadine; bromantane; neramexane; or tromantine; or a pharmaceutically acceptable salt of memantine, amantadine, adapromine, nitromemantine, rimantadine, bromantane, or tromantine. In some embodiments of the gastric resident system, the therapeutic agent may include memantine. In some embodiments of the gastric resident system, the therapeutic agent may include a pharmaceutically acceptable salt of memantine. In some embodiments of the gastric resident system, the treatment may not include an adamantane. In some embodiments of the gastric resident system, the treatment may not include any one or more of memantine; amantadine; adapromine; nitromemantine; rimantadine; bromantane; neramexane; or tromantine; or a pharmaceutically acceptable salt of memantine, amantadine, adapromine, nitromemantine, rimantadine, romantane, or tromantine. In some embodiments of the gastric resident system, the treatment may not include memantine. In some embodiments of the gastric resident system, the treatment may not include a salt of memantine or a pharmaceutically acceptable salt of memantine.
[0016] In some embodiments of the gastric retention system, the carrier polymer-active agent component further comprises iii) a release enhancer. The release enhancer comprises about 2% to about 30% of the carrier polymer-active agent component. For hydrophobic drugs, such as drugs having a solubility of less than 1 mg / ml or less than or equal to 1 mg / ml, the release enhancer comprises about 2% to about 50% of the carrier polymer-active agent component. The release enhancer may be selected from acrylate polymers, acrylic acid copolymers, polydioxanone-polyethylene glycol polymers, and polyvinylpyrrolidone. The acrylic acid polymer or acrylate copolymer may comprise a copolymer of ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate, the optional molar ratio of which is about 1:2:0.1, about 1:2:0.2, or about 1:2:0.1 to about 1:2:0.2; or the acrylate polymer or acrylate copolymer may comprise a copolymer of dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate, the optional molar ratio of which is about 2:1:1 to about 1:1:1.
[0017] In some embodiments of the gastric retention system, the carrier polymer-active agent component further comprises iv) a dispersant. The dispersant may comprise about 0.1% to about 4% of the carrier polymer-active agent component. The dispersant may be selected from porous inorganic materials, polar inorganic materials, non-toxic metal oxides, amphiphilic organic molecules, polysaccharides, cellulose, cellulose derivatives, fatty acids, detergents, silica, hydrophilic-fumed silica, hydrophobic colloidal silica, magnesium aluminum silicate, stearate, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, phospholipids, polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, sodium lauryl sulfate and alumina. The dispersant may comprise silica, such as hydrophilic-fumed silica.
[0018] In some embodiments of the gastric retention system, the carrier polymer-active agent component further comprises v) a solubilizer. The solubilizer may comprise about 1% to about 10% of the carrier polymer-active agent component. The solubilizer may be selected from polyalkylene oxides, polyethoxylated castor oils, and detergents. When the solubilizer is a polyalkylene oxide, it may be selected from polyethylene glycol (PEG), polypropylene glycol (PPG), and a block copolymer of PEG and PPG. When the solubilizer is a block copolymer of PEG and PPG, it may have the formula H-(OCH2CH2) x -(O-CH(CH3)CH2) y -(OCH2CH2) z -OH, wherein x and z are independently about 95 to about 105, and y is about 50 to about 60, such as wherein x and z are about 101, and y is about 56.
[0019] In some embodiments of the gastric retention system, the carrier polymer-active agent component further comprises vi) a stabilizer. The stabilizer may comprise about 0.1% to about 2% of the carrier polymer-active agent component. The stabilizer may comprise one or more compounds selected from antioxidants, tocopherol, α-tocopherol, ascorbic acid, ascorbate, carotene, butylated hydroxyanisole, butylated hydroxytoluene, fumaric acid, antimicrobial agents, buffer substances, calcium carbonate, calcium lactate, calcium phosphate, sodium phosphate and sodium bicarbonate.
[0020] In some embodiments of the gastric retention system, the carrier polymer comprises a polylactone.
[0021] In some embodiments, the polylactone comprises polycaprolactone, for example having an average M of about 60,000-100,000. n Polycaprolactone; having an M of about 75,000-85,000 n or polycaprolactone having an M of about 80,000 n of polycaprolactone.
[0022] In some embodiments of the gastric retention system, if a solubilizer is present, the solubilizer comprises no more than about 5% of the carrier polymer-active agent component; and if one or more of a solubilizer, a release enhancer, a dispersant, or a stabilizer is present, the total combined amount of any solubilizer, release enhancer, dispersant, and stabilizer present comprises no more than about 30% of the carrier polymer-active agent component.
[0023] In one embodiment, the present invention encompasses a gastric retention system for administration to a patient, comprising a plurality of carrier polymer-active agent components, wherein the carrier polymer-active agent component comprises i) a carrier polymer, ii) a dispersing agent, and iii) a therapeutic agent or a salt thereof, wherein the plurality of carrier polymer-active agent components are connected to each other by one or more coupling polymer components, wherein at least one of the one or more coupling polymer components is an elastomer; wherein the retention system is configured to have a compressed form in a container that is suitable for oral administration or administration via a feeding tube; and to have an uncompressed form when released from the container in the stomach of the patient; wherein the gastric retention system remains in the stomach for at least about 24 hours; and wherein the system releases a therapeutically effective amount of the therapeutic agent during at least a portion of the time period in which the system remains in the stomach.
[0024] The dispersant may comprise a compound selected from porous inorganic materials, polar inorganic materials, silica, hydrophilic-fumed silica, stearates, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethyl cellulose, hydrophobic colloidal silica, hypromellose, magnesium aluminum silicate, phospholipids, polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, fatty acids, sodium lauryl sulfate, non-toxic metal oxides and alumina. The dispersant may comprise silica or hydrophilic-fumed silica, such as CAB-O- M-5P (CAS#112945-52-5).
[0025] In the gastric retention system, the therapeutic agent or salt thereof may consist of particles dispersed in a carrier polymer. In one embodiment, at least about 80% of the therapeutic agent particles are between about 2 microns and about 50 microns in mass.
[0026] In one embodiment, the therapeutic agent or salt thereof in the gastric resident system can be a hydrophilic therapeutic agent or salt thereof. In one embodiment, the hydrophilic therapeutic agent or salt thereof can have a log P oct Less than or equal to about 0.5. In one embodiment, the hydrophilic therapeutic agent or salt thereof may have a solubility in water of at least about 1 mg / ml. In another embodiment, less than about 10% of the hydrophilic therapeutic agent or salt thereof contained in the system is eluted within about the first 6 hours of exposure to gastric fluid. In another embodiment, the amount of hydrophilic therapeutic agent or salt thereof eluted from the system within about the first 6 hours of exposure to gastric fluid is about 50% or less of the amount of the therapeutic agent or salt thereof eluted from the system without a dispersant.
[0027] In another embodiment, when the gastric retention system comprises a hydrophilic therapeutic agent or a salt thereof, the carrier polymer-active agent component comprises about 1% to about 30% of the hydrophilic therapeutic agent or a salt thereof, about 0.5% to about 2.5% of the dispersing agent, and about 67.5% to about 98.5% of the carrier polymer.
[0028] In one embodiment, the therapeutic agent or salt thereof in the gastric resident system can be a hydrophobic therapeutic agent or salt thereof. In one embodiment, the hydrophobic therapeutic agent or salt thereof has a log P greater than or equal to about 1. oct In one embodiment, the hydrophobic therapeutic agent or salt thereof may have a solubility in water of less than about 1 mg / ml. In one embodiment, the hydrophobic therapeutic agent or salt thereof has a higher solubility in ethanol than in water. In one embodiment, the hydrophobic therapeutic agent or salt thereof has a higher solubility in 40% ethanol / 60% simulated gastric fluid than in 100% simulated gastric fluid.
[0029] In another embodiment, when the gastric retention system comprises a hydrophobic therapeutic agent or a salt thereof, the carrier polymer-active agent component comprises about 1% to about 30% of the hydrophobic therapeutic agent or a salt thereof, about 0.5% to about 2.5% of the dispersing agent, and about 67.5% to about 98.5% of the carrier polymer.
[0030] In any embodiment of the gastric retention system, the carrier polymer for the gastric retention system can include polycaprolactone, such as a linear polycaprolactone having a number average molecular weight (M) of about 60 kilodaltons (kDa) to about 100 kDa; 75 kDa to 85 kDa; or about 80 kDa; or about 45 kDa to about 55 kDa. n )scope.
[0031] In any embodiment of the gastric retention system, a plurality of carrier polymer-active agent components may be linked to each other via two or more coupling polymer components, wherein at least one of the two or more coupling polymer components is an elastomer and another of the at least two or more coupling polymer components is an enteric polymer. In a further embodiment, the enteric polymer may be selected from poly(methacrylic acid-co-ethyl acrylate), cellulose acetate phthalate, cellulose acetate succinate, and hydroxypropyl methylcellulose phthalate.
[0032] In another embodiment, the gastric resident system remains in the stomach for about 5 days to about 7 days.
[0033] Where appropriate and practicable, features of any of the embodiments described above and herein may be combined with any further embodiments described above and herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 One embodiment of the gastric retention system of the present invention is shown.
[0036] Figure 2 Another embodiment of the gastric retention system of the present invention is shown.
[0037] Figure 2A Another embodiment of the gastric retention system of the present invention is shown.
[0038] Figure 2B show Figure 2B Certain dimensions of the gastric resident system.
[0039] Figure 2C Another embodiment of the gastric retention system of the present invention is shown.
[0040] Figure 3 show Figure 2 An embodiment of a gastric retention system of the invention in a folded configuration. The capsule that maintains the system in the folded configuration is not shown.
[0041] Figure 4 shows the protection of cetirizine from oxidative degradation in a carrier polymer formulation. Trace A shows the HPLC analysis of cetirizine extracted from a polycaprolactone / Pluronic 407 carrier polymer formulation before exposure to oxidative conditions. Trace B shows the HPLC analysis of cetirizine in solution exposed to oxidative conditions. Traces C, D and E show the HPLC analysis of cetirizine in a polycaprolactone / Pluronic 407 carrier polymer formulation after exposure to oxidative conditions for different time periods.
[0042] Figure 5 shows the burst release of cetirizine from polycaprolactone carrier polymer formulations with different amounts of Pluronic P407 excipient polymer. Group A shows release into simulated gastric fluid after 3 hours, while Group B shows release into simulated gastric fluid after 6 hours.
[0043] Figure 6 Shown is the burst release of cetirizine from polycaprolactone carrier polymer-active agent formulations without additional excipients or dispersants and with varying amounts of excipients or dispersants. Black (solid) bars, release after 3 hours; white (open) bars, release after 6 hours.
[0044] Figure 7 The burst release of cetirizine from polycaprolactone carrier polymer-active agent formulations without additional dispersing agent and with varying amounts of SiO2 dispersing agent is shown.
[0045] Figure 8 Cumulative release of cetirizine from different polycaprolactone carrier polymer-active agent formulations over a 7-day period is shown. At 7 days, the PCL-cetirizine formulation without additional excipients or dispersants (solid circles) exhibited the greatest cetirizine release, followed by the PCL-cetirizine formulation with 2% P407 (solid triangles), the PCL-cetirizine formulation with 2% P407 and rapid cooling (open triangles), the PCL-cetirizine formulation with 5% hydroxypropylmethylcellulose (HMPC) (solid squares), while the PCL-cetirizine formulation with 2% SiO2 (marked with X) exhibited the lowest release after 7 days and on each day over the 7-day period.
[0046] Figure 9 shows images of raw ivermectin (A), ivermectin ground for 1 hour (B), and ivermectin ground with 1% SiO2 for 1 hour (C); PCL formulations with raw ivermectin (AA), PCL formulations with ivermectin ground for 1 hour (BB), and PCL formulations with ivermectin ground with 1% SiO2 for 1 hour (CC).
[0047] Figure 10 shows images of unprocessed risperidone (A), risperidone ground with 1% SiO2 (B, 2x magnification; C, 40x magnification); PCL formulation with unprocessed risperidone (AA), PCL formulation with risperidone ground with 1% SiO2 (BB, 2x magnification; CC, 40x magnification).
[0048] Fig.11 Shown is the release from ivermectin formulations in simulated gastric fluid over 24 hours.
[0049] Fig.12 Shown is a 4-point bend test of the ivermectin drug loading arm.
[0050] Fig.13 Shown is the burst release of different risperidone formulations in simulated gastric fluid over 6 hours.
[0051] Fig.14 Shown are the burst release of different risperidone formulations in simulated gastric fluid over 6 hours based on the flattened longitudinal dimension.
[0052] Fig.15 In vitro release rates of rosuvastatin (RS) from different polycaprolactone and additional excipient formulations (25% rosuvastatin + indicated additional excipient percentages; balanced polycaprolactone) are shown. Abbreviations: PCL, polycaprolactone; RH40, Kolliphor RH 40; P407, Pluronic P407; VA74, Kollidon VA 64; PVA, polyvinyl acetate; PVP, polyvinyl pyrrolidone.
[0053] Figure 16 shows UPLC analysis of rosuvastatin under different conditions. Trace A shows UPLC analysis of pure rosuvastatin. Trace B shows UPLC analysis of rosuvastatin after 2 days in 0.1M HCl solution at 37°C. Trace C shows UPLC analysis of rosuvastatin released from a polycaprolactone formulation after 2 days in 0.1M HCl solution at 37°C. Trace D shows UPLC analysis of rosuvastatin released from a polycaprolactone formulation after 18 days in 0.1M HCl solution at 37°C.
[0054] Fig.17A Bright field microscopy image showing the surface of polycaprolactone beads into which rosuvastatin calcium powder has been mixed. The scale bar in the image is 100 microns.
[0055] Fig. 17B Bright field microscopy images showing rosuvastatin calcium powder on the edge of polycaprolactone beads. The scale bar in the image is 100 microns.
[0056] Fig.18 Evaluation of formulation mixing by microscopic examination is shown.
[0057] Fig.19 Shown are X-ray diffraction patterns of rosuvastatin calcium powder, polycaprolactone (PCL), and rosuvastatin calcium formulated in PCL.
[0058] Fig. 20 The acid stability of rosuvastatin in solution compared to that in PCL formulation is shown.
[0059] Fig.21 The thermal stability of rosuvastatin in solution compared to that in PCL formulation is shown.
[0060] Fig. 22 Shown is the burst release of rosuvastatin when exposed to 40% ethanol / 60% simulated gastric fluid compared to when exposed to simulated gastric fluid.
[0061] Figure 23 shows the burst release of rosuvastatin from polycaprolactone carrier polymer formulations with different amounts of Pluronic P407 excipient polymer. Group A shows release into simulated gastric fluid after 3 hours, while Group B shows release into simulated gastric fluid after 6 hours.
[0062] Fig.24 Shown is the burst release of rosuvastatin from polycaprolactone carrier polymer-drug formulations with different amounts of SiO2 dispersant and hydroxypropylmethylcellulose (HMPC) after 1 hour at 37°C in simulated gastric fluid (SGF) (black bars) or 40% ethanol / 60% simulated gastric fluid (white bars).
[0063] Fig.25 Shown is the burst release of rosuvastatin from polycaprolactone carrier polymer-drug formulations with 5% Pluronic P407 (5% P407), 10% Pluronic P407 (10% P407), or 10% polyvinylpyrrolidone (PVP) after 1 hour at 37°C in simulated gastric fluid (SGF) (black bars) or 40% ethanol / 60% simulated gastric fluid (white bars).
[0064] Fig.26 The in vitro release of doxycycline from a drug formulation is shown in FaSSGF (fasted simulated gastric fluid). The doxycycline base formulation contained 25% doxycycline, 0.5% SiO2, 0.5% P407, and 0.5% alpha tocopherol. The release from the doxycycline base formulation was compared to that from formulations containing additional 2% PVP and 5% PVP.
[0065] Fig. 27The in vitro release of doxycycline from drug formulations in FaSSGF is shown. The doxycycline base formulation contained 25% doxycycline, 0.5% SiO2, and 0.5% alpha tocopherol. The release of doxycycline from formulations containing 0.5%, 2%, 3%, 4%, and 5% P407 was compared.
[0066] Fig.28 Shown is the in vitro release assay of donepezil formulations Dn-1, Dn-2 and Dn-3 in FaSSGF.
[0067] Fig.29 Fourier transform infrared spectra of a formulation without drug (top), a formulation containing memantine (middle), and no formulation drug (bottom) are shown.
[0068] Fig.30 X-ray diffraction patterns of memantine (top), a formulation without drug (middle), and a formulation containing memantine (bottom) are shown.
[0069] Fig.31 Raman spectra of memantine (upper spectrum), a formulation without drug (middle spectrum) and a formulation containing memantine (lower spectrum) are shown.
[0070] Fig.32 The in vivo pharmacokinetics of Lyndra-memantine formulation M18 and Namenda XR memantine capsules in dogs are shown.
[0071] Fig.33 The in vivo pharmacokinetics of Lyndra-memantine in pigs were shown.
[0072] Fig.34 Shown is an in vitro release assay of aripiprazole formulations A1 and A2 in FaSSGF.
[0073] Fig.35 Shown is an in vitro release assay of aripiprazole formulations A3 and A4 in FaSSGF.
[0074] Fig.36 Shown is an in vitro release assay of aripiprazole formulation A5 in FaSSGF.
[0075] Fig.37 Shown is an in vitro release assay of aripiprazole formulations A6, A7, and A10 in FaSSGF.
[0076] Fig.38 Shown is an in vitro release assay of aripiprazole formulations A8 and A9 in FaSSGF.
[0077] Fig.39 Shown is an in vitro release assay of aripiprazole formulations A11 and A12 in FaSSGF.
[0078] Fig.40 Shown is an in vitro release assay of aripiprazole formulations A13 and A16 in FaSSGF.
[0079] Fig.41 Shown is the in vitro release assay of aripiprazole formulations A14 and A1 in FaSSGF 5.
[0080] Fig.42 Shown is an in vitro release assay of aripiprazole formulations A17 and A18 in FaSSGF.
[0081] Fig.43 Shown is an in vitro release assay of aripiprazole formulations A19 and A20 in FaSSGF.
[0082] Fig.44 Shown is an in vitro release assay of aripiprazole formulations A21 and A22 in FaSSGF.
[0083] Fig.45 Shown is an in vitro release assay of aripiprazole formulations A23, A24, and A25 in FaSSGF.
[0084] Fig.46 Shown is the in vitro release assay of risperidone formulations R1, R3 and R8 in FaSSGF.
[0085] Fig.47 Shown is an in vitro release assay of risperidone formulations R6, R7 and R16 in FaSSGF.
[0086] Fig.48 Shown is an in vitro release assay of risperidone formulation R9 in FaSSGF.
[0087] Fig.49 The results showed that the in vitro release assay of peridone formulations R13 and R15 in FaSSGF was beneficial.
[0088] Fig.50 Shown is an in vitro release assay of risperidone formulations R18 and R22 in FaSSGF.
[0089] Fig.51 Shown is an in vitro release assay of risperidone formulations R20 and R21 in FaSSGF.
[0090] Fig.52 Shown is an in vitro release assay of risperidone formulations R14 and R19 in FaSSGF.
[0091] Fig.53 Shown is the in vitro release assay of memantine formulations M1, M2 and M3 in FaSSGF.
[0092] Fig.54Shown is the in vitro release assay of memantine formulations M4 and M5 in FaSSGF.
[0093] Fig.55 Shown is an in vitro release assay of memantine formulation M7 in FaSSGF.
[0094] Fig.56 Shown is an in vitro release assay of memantine formulation M17 in FaSSGF.
[0095] Fig.57 Shown is an in vitro release assay of memantine formulations M18, M21 and M24 in FaSSGF.
[0096] Fig.58 Shown is an in vitro release assay of memantine formulations M19 and M20 in FaSSGF.
[0097] Fig.59 Shown is an in vitro release assay of memantine formulation M22 in FaSSGF.
[0098] Fig.60 Shown is an in vitro release assay of memantine formulations M25 and M29 in FaSSGF.
[0099] Fig.61 Shown is an in vitro release assay of memantine formulations M26, M27 and M31 in FaSSGF.
[0100] Fig.62 Shown is an in vitro release assay of memantine formulation M30 in FaSSGF.
[0101] Fig.63 Shown is the in vitro release assay of memantine formulations M1 and M3 in FaSSGF and FeSSGF.
[0102] Fig.64 Shown is an in vitro release assay of memantine formulations M16 and M23 in FaSSGF and FeSSGF.
[0103] Fig.65 Shown is an in vitro release assay of risperidone formulation R6 in FaSSGF and FeSSGF.
[0104] Fig.66 In vitro release assays of risperidone formulations R9 and R13 in FaSSGF and FeSSGF are shown.
[0105] Fig.67 Shown is PCL punch extrusion.
[0106] Fig.68 Shown is the in vitro release assay of ivermectin formulations at pH 1.6 and 6.8. DETAILED DESCRIPTION OF THE INVENTION
[0108] Advantages of Dispersants in Gastric Retention Systems
[0109] Obtaining a stable and continuous release of a therapeutic agent from a gastric resident device may be challenging. Especially for hydrophilic therapeutic agents, limiting the initial burst period is very important. Hydrophilic active agents have the potential to be rapidly eluted from a gastric resident system in an aqueous gastric environment. The burst of active agents is absorbed by the patient, resulting in a sudden increase in plasma levels. The burst release may result in an undesirable initial peak level of the therapeutic agent, and may also result in insufficient delivery of the active agent during the remaining residence time of the system. In the initial stage after administration (i.e., after the burst release period occurs), a stable release rate of the therapeutic agent is desirable for predictable administration and maintaining an appropriate plasma level of the active agent. On the contrary, for hydrophobic therapeutic agents, obtaining a significant release of the active agent from a gastric resident system in the aqueous environment of the stomach may constitute a challenge.
[0110] In some embodiments of the invention described herein, the inclusion of a dispersant in a gastric retention system limits the sudden initial burst release of a hydrophilic therapeutic agent after systemic administration. The combination of a dispersant, a hydrophilic therapeutic agent, and a carrier polymer provides a more stable initial release of the active agent than a combination of a hydrophilic active agent and a carrier polymer without a dispersant. The dispersant can ensure better mixing of the hydrophilic therapeutic agent into the carrier polymer, preventing excess active agent from being exposed to the surface of the carrier polymer-active agent mixture. The dispersant can also prevent large agglomerations of hydrophilic active agent "capsules" from forming in the carrier polymer, thereby preventing sudden "dumping" of the active agent.
[0111] Inclusion of a dispersant can also aid in the administration of hydrophobic therapeutic agents in gastric resident systems. Small, evenly dispersed particles of the hydrophobic active agent provide greater surface area in contact with water diffusing through the carrier polymer compared to larger particles of the hydrophobic material.
[0112] In some embodiments of the present invention described herein, the inclusion of a release enhancer in a gastric resident system helps release a hydrophobic therapeutic agent after system administration. Release enhancers include, but are not limited to, porogens and wicking agents. Porogens are substances that dissolve when in contact with a solution, thereby opening the pores and channels in which they are dispersed in a carrier polymer matrix, and allowing water to more thoroughly penetrate into the matrix. Wicking agents are materials that absorb water into a polymer matrix. In both cases, release enhancers are used to increase the effective surface area of the therapeutic agent in the matrix exposed to water, which increases the rate at which the active agent is eluted (released) from the carrier polymer. Release enhancers are also useful in gastric resident systems comprising hydrophilic therapeutic agents. In other useful properties, release enhancers can promote the delivery of a higher percentage of the therapeutic agent in the resident system, so that excess active agents do not need to be included in the gastric resident system to provide a therapeutically effective amount to the patient.
[0113] Prior to incorporating the active agent into the gastric resident system, grinding the therapeutic agent to obtain a desired particle size or particle size range may also aid in improving the performance of the system.
[0114] The present invention provides various embodiments of gastric resident systems for sustained release of therapeutic agents, including hydrophilic and hydrophobic therapeutic agents. Several parameters of the system, such as the inclusion and concentration of a release enhancing agent, the inclusion and concentration of a dispersing agent, the inclusion and concentration of a solubilizing agent, the grinding of the therapeutic agent used in the system, the geometric configuration of the system, and the chemical and physical properties of the system can be varied in order to adjust the period of time that the gastric resident system is retained in the stomach, the effective release period for releasing a therapeutically effective amount of the therapeutic agent, and to adjust the release rate of the therapeutic agent.
[0115] Advantages of sustained therapeutic release
[0116] The present invention provides a gastric resident system that releases a therapeutic agent over an extended period of time. Gradual release over a period of time at a zero-order or pseudo-zero-order release rate can provide a substantially constant plasma level of the therapeutic agent at steady state. In turn, the substantially constant plasma level of the therapeutic agent can provide advantages over the peak-trough plasma levels observed with periodic dosing, such as minimizing side effects while maximizing therapeutic efficacy.
[0117] In studies comparing continuous versus on-demand treatment with an exemplary active agent, the hydrophilic compound cetirizine (Ciprandi et al., Ann. Allergy Asthma Immunol. 79(6):507-511 (1997)) suggests that sustained levels of cetirizine have an advantage over intermittent administration of cetirizine in reducing inflammatory responses, as measured by skin wheals. Mechanistically, this may be due to the effects of cetirizine on the marginalization of immune cells into mucosal tissues. Shimizu et al. Clin. Exp. Allergy 34, 103-109 (2004) found that cetirizine inhibited the expression of macrophage migration inhibitory factor in mice. These immunomodulatory effects of cetirizine may be particularly dependent on the sustained drug levels that can be provided by the present invention, thus demonstrating the advantages of the embodiments of the present invention for delivering cetirizine.
[0118] General Principles of Operation
[0119] The gastric resident system of the present invention is designed to be administered to the patient's stomach by swallowing or other administration methods (e.g., feeding tube or gastric tube). Once the gastric resident system is present in the stomach, the system stays in the stomach for a desired residence time (e.g., three days, seven days, two weeks, etc.), which therefore requires blocking the pyloric valve that separates the stomach and the small intestine. It releases the therapeutic agent during the residence period or at least a portion of the residence period ("effective release period") with minimal burst release. While residing in the stomach, the system does not interfere with the normal passage of food or other gastric contents. The system is discharged from the stomach at the end of the desired residence time (i.e., at the end of the residence period) and is easily eliminated from the patient. If the system enters the small intestine from the stomach prematurely, it will not cause intestinal obstruction and is easily eliminated from the patient.
[0120] Application
[0121] The gastric resident system is contained in a capsule or other container that can be swallowed by the patient or is otherwise capable of being administered to the stomach for patients who are unable to swallow (e.g., via a gastrostomy tube, feeding tube, gastric tube, or other route of administration to the stomach). Thus, the gastric resident system can be compressed or compacted into a form small enough to be swallowed or otherwise administered, and is preferably placed in a container such as a capsule. Thus, the system is configured to have a compressed form in a container (by folding, compressing, or other method of reducing the size of the system).
[0122] Such compressible or compressible systems are Figure 1 , Figure 2 and Figure 2A as shown in . Figure 1 The ring-shaped design for a gastric retention system shown in can be twisted into a double helix structure, which compresses the structure into a generally cylindrical shape that can be placed in a capsule. Figure 2 and Figure 2A The star-shaped (star-like) design of the gastric retention system shown can be folded at its center portion, such as Figure 3 As illustrated, it can then be placed in a capsule. The system is administered to the patient by swallowing the capsule or through a stomach tube.
[0123] System development in the stomach
[0124] Once the capsule or other container reaches the patient's stomach, the capsule dissolves and releases the compressed gastric resident system. Upon release, the system returns to its original shape, such as a ring or star. The size of the uncompressed / unpressed system is suitable to prevent the system from passing through the pyloric sphincter during the time period the system resides in the stomach.
[0125] When in the stomach, the gastric-retaining system is compatible with digestion and other normal functions of the stomach or gastrointestinal tract. The gastric-retaining system does not interfere with or prevent chyme (partially digested food) or other gastric contents from being expelled from the stomach through the pyloric sphincter into the duodenum.
[0126] Elution of therapeutic agent from the system while residing in the stomach; linear release
[0127] Gastric retention system comprises multiple carrier polymer-active agent components.Carrier polymer-active agent components include carrier polymer and therapeutic agent (or its salt).Release promoter, solubilizing agent, dispersant and stabilizer can also be added to carrier polymer-active agent components.Multiple carrier polymer-active agent components are connected to each other by one or more coupling polymer components.In the effective release period or the expected residence time (residence period) of the system, the active agent in the carrier polymer-active agent component is eluted into the patient's gastric juice.The release of the therapeutic agent is controlled by the appropriate formulation of the carrier polymer-active agent component, including by using the dispersant in the formulation of the carrier polymer-active agent component and by grinding the therapeutic agent into a desired particle size, and then the active agent is blended with the carrier polymer and the dispersant.
[0128] The elution or release of the therapeutic agent is preferably as close to linear as possible. As mentioned above, dispersants can help reduce burst release, thereby improving linearity. In some embodiments, after about 6 hours in 0.1N HCl, after about 6 hours in simulated gastric juice (fasting), after about 6 hours in simulated gastric juice (feeding), after about 6 hours in pig stomach, after about 6 hours in dog stomach or in human stomach, the burst release is less than about 20% of the total drug load. In some embodiments, after about 6 hours in 0.1N HCl, after about 6 hours in simulated gastric juice (fasting), after about 6 hours in simulated gastric juice (feeding), after about 6 hours in pig stomach, after about 6 hours in dog stomach or in human stomach, the burst release is less than about 5% of the total drug load.
[0129] When the release of the therapeutic agent is approximately linear, about half of the total amount of drug released will be released at about the middle point of the residence period or effective release period. Thus, when the gastric resident system is in 0.1N HCl, simulated gastric fluid (fasted), simulated gastric fluid (fed), porcine stomach, dog stomach, or human stomach, if the gastric resident system is D days, about 30% to about 70% of the total drug load will be released after a time of about 0.4D to 0.6D, for example, at time 0.5D. Similarly, when the gastric resident system is in 0.1N HCl, simulated gastric fluid (fasted), simulated gastric fluid (fed), porcine stomach, dog stomach, or human stomach, if the effective release period of the gastric resident system is E days, about 30% to about 70% of the total drug load will be released after a time of about 0.4E to 0.6E, for example, at time 0.5E.
[0130] When the release of the therapeutic agent is approximately linear, most of the active agent in the stomach will be eluted. Therefore, in some embodiments, when the gastric resident system is in 0.1N HCl, simulated gastric fluid (fasting), simulated gastric fluid (fed), pig stomach, dog stomach or human stomach, if the residence period of the gastric resident system is D days, about 70% or more of the total drug load is released after a time of about 0.8D-1D. In some embodiments, when the gastric resident system is in 0.1N HCl, simulated gastric fluid (fasting), simulated gastric fluid (fed), pig stomach, dog stomach or human stomach, if the residence period of the gastric resident system is D days, about 80% or more of the total drug load is released after a time of about 0.8D-1D. In some embodiments, when the gastric resident system is in 0.1N HCl, simulated gastric fluid (fasted), simulated gastric fluid (fed), porcine stomach, dog stomach, or human stomach, if the residence period of the gastric resident system is D days, about 90% or more of the total drug load is released after a time of about 0.8D-1D. In some embodiments, when the gastric resident system is in 0.1N HCl, simulated gastric fluid (fasted), simulated gastric fluid (fed), porcine stomach, dog stomach, or human stomach, if the effective release period of the gastric resident system is E days, about 70% or more of the total drug load is released after a time of about 0.8E-1E. In some embodiments, when the gastric resident system is in 0.1N HCl, simulated gastric fluid (fasted), simulated gastric fluid (fed), porcine stomach, dog stomach, or human stomach, about 80% or more of the total drug load is released after a time of about 0.8E-1E. In some embodiments, when the gastric resident system is in 0.1N HCl, simulated gastric fluid (fasting), simulated gastric fluid (fed), porcine stomach, dog stomach, or human stomach, about 90% or more of the total drug load is released after a time elapsed between about 0.8E-1E.
[0131] Additional initial burst release parameters; In some embodiments, the gastric resident system of the present invention releases no more than about 30% of the therapeutic agent or salt thereof before about 5% of the residence period has passed. In some embodiments, the gastric resident system of the present invention releases no more than about 25% of the therapeutic agent or salt thereof before about 5% of the residence period has passed. In some embodiments, the gastric resident system of the present invention releases no more than about 20% of the therapeutic agent or salt thereof before about 5% of the residence period has passed. In some embodiments, the gastric resident system of the present invention releases no more than about 15% of the therapeutic agent or salt thereof before about 5% of the residence period has passed. In some embodiments, the gastric resident system of the present invention releases no more than about 10% of the therapeutic agent or salt thereof before about 5% of the residence period has passed. In some embodiments, the gastric resident system of the present invention releases no more than about 30% of the therapeutic agent or salt thereof before about 5% of the residence period has passed. In some embodiments, the gastric resident system of the present invention releases no more than about 25% of the therapeutic agent or salt thereof before about 5% of the effective release period has passed. In some embodiments, the gastric retention system of the present invention releases no more than about 20% of the therapeutic agent or salt thereof before about 5% of the effective release period has passed. In some embodiments, the gastric retention system of the present invention releases no more than about 15% of the therapeutic agent or salt thereof before about 5% of the effective release period has passed. In some embodiments, the gastric retention system of the present invention releases no more than about 10% of the therapeutic agent or salt thereof before about 5% of the effective release period has passed.
[0132] Additional Initial Burst Release Parameters (Continued); In some embodiments, the gastric resident systems of the present invention release no more than about 30% of the therapeutic agent or salt thereof before about 6 hours have elapsed. In some embodiments, the gastric resident systems of the present invention release no more than about 25% of the therapeutic agent or salt thereof before about 6 hours have elapsed. In some embodiments, the gastric resident systems of the present invention release no more than about 20% of the therapeutic agent or salt thereof before about 6 hours have elapsed. In some embodiments, the gastric resident systems of the present invention release no more than about 15% of the therapeutic agent or salt thereof before about 6 hours have elapsed.
[0133] Intermediate release parameters: In some embodiments, the gastric resident system of the present invention releases about 30-70% of the therapeutic agent or salt thereof within about 30-70% of the residence period. In some embodiments, the gastric resident system of the present invention releases about 30-70% of the therapeutic agent or salt thereof within about 40-60% of the residence period. In some embodiments, the gastric resident system of the present invention releases about 30-70% of the therapeutic agent or salt thereof within about 45-55% of the residence period. In some embodiments, the gastric resident system of the present invention releases about 40-60% of the therapeutic agent or salt thereof within about 30-70% of the residence period. In some embodiments, the gastric resident system of the present invention releases about 40-60% of the therapeutic agent or salt thereof within about 40-60% of the residence period. In some embodiments, the gastric resident system of the present invention releases about 40-60% of the therapeutic agent or salt thereof within about 45-55% of the residence period. In some embodiments, the gastric retention system of the present invention releases about 45-55% of the therapeutic agent or salt thereof within about 30-70% of the residence period. In some embodiments, the gastric retention system of the present invention releases about 45-55% of the therapeutic agent or salt thereof within about 40-60% of the residence period. In some embodiments, the gastric retention system of the present invention releases about 45-55% of the therapeutic agent or salt thereof within 45-55% of the residence system. In some embodiments, the gastric retention system of the present invention releases about 30-70% of the therapeutic agent or salt thereof within about 30-70% of the effective release period. In some embodiments, the gastric retention system of the present invention releases about 30-70% of the therapeutic agent or salt thereof within about 40-60% of the effective release period. In some embodiments, the gastric retention system of the present invention releases about 30-70% of the therapeutic agent or salt thereof within about 45-55% of the effective release period. In some embodiments, the gastric retention system of the present invention releases about 40-60% of the therapeutic agent or salt thereof within an effective release period of about 30-70%. In some embodiments, the gastric retention system of the present invention releases about 40-60% of the therapeutic agent or salt thereof within an effective release period of about 40-60%. In some embodiments, the gastric retention system of the present invention releases about 40-60% of the therapeutic agent or salt thereof within an effective release period of about 45-55%. In some embodiments, the gastric retention system of the present invention releases about 40-60% of the therapeutic agent or salt thereof within an effective release period of about 45-55%. In some embodiments, the gastric retention system of the present invention releases about 45-55% of the therapeutic agent or salt thereof within an effective release period of about 30-70%. In some embodiments, the gastric retention system of the present invention releases about 45-55% of the therapeutic agent or salt thereof within an effective release period of about 40-60%. In some embodiments, the gastric retention system of the present invention releases about 45-55% of the therapeutic agent or salt thereof within an effective release period of about 45-55%.
[0134] Termination release parameters; In some embodiments, the gastric resident system of the present invention releases at least about 60% of the therapeutic agent or salt thereof after about 70% or more of the residence period. In some embodiments, the gastric resident system of the present invention releases at least about 70% of the therapeutic agent or salt thereof after about 70% or more of the residence period. In some embodiments, the gastric resident system of the present invention releases at least about 70% of the therapeutic agent or salt thereof after about 80% or more of the residence period. In some embodiments, the gastric resident system of the present invention releases at least about 80% of the therapeutic agent or salt thereof after about 80% or more of the residence period. In some embodiments, the gastric resident system of the present invention releases at least about 80% of the therapeutic agent or salt thereof after about 90% or more of the residence period. In some embodiments, the gastric resident system of the present invention releases at least about 90% of the therapeutic agent or salt thereof after about 90% or more of the residence period. In some embodiments, the gastric resident system of the present invention releases at least about 60% of the therapeutic agent or salt thereof after about 70% or more of the effective release period. In some embodiments, the gastric resident system of the present invention releases at least about 70% of the therapeutic agent or salt thereof after about 70% or more of the effective release period has passed. In some embodiments, the gastric resident system of the present invention releases at least about 70% of the therapeutic agent or salt thereof after about 80% or more of the effective release period has passed. In some embodiments, the gastric resident system of the present invention releases at least about 80% of the therapeutic agent or salt thereof after about 80% or more of the effective release period has passed. In some embodiments, the gastric resident system of the present invention releases at least about 80% of the therapeutic agent or salt thereof after about 90% or more of the effective release period has passed. In some embodiments, the gastric resident system of the present invention releases at least about 90% of the therapeutic agent or salt thereof after about 90% or more of the effective release period has passed.
[0135] Gastric retention systems having any combination of the above-described initial burst release parameters, intermediate release parameters, and terminal release parameters are contemplated as being part of the present invention. For example, in some embodiments, the gastric retention system of the present invention releases no more than about 25% of the therapeutic agent or salt thereof before about 5% of the residence period; releases about 40-60% of the therapeutic agent or salt thereof within about 30-70% of the residence period; and releases about 60% or more of the therapeutic agent or salt thereof after about 70% or more of the residence period. In some embodiments, the gastric retention system of the present invention releases no more than about 20% of the therapeutic agent or salt thereof before about 5% of the residence period; releases about 40-60% of the therapeutic agent or salt thereof within about 40-60% of the residence period; and releases about 60% or more of the therapeutic agent or salt thereof after about 70% or more of the residence period. In some embodiments, the gastric retention system of the present invention releases no more than about 15% of the therapeutic agent or its salt before about 5% of the residence period; releases about 40-60% of the therapeutic agent or its salt by about 45-55% of the residence period; and releases about 70% or more of the therapeutic agent or its salt after about 70% or more of the residence period. In some embodiments, the gastric retention system of the present invention releases no more than about 25% of the therapeutic agent or its salt before about 5% of the effective release period; releases about 40-60% of the therapeutic agent or its salt within about 30-70% of the effective release period; and releases about 60% or more of the therapeutic agent or its salt after about 70% or more of the effective release period. In some embodiments, the gastric retention system of the present invention releases no more than about 20% of the therapeutic agent or its salt before about 5% of the effective release period; releases about 40-60% of the therapeutic agent or its salt within about 40-60% of the effective release period; and releases about 60% or more of the therapeutic agent or its salt after about 70% or more of the effective release period. In some embodiments, the gastric retention system of the present invention releases no more than about 15% of the therapeutic agent or its salt before about 5% of the effective release period; releases about 40-60% of the therapeutic agent or its salt by about 45-55% of the effective release period; and releases about 70% or more of the therapeutic agent or its salt after about 70% or more of the effective release period.
[0136] As described above, these release parameters can be determined for a gastric resident system for a specified time for any of the following conditions: 0.1 N HCl, simulated gastric fluid (fasted), simulated gastric fluid (fed), porcine stomach, dog stomach, or human stomach. 0.1 N HCl is preferred for normalization and comparison of release rates.
[0137] Gastric resident systems for delivering therapeutic agents have relatively long half-lives (greater than about 1 day, greater than about 2 days, greater than about 3 days, greater than about 4 days, greater than about 5 days, greater than about 6 days, or greater than about 7 days), and / or relatively large therapeutic windows, and the system has less stringent requirements for linearity of release. That is, any of the release ranges provided above can be used in such systems, either wider or narrower. In contrast, gastric resident systems for delivering therapeutic agents with relatively short half-lives (less than about 1 day, less than about 18 hours, less than about 12 hours, less than about 9 hours, less than about 6 hours, or less than about 3 hours) and / or relatively narrow therapeutic windows should have greater linearity, i.e., in such systems, the narrower ranges of release provided above are preferred (e.g., the two narrowest or most linear ranges for burst release, intermediate release, and terminal release parameters).
[0138] Resistance to alcohol-induced release
[0139] The release rate of a therapeutic agent from a gastric resident system may be affected by changes in the environment in which the system is deployed. In addition to changes between the fed state (postprandial) and the fasted state (long after the last meal), the gastric environment of a person may also change due to the consumption of alcoholic beverages (i.e., beverages containing ethanol). For any therapeutic agent, and particularly a hydrophobic therapeutic agent (e.g., rosuvastatin, discussed in more detail herein), it is expected that the consumption of ethanol should not significantly affect the release rate of the therapeutic agent from a gastric resident system.
[0140] The release of the ethanol-induced therapeutic agent from the gastric resident system of the present invention can be measured by placing the system in 40% ethanol / 60% 0.1N HCl for a period of time, such as about 2 hours, and measuring the release of the therapeutic agent from the system. In some embodiments, no more than about 30% of the therapeutic agent is released from the gastric resident system after about 2 hours in 40% ethanol / 60% 0.1N HCl. In some embodiments, no more than about 25% of the therapeutic agent is released from the gastric resident system after about 2 hours in 40% ethanol / 60% 0.1N HCl. In some embodiments, no more than about 20% of the therapeutic agent is released from the gastric resident system after about 2 hours in about 40% ethanol / 60% 0.1N HCl. In some embodiments, no more than about 15% of the therapeutic agent is released from the gastric resident system after about 2 hours in about 40% ethanol / 60% 0.1N HCl. In some embodiments, no more than about 10% of the therapeutic agent is released from the gastric resident system after about 2 hours in about 40% ethanol / 60% 0.1N HCl. In some embodiments, no more than about 5% of the therapeutic agent is released from the gastric retention system after about 2 hours in 40% ethanol / 60% 0.1 N HCl.
[0141] Ethanol-induced release of therapeutic agents from the gastric retention systems of the present invention can also be determined by comparing the release of the active agent in fasted simulated gastric fluid, fed simulated gastric fluid, or 0.1 N HCl with the release of the active agent in 40% ethanol / 60% fasted simulated gastric fluid, 40% ethanol / 60% fed simulated gastric fluid, 40% ethanol / 60% 0.1 N HCl, or 40% ethanol / 60% water. In some embodiments, release in 40% ethanol / 60% 0.1N HCl aqueous solution does not increase release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) by no more than about 50% compared to release in 0.1N HCl over the same time period, or release in 40% ethanol / 60% simulated gastric fluid does not increase release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) by no more than about 50% compared to release in simulated gastric fluid over the same time period, or release in 40% ethanol / 60% fasted simulated gastric fluid does not increase release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) by no more than about 50% compared to release in fasted simulated gastric fluid over the same time period, or release in 40% ethanol / 60% fed simulated gastric fluid does not increase release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) by no more than about 50% compared to release in fasted simulated gastric fluid over the same time period. In some embodiments, the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% 0.1N HCl aqueous solution is increased by no more than about 40% compared to the release in 0.1N HCl over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% simulated gastric fluid is increased by no more than about 40% compared to the release in simulated gastric fluid over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% fasted simulated gastric fluid is increased by no more than about 40% compared to the release in fasted simulated gastric fluid over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% fed simulated gastric fluid is increased by no more than about 40% compared to the release in fed simulated gastric fluid over the same time period.In some embodiments, the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% 0.1N HCl aqueous solution is increased by no more than about 30% compared to the release in 0.1N HCl over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% simulated gastric fluid is increased by no more than about 30% compared to the release in simulated gastric fluid over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% fasted simulated gastric fluid is increased by no more than about 30% compared to the release in fasted simulated gastric fluid over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% fed simulated gastric fluid is increased by no more than about 30% compared to the release in fed simulated gastric fluid over the same time period. In some embodiments, the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% 0.1N HCl aqueous solution is increased by no more than about 20% compared to the release in 0.1N HCl over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% simulated gastric fluid is increased by no more than about 20% compared to the release in simulated gastric fluid over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% fasted simulated gastric fluid is increased by no more than about 20% compared to the release in fasted simulated gastric fluid over the same time period, or the release of the therapeutic agent (or a pharmaceutically acceptable salt of the therapeutic agent) in 40% ethanol / 60% fed simulated gastric fluid is increased by no more than about 20% compared to the release in fed simulated gastric fluid over the same time period.
[0142] The time period over which comparative release is measured can be about 15 minutes, about 30 minutes, about 45 minutes, about 1 hour, about 90 minutes, or about 2 hours.
[0143] In the above paragraphs concerning release assays in solutions containing ethanol, “40% ethanol” may be “about 40% ethanol”; “60% simulated gastric fluid” may be “about 60% simulated gastric fluid”; “60% fasted simulated gastric fluid” may be “about 60% fasted simulated gastric fluid”; “60% fed simulated gastric fluid” may be “about 60% fed simulated gastric fluid”; and “0.1 N HCl” may be “about 0.1 N HCl”.
[0144] Retention in the stomach; systemic passage through the stomach
[0145] At an appropriate point in time, the gastric resident system is disengaged from the stomach, i.e., once the useful therapeutic agent delivery life of the system is reached, or at a reasonable portion of the useful therapeutic agent delivery life of the system. This is achieved by appropriate selection of the coupling polymer components and the size of the system. In its intact, uncompressed form, the gastric resident system is designed to prevent passage through the pyloric sphincter. That is, in its intact form, the gastric resident system is too large to pass through the pyloric sphincter. The gastric resident system should also be able to resist transient refolding due to compressive forces in the stomach, which could result in premature passage of the system. To prevent transient refolding in the stomach, the gastric resident system should maintain its uncompressed form or approximate its uncompressed form when subjected to forces typically present in the stomach. Thus, in some embodiments, the force required to fold or compress the structure is at least about 0.2 Newtons (N), at least about 0.3 N, at least about 0.4 N, at least about 0.5 N, at least about 0.75 N, at least about 1 N, at least about 1.5 N, at least about 2 N, at least about 2.5 N, at least about 3 N, at least about 4 N, or at least about 5 N. In some embodiments, the force required to fold or compress the structure is at least about 0.2 N to about 5 N, about 0.3 N to about 5 N, about 0.4 N to about 5 N, about 0.5 N to about 5 N, about 0.75 N to about 5 N, about 1 N to about 5 N, about 1.5 N to about 5 N, about 2 N to about 5 N, about 2.5 N to about 5 N, about 3 N to about 5 N, or about 4 N to about 5 N.
[0146] The coupling polymer components are selected so that they gradually degrade on the resident system in the stomach. When the coupling polymer components are sufficiently weakened by degradation, the gastric resident system disintegrates into smaller pieces, small enough to pass through the pyloric sphincter. The system then passes through the small intestine and is eliminated from the patient.
[0147] Security factors
[0148] In its desired mode of operation, the gastric resident system has its intact uncompressed form while resident in the stomach, and does not pass through the pylorus until they break apart after the desired residence time (residence period). If the gastric resident system enters the intestine intact, it may potentially cause intestinal obstruction. Therefore, the gastric resident system is designed to be rapidly uncoupled in the intestinal environment by dissolving one or more coupling polymers within 48 hours, preferably within 24 hours, more preferably within 12 hours, and even more preferably within 1-2 hours to avoid potential intestinal obstruction. This is easily achieved by using enteric polymers as some or all of the coupling polymers in the system. Enteric polymers are relatively tolerant to the acidic pH encountered in the stomach, but dissolve rapidly at the higher pH found in the duodenum. The use of enteric coupling polymers as a safety factor prevents the unintended passage of the intact gastric resident system into the small intestine. The use of enteric coupling polymers also provides a means of removing the gastric resident system prior to its designed residence time (residence period); if the system needs to be removed, the patient can drink a mild alkaline solution, such as sodium bicarbonate solution or take an antacid preparation, such as hydrated magnesium hydroxide (milk of magnesia) or calcium carbonate, which will increase the pH in the stomach and cause rapid degradation of the enteric coupling polymer. The gastric resident system will then break down and be eliminated from the patient.
[0149] definition
[0150] A "carrier polymer" is a polymer suitable for blending with a therapeutic agent, such as a drug, for use in the present invention.
[0151] A "hydrophilic therapeutic agent," "hydrophilic agent," or "hydrophilic drug" is an active agent that is readily soluble in water. A hydrophilic active agent is defined as an active agent having a solubility of 1 mg / ml or more in water. Alternatively, a hydrophilic active agent may be defined as an active agent having a log P value of less than 0.5 in a 1-octanol / water system. oct (log partition coefficient P oct , where P oct =(concentration in 1-octanol) / (concentration in H2O)) of the active agent. Determination of solubility or log P oct The pH is 1.6, which is close to the gastric environment.
[0152] A "hydrophobic therapeutic agent," "hydrophobic agent," or "hydrophobic drug" is an active agent that is not readily soluble in water. A hydrophobic active agent is defined as an active agent having a solubility in water of less than 1 mg / ml. Alternatively, a hydrophobic active agent may be defined as an active agent having a log P greater than 1 in a 1-octanol / water system. oct (log partition coefficient P octAlternatively, a hydrophobic therapeutic agent is defined as an active agent that has a higher solubility in ethanol than in water. Alternatively, a hydrophobic therapeutic agent can be defined as an active agent that has a higher solubility in 40% ethanol / 60% simulated gastric fluid than in 100% simulated gastric fluid.
[0153] In addition to log P oct , where the partition coefficient of the substance is determined in the 1-octanol / water system, other systems can also be used to determine the partitioning behavior. Another such system is to partition the substance between a polycaprolactone phase (PCL phase) and a simulated gastric fluid phase (SGF phase) to give a partition coefficient P between the two phases. PCL-SGF . You can also calculate Log P PCL-SGF A 5:1 mixture of polycaprolactone diol (MW 530):ethyl acetate may be used as the PCL phase, and fasted state simulated gastric fluid (FaSSGF) may be used as the SGF phase.
[0154] A "dispersant" is defined as a substance that helps minimize the particle size of the therapeutic agent and disperse the therapeutic agent particles in the carrier polymer matrix. That is, the dispersant helps minimize or prevent particle aggregation or flocculation during the system manufacturing process. Thus, the dispersant has anti-aggregation activity and anti-flocculation activity, and helps maintain a uniform distribution of the therapeutic agent particles in the carrier polymer matrix.
[0155] An "excipient" is any substance added to a formulation of a therapeutic agent other than the therapeutic agent itself. Excipients include, but are not limited to, binders, coatings, diluents, disintegrants, emulsifiers, flavoring agents, glidants, lubricants, and preservatives. The specific class of dispersants falls within the more general class of excipients.
[0156] An "elastic polymer" or "elastomer" (also called a "tensile polymer") is a polymer that can be deformed from its original shape by an applied force for a period of time and then substantially return to its original shape once the applied force is removed.
[0157] A "coupling polymer" is a polymer suitable for coupling any additional polymers to one another, for example coupling a first carrier polymer-active agent component to a second carrier polymer-active agent component.
[0158] "Substantially constant plasma levels" refers to plasma levels that remain within ±25% of the mean plasma levels measured over the period of time that the gastric-resident system is resident in the stomach.
[0159] "Residence time" or "residence duration" is the time from when a gastric resident system is deployed in the stomach to when the gastric resident system exits the stomach.
[0160] The "effective release period" or "effective release time" is the time over which a gastric-resident system releases a therapeutically effective amount of a therapeutic agent contained in the system. For therapeutic agents that are released only in therapeutically effective amounts while the gastric-resident system resides in the stomach, the effective release period will be less than or equal to the residence period. For therapeutic agents that are released in therapeutically effective amounts while the gastric-resident system resides in the stomach and additionally while the components of the gastric-resident system are transported to the intestine after the residence period, the effective release period may be greater than the residence period.
[0161] "Biocompatibility" when used to describe a material or system means that the material or system causes no adverse reactions or only minimal, tolerable adverse reactions when in contact with an organism such as a human. In the context of gastric resident systems, biocompatibility in the gastrointestinal environment is evaluated.
[0162] As used herein, the singular forms "a," "an," and "the" include plural counterparts unless otherwise indicated or the context clearly dictates otherwise.
[0163] "Patient", "individual" or "subject" refers to a mammal, preferably a human or a livestock animal, such as a dog or cat. In a preferred embodiment, the patient, individual or subject is a human.
[0164] As used herein, the "diameter" of a particle refers to the longest dimension of the particle.
[0165] "Treating" a disease or disorder with the systems and methods disclosed herein is defined as administering one or more systems disclosed herein with or without additional therapeutic agents to a patient in need thereof to reduce or eliminate the disease or disorder or one or more symptoms of the disease or disorder, or to slow the progression of the disease or disorder or one or more symptoms of the disease or disorder or to reduce the severity of the disease or disorder or one or more symptoms of the disease or disorder. "Suppressing" a disease or disorder with the systems and methods disclosed herein is defined as administering one or more systems disclosed herein with or without additional therapeutic agents to a patient in need thereof to suppress the clinical manifestations of the disease or disorder or to suppress the manifestation of adverse symptoms of the disease or disorder. The difference between treating and suppressing is that treating occurs after the adverse symptoms of the disease or disorder manifest in the patient, while suppressing the occurrence of adverse symptoms of the disease or disorder before the occurrence of adverse symptoms in the patient. Suppression may be partial, substantially complete, or complete. Since some diseases or disorders are inherited, genetic screening can be used to identify patients at risk of the disease or disorder. The systems and methods of the present invention can then be used to treat asymptomatic patients at risk of developing clinical symptoms of the disease or disorder in order to suppress the appearance of any adverse symptoms.
[0166] A "therapeutic use" of the systems disclosed herein is defined as the use of one or more systems disclosed herein to treat a disease or disorder as defined above. A "therapeutically effective amount" of a therapeutic agent is an amount of the therapeutic agent that, when administered to a patient, is sufficient to reduce or eliminate a disease or disorder or one or more symptoms of a disease or disorder or to slow the progression of a disease or disorder or one or more symptoms of a disease or disorder or to reduce the severity of a disease or disorder or one or more symptoms of a disease or disorder. A therapeutically effective amount can be administered to a patient as a single dose, or can be divided and administered as multiple doses.
[0167] A "prophylactic use" of the systems disclosed herein is defined as the use of one or more systems disclosed herein to inhibit a disease or disorder as defined above. A "prophylactically effective amount" of a therapeutic agent is an amount of the therapeutic agent that, when administered to a patient, is sufficient to inhibit the clinical manifestations of a disease or disorder or to inhibit the manifestation of adverse symptoms of a disease or disorder. A prophylactically effective amount can be administered to a patient as a single dose, or can be divided and administered in multiple doses.
[0168] When the term "about" or the term "approximately" is used herein to express a numerical value, it should be understood that the specified value and the value reasonably close to the specified value are included. For example, the description of "about 50°C" or "approximately 50°C" includes both the disclosure of 50°C itself and the disclosure of values close to 50°C. Therefore, the phrase "about X" or "approximately X" includes the description of the numerical value X itself. If a range is indicated, such as "approximately 50°C-60°C" or "about 50°C-60°C", it should be understood that the values specified by the endpoints and the values close to each endpoint are included or the two endpoints or two endpoints for each endpoint are included; that is, "approximately 50°C-60°C" (or "about 50°C-60°C") is equivalent to describing "50°C-60°C" and "approximately 50°C-approximately 60°C" (or "about 50°C-60°C") at the same time.
[0169] With respect to the numerical ranges disclosed in this specification, any disclosed upper limit of a component can be combined with any disclosed lower limit of the component to provide a range (provided that the upper limit is greater than the lower limit combining it). Each of these combinations of disclosed upper and lower limits is expressly contemplated herein. For example, if the range of the amount of a given particular component is 10%-30%, 10%-12%, and 15%-20% 10, then ranges of 10%-20% and 15%-30% are also contemplated, while the combination of a 15% lower limit and a 12% upper limit is not possible and is therefore not contemplated.
[0170] Unless otherwise indicated, the percentages of components in the compositions are expressed as weight percent or weight / weight percent. It should be understood that reference to relative weight percents in a composition presumes that the total weight percents of all ingredients in the composition sum to 100. It should be further understood that the relative weight percents of one or more ingredients may be adjusted upward or downward so that the weight percents of the ingredients in the composition combine to total 100, provided that the weight percent of any particular ingredient does not exceed the limits of the range specified for that ingredient.
[0171] Some embodiments described herein are described as "comprising" or "including" with respect to their various elements. In alternative embodiments, those elements may be described with the transitional phrases "consisting essentially of" or "consisting primarily of" applied to those elements. In further alternative embodiments, those elements may be described with the transitional phrases "consisting of" or "consisting of" applied to those elements. Thus, for example, if a composition or method is disclosed herein as comprising A and B, an alternative embodiment "consisting essentially of A and B" for the composition or method and "consisting of A and B" for the composition or method are also considered to have been disclosed herein. Similarly, embodiments listed as "consisting essentially of" or "consisting of" with respect to their various elements may also be described as "comprising" applied to those elements. Finally, embodiments listed as "consisting essentially of" with respect to their various elements may also be described as "consisting of" applied to those elements, and embodiments listed as "consisting of" with respect to their various elements may also be described as "consisting essentially of" applied to those elements.
[0172] When a composition or system is described as "consisting essentially of the listed elements," the composition or system contains the elements explicitly listed, and may contain other elements that do not materially affect the condition being treated (for compositions for treating a condition) or the properties of the system (for compositions comprising systems). However, the composition or system either does not contain any other elements that materially affect the condition being treated other than those elements explicitly listed (for compositions for treating systems), or does not contain any other elements that materially affect the properties of the system (for compositions comprising systems); or, if the composition or system does contain additional elements other than those listed that may materially affect the condition being treated or the properties of the system, the composition or system does not contain sufficient concentrations or amounts of these additional elements to materially affect the properties of the disorder being treated or the system being treated. When a method is described as "consisting essentially of the listed steps," the method comprises the listed steps, and may contain other steps that do not materially affect the condition being treated by the method or the properties of the system produced by the method, but the method does not contain any other steps other than those explicitly listed that materially affect the condition being treated or the system produced.
[0173] The present disclosure provides several embodiments. It is contemplated that any feature from any embodiment can be combined with any feature in any other embodiment possible. In this way, hybrid configurations of the disclosed features are within the scope of the present invention.
[0174] Dispersants for therapeutic agent release modulation and polymer compound stability
[0175] The use of dispersants in carrier polymer-active agent compositions provides many advantages. The rate at which the therapeutic agent is eluted from the carrier polymer-active agent composition is affected by many of the factors mentioned above, including the composition and properties of the carrier polymer (which itself may contain a variety of polymers and non-polymer components); the physical and chemical properties of the therapeutic agent; and the gastric environment. Avoiding the burst release of therapeutic agents, especially hydrophilic active agents, and maintaining the sustained release of therapeutic agents within the effective release period or residence period are important features of these systems. The use of dispersants of the present invention can better control the release rate and inhibit burst release. Burst release and release rate can be adjusted by using dispersants of different concentrations. Example 9 describes the effects of different dispersants and different excipients at different concentrations on the burst release of cetirizine in simulated gastric fluid.
[0176] Dispersants that can be used in the present invention include: silicon dioxide (silicon dioxide, SiO2) (hydrophilic fumed type); stearates such as calcium stearate and magnesium stearate; microcrystalline cellulose; carboxymethyl cellulose; hydrophobic colloidal silicon dioxide; hypromellose; magnesium aluminum silicate; phospholipids; polyoxyethylene stearate; zinc acetate; alginic acid; lecithin; fatty acids; sodium lauryl sulfate; and non-toxic metal oxides such as alumina. Porous inorganic materials and polar inorganic materials can be used. Hydrophilic-fumed silica is a preferred dispersant.
[0177] In addition to the anti-aggregation / deflocculation activity, the dispersant may also help prevent phase separation during system manufacture and / or storage. This is particularly useful for enhancing hot melt extrusion manufacturing of the system.
[0178] The weight / weight ratio of the dispersant to the therapeutic agent substance can be about 0.1% to about 5%, about 0.1% to about 4%, about 0.1% to about 3%, about 0.1% to about 2%, about 0.1% to about 1%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 4%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, or about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, or about 5%.
[0179] The dispersion may comprise from about 0.1% to about 4% of the carrier polymer-active agent component, e.g., from about 0.1% to about 3.5%, from about 0.1% to about 3%, from about 0.1% to about 2.5%, from about 0.1% to about 2%, from about 0.1% to about 1.5%, from about 0.1% to about 1%, from about 0.1% to about 0.5%, or from about 0.2% to about 0.8%.
[0180] The amount of burst release that can be tolerated during the initial phase of administration of the gastric resident system will depend on the desired effective release period, or in some cases, the desired gastric residence period. In embodiments of gastric resident systems that are administered once a week (i.e., wherein the effective release period is about 1 week), the burst release within about the first 6 hours after the initial administration is less than about 8%, preferably less than about 6%, of the total amount of drug in the system. In embodiments of gastric resident systems that are administered once every 3 days, the burst release within about the first 6 hours after the initial administration is less than about 12%, preferably less than about 10%, of the total amount of drug in the system. In embodiments of gastric resident systems that are administered once a day, the burst release within about the first 6 hours after the initial administration is less than about 40%, preferably less than about 30%, of the total amount of drug in the system. Generally, if a new gastric retention system is administered every E days and the total mass of the drug is M, the gastric retention system releases less than about [(M divided by E) times 0.5], preferably less than about [(M divided by E) times 0.4 or less than about [(M divided by E) times 3 / 8], more preferably less than about [[M divided by E] times 0.3] in about the first 6 hours after the initial administration. In a further embodiment, the gastric retention system releases at least about [(M divided by E) times 0.25] in about the first 6 hours after the initial administration, i.e., the system releases at least about a quarter of the daily dose in the first quarter of the first day of administration.
[0181] Therapeutic agent stabilization
[0182] Many therapeutic agents are susceptible to oxidative degradation when exposed to reactive oxygen species that may be present in the stomach. Therapeutic agents contained in the system may therefore oxidize due to prolonged residence in the stomach of the system and prolonged release of the therapeutic agent from the system. Therefore, it is desirable to include a stabilizer or preservative in the system to stabilize the active agent to prevent oxidation and other degradation.
[0183] Stabilizers, such as antioxidants, including tocopherol, alpha-tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, and fumaric acid can comprise about 0.1% to about 4%, for example, about 0.1% to about 3.5%, about 0.1% to about 3%, about 0.1% to about 2.5%, about 0.1% to about 2%, about 0.1% to about 1.5%, about 0.1% to about 1%, about 0.1% to about 0.5%, or about 0.2% to about 0.8% of the carrier polymer-active agent ingredient.
[0184] Antioxidant stabilizers that can be included in the system to reduce or prevent oxidation of the therapeutic agent include alpha-tocopherol (about 0.01-about 0.05% v / v), ascorbic acid (about 0.01-about 0.1% w / v), ascorbyl palmitate (about 0.01-about 0.1% w / v), butylated hydroxytoluene (about 0.01-about 0.1% w / w), butylated hydroxyanisole (about 0.01-about 0.1% w / w), and fumaric acid (up to 3600 ppm).
[0185] Certain therapeutic agents can be pH-sensitive, especially at low pH present in the gastric environment. Buffer or pH-stabilizer compounds that can be included in the system to reduce or prevent degradation of therapeutic agents at low pH include calcium carbonate, calcium lactate, calcium phosphate, sodium phosphate and sodium bicarbonate. They are typically used in an amount of up to about 2% w / w. Buffer or pH-stabilizer compounds can include about 0.1% to about 4% of the carrier polymer-active agent component, such as about 0.1% to about 3.5%, about 0.1% to about 3%, about 0.1% to about 2.5%, about 0.1% to about 2%, about 0.1% to about 1.5%, about 0.1% to about 1%, about 0.1% to about 0.5% or about 0.2% to about 0.8%.
[0186] Antioxidant stabilizers, pH stabilizers, and other stabilizer compounds are blended into the polymer containing the therapeutic agent by blending the stabilizer into the molten carrier polymer-active agent. The stabilizer can be blended into the molten carrier polymer before the therapeutic agent is blended into the polymer-stabilizer mixture; or the stabilizer can be blended before the blended active agent-stabilizer mixture in the carrier polymer is prepared; or the stabilizer, active agent, and molten carrier polymer can be blended simultaneously. The therapeutic agent can also be blended with the molten carrier polymer before the stabilizer is blended into the polymer-active agent mixture.
[0187] In one embodiment, less than about 10% of the therapeutic agent retained in the system after about 24 hours of gastric residence or effective release period is degraded or oxidized. In one embodiment, less than about 10% of the therapeutic agent retained in the system after about 48 hours of gastric residence or effective release period is degraded or oxidized. In one embodiment, less than about 10% of the therapeutic agent retained in the system after about 72 hours of gastric residence or effective release period is degraded or oxidized. In one embodiment, less than about 10% of the therapeutic agent retained in the system after about 96 hours of gastric residence or effective release period is degraded or oxidized. In one embodiment, less than about 10% of the therapeutic agent retained in the system after about 5 days of gastric residence or effective release period is degraded or oxidized. In another embodiment, less than about 10% of the therapeutic agent retained in the system after about 1 week of gastric residence or effective release period is degraded or oxidized. In another embodiment, less than about 10% of the therapeutic agent retained in the system after about 2 weeks of gastric residence or effective release period is degraded or oxidized. In another embodiment, less than about 10% of the therapeutic agent remaining in the system degrades or oxidizes after a gastric residence period or effective release period of about 3 weeks. In another embodiment, less than about 10% of the therapeutic agent remaining in the system degrades or oxidizes after a gastric residence period or effective release period of about 4 weeks. In another embodiment, less than about 10% of the therapeutic agent remaining in the system degrades or oxidizes after a gastric residence period or effective release period of about 1 month.
[0188] In one embodiment, less than about 5% of the therapeutic agent retained in the system after about 24 hours of gastric residence period or effective release period is degraded or oxidized. In one embodiment, less than about 5% of the therapeutic agent retained in the system after about 48 hours of gastric residence period or effective release period is degraded or oxidized. In one embodiment, less than about 5% of the therapeutic agent retained in the system after about 72 hours of gastric residence period or effective release period is degraded or oxidized. In one embodiment, less than about 5% of the therapeutic agent retained in the system after about 96 hours of gastric residence period or effective release period is degraded or oxidized. In one embodiment, less than about 5% of the therapeutic agent retained in the system after about 5 days of gastric residence period or effective release period is degraded or oxidized. In another embodiment, less than about 5% of the therapeutic agent retained in the system after about 1 week of gastric residence period or effective release period is degraded or oxidized. In another embodiment, less than about 5% of the therapeutic agent retained in the system after about 2 weeks of gastric residence period or effective release period is degraded or oxidized. In another embodiment, less than about 5% of the therapeutic agent remaining in the system degrades or oxidizes after a gastric residence period or effective release period of about 3 weeks. In another embodiment, less than about 5% of the therapeutic agent remaining in the system degrades or oxidizes after a gastric residence period or effective release period of about 4 weeks. In another embodiment, less than about 5% of the therapeutic agent remaining in the system degrades or oxidizes after a gastric residence period or effective release period of about 1 month.
[0189] The degradation and / or oxidation of the gastric resident system can be measured over time at a specific time in any of the following: 0.1 N HCl, simulated gastric fluid (fasted), simulated gastric fluid (fed), porcine stomach, dog stomach, or human stomach. For normalization and comparison of release rates, 0.1 N HCl is preferred.
[0190] Therapeutic agent particle size and grinding
[0191] Controlling the particle size used in the gastric retention system is important for both optimal release of the therapeutic agent and mechanical stability of the system. The particle size of the therapeutic agent affects the surface area of the active agent available for dissolution as gastric fluid permeates the carrier polymer-active agent component. Moreover, since the diameter of the "arms" (elongated members) of the system is relatively thin (e.g., 1 mm to 5 mm), the presence of therapeutic agent particles that exceed a few percent of the diameter of the arm will result in weaker arms, both before and after the active agent is eluted from the device, when voids are left in the space previously occupied by the active agent particles. This weakening of the arm is disadvantageous because it can cause the system to break prematurely and pass through the system before the desired residence period ends.
[0192] In one embodiment, the therapeutic agent particles for blending into the carrier polymer-active agent component are less than about 100 microns. In another embodiment, the therapeutic agent particles are less than about 75 microns in diameter. In another embodiment, the therapeutic agent particles are less than about 50 microns in diameter. In another embodiment, the therapeutic agent particles are less than about 40 microns in diameter. In another embodiment, the therapeutic agent particles are less than about 30 microns in diameter. In another embodiment, the therapeutic agent particles are less than about 25 microns in diameter. In another embodiment, the therapeutic agent particles are less than about 20 microns in diameter. In another embodiment, the therapeutic agent particles are less than about 10 microns in diameter. In another embodiment, the therapeutic agent particles are less than about 5 microns in diameter.
[0193] In one embodiment, 80% of the therapeutic agent particles for blending into the carrier polymer-active agent component have a diameter of less than about 100 microns. In another embodiment, at least about 80% of the therapeutic agent particles have a diameter of less than about 75 microns. In another embodiment, at least about 80% of the therapeutic agent particles have a diameter of less than about 50 microns. In another embodiment, at least about 80% of the therapeutic agent particles have a diameter of less than about 40 microns. In another embodiment, at least about 80% of the therapeutic agent particles have a diameter of less than about 30 microns. In another embodiment, at least about 80% of the therapeutic agent particles have a diameter of less than about 25 microns. In another embodiment, at least about 80% of the therapeutic agent particles have a diameter of less than about 20 microns. In another embodiment, at least about 80% of the therapeutic agent particles have a diameter of less than about 10 microns. In another embodiment, at least about 80% of the therapeutic agent particles have a diameter of less than about 5 microns.
[0194] In one embodiment, at least about 80% of the mass of therapeutic agent particles for blending into the carrier polymer-active agent component have a size of about 1 micron to about 100 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 1 micron to about 75 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 1 micron to about 50 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 1 micron to about 40 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 1 micron to about 30 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 1 micron to about 25 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 1 micron to about 20 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 1 micron to about 10 microns in diameter. In another embodiment, at least about 80% by mass of the therapeutic agent particles have a size of about 1 micron to about 5 microns in diameter.
[0195] In one embodiment, at least about 80% of the mass of therapeutic agent particles for blending into the carrier polymer-active agent component have a size of about 2 microns to about 100 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 2 microns to about 75 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 2 microns to about 50 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 2 microns to about 40 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 2 microns and - about 30 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 2 microns to about 25 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 2 microns to about 20 microns in diameter. In another embodiment, at least about 80% of the mass of therapeutic agent particles have a size of about 2 microns to about 10 microns in diameter. In another embodiment, at least about 80% by mass of the therapeutic agent particles have a size of about 2 microns to about 5 microns in diameter.
[0196] In one embodiment, at least about 80% of the mass of the therapeutic agent particles for blending into the carrier polymer-active agent component have a size of about 5 microns to about 100 microns in diameter. In another embodiment, at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 75 microns in diameter. In another embodiment, at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 50 microns in diameter. In another embodiment, at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 40 microns in diameter. In another embodiment, at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 30 microns in diameter. In another embodiment, at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 25 microns in diameter. In another embodiment, at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 20 microns in diameter. In another embodiment, at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 10 microns in diameter.
[0197] The particle size of the therapeutic agent can be easily adjusted by milling. There are several milling techniques that can reduce larger particles to smaller particles of the desired size. Fluid energy milling is a dry milling technique that uses inter-particle collisions to reduce the size of particles. One type of fluid energy mill, known as a jet mill, injects air into a cylindrical chamber in a manner to maximize collisions between particles of the therapeutic agent. Ball milling employs a rolling cylindrical chamber that rotates about its main axis. The therapeutic agent and the grinding material (e.g., steel balls made of chrome steel or CR-NI steel; ceramic balls, such as zirconium oxide; or plastic polyamide) collide, resulting in a reduction in the particle size of the active agent. Ball milling can be performed in a dry state or a liquid can be added to the cylinder in which the therapeutic agent and grinding material are not soluble in the liquid. More information about milling is described in the chapter entitled "Particle Size Reduction" by RW Lee et al., Water-Insoluble Drug Formulation, 2nd edition (Ron Liu, editor), Boca Raton, Florida: CRC Press, 2008; and in the chapter entitled "Granulation of Poorly Water-Soluble Drugs" by AW Brzeczko et al., Handbook of Pharmaceutical Granulation Technology, 3rd edition (Dilip M. Parikh, editor), Boca Raton, Florida: CRC Press / Taylor & Francis Group, 2010 (and other parts of the handbook). Fluid energy milling (i.e., jet milling) is a preferred milling method because it is more suitable for scale-up than other dry milling techniques (e.g., ball milling).
[0198] Grinding additives
[0199] In the grinding process, materials can be added to the therapeutic material to help obtain particles of the desired size and minimize aggregation during the treatment. Silicon dioxide (silicon dioxide, SiO2) is a preferred grinding additive because it is cheap, widely available and nontoxic. Other additives that can be used include silicon dioxide, calcium phosphate, powdered cellulose, colloidal silicon dioxide, hydrophobic colloidal silicon dioxide, magnesium oxide, magnesium silicate, magnesium trisilicate, talc, polyvinyl pyrrolidone, cellulose ether, polyethylene glycol, polyvinyl alcohol and surfactant. In particular, hydrophobic particles less than 5 microns are particularly prone to agglomeration, and hydrophilic additives are used when grinding these particles. Weight / weight ratios of about 0.1% to about 5% or about 0.1% to about 4%, about 0.1% to about 3%, about 0.1% to about 2%, about 0.1% to about 1%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, or about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4% or about 5% of a grinding additive such as silica can be used for fluid milling or ball milling.
[0200] Particle sorting
[0201] After grinding, the particles can be passed through a screen of appropriate size to obtain particles of the desired size. To obtain particles of the desired maximum size, the particles are passed through a screen having holes of the desired maximum size; particles that are too large will be retained on the screen, and particles that pass through the screen will be of the desired maximum size. To obtain particles of the desired minimum size, the particles are passed through a screen having holes of the desired minimum size; particles that pass through the screen are too small, and the desired particles will be retained on the screen.
[0202] System geometry
[0203] Gastric retention systems may be used in a variety of geometric configurations. Figure 1 , which takes the shape of a ring in uncompressed form. The gastric retention system 100 is composed of a carrier polymer-active agent component 102 comprising a coupling polymer and a coupling agent 104. The system can be folded or twisted into a spiral shape at the coupling polymer connection and packaged into a capsule in compressed form. Once the capsule dissolves in the stomach, the system 100 unfolds into a circular shape in uncompressed form, preventing passage through the pyloric sphincter. In this embodiment, the coupling polymer also serves as an elastomer. The carrier polymer-active agent component 102 and the coupling body 104 are not necessarily drawn to scale; the dimensions (e.g., length or diameter) of the "arm" 102 and the coupling body 104 may be different from the dimensions shown in the figure.
[0204] Another structure of star-shaped (star-shaped) is as in Figure 2. The gastric retention system 200 is constructed around a central elastomer 206 having radially projecting elongated members or "arms", one such arm being labeled 208 in the figure. The arms are formed by an outer carrier polymer-active agent component 202, an inner carrier polymer-active agent component 203, and a coupling polymer conjugate 204. Components 202, 204, and 203 together comprise the "arms" of this "star" structure. Elastomer 206 enables the system to be folded for packaging into a capsule. In addition, the components are not necessarily drawn to scale.
[0205] Figure 2A Another embodiment of the display system has three arms. Figure 2 or Figure 2A For a star-shaped structure, it will be appreciated that the arms may be substantially evenly spaced around the circumference of the connecting elastomer 206. Thus, for a star-shaped device having N arms, the arms would be spaced (360 / N) degrees apart. For example, Figure 2A The 3 arms of the device are spaced approximately 120 degrees apart. Figure 1 and Figure 2 , Figure 2A The components in the drawings are not necessarily drawn to scale.
[0206] Figure 3 show Figure 2 or Figure 2A The folded state of the system as it will be folded for packaging into a capsule (not shown), wherein the arm 308 comprises an outer carrier polymer-active agent component 302, an inner carrier polymer-active agent component 303, a conjugate 304 comprising a coupling polymer and an elastomer 306, wherein the elastomer has been removed from the Figure 2 or Figure 2A For clarity, Figure 3 Only two "arms" formed by the outer carrier polymer-active agent component 302, the conjugate 304, and the inner carrier polymer-active agent component 303 are shown; additional arms may exist, such as Figure 2 and Figure 2A As the capsule dissolves in the stomach, the system 300 expands into Figure 2 or Figure 2A The star-shaped structure shown prevents passage through the pyloric sphincter during the system's (residence period). The carrier polymer-active agent component, conjugate, and elastomer are not necessarily drawn to scale; the dimensions (e.g., length or diameter) of the carrier polymer-active agent component, conjugate, and elastomer may vary from those shown in the figures.
[0207] System Dimension
[0208] The system must be able to adopt a compact state having a size that enables the patient to swallow the system (or for introduction of the system into the stomach by alternative means, such as a feeding tube or gastrostomy tube). Typically, the system is held in a compacted state by a container (e.g., a capsule). Upon entering the stomach, the system is subsequently released from the container and adopts an uncompacted state, i.e., an expanded configuration having a size that prevents the system from passing through the pyloric sphincter, thereby allowing the system to remain in the stomach.
[0209] Therefore, the system should be able to be placed in a capsule of a standard size of the type commonly used in a pharmacy. The standard capsule sizes used in the United States are provided in Table 1 (see "Draft Guidance for Industry 0n Size. Shape and Other Physical Attributes of Generic Tablets and Capsules", at URL www.regulations.gov / #!documentDetail;D=FDA-2013-N-1434-0002). Since these are the outer dimensions of the capsule, and since the dimensions between capsule manufacturers vary slightly, the system should be able to adopt a configuration that is approximately 0.5-1 mm smaller than the outer diameter shown and 1-2 mm shorter than its length as shown in Table 1.
[0210] Table 1
[0211] Capsule size Outer diameter(mm) Length(mm) 000 9.9 26.1 00 8.5 23.3 0 7.6 21.7 1 6.9 19.4 2 6.3 18.0 3 5.8 15.9 4 5.3 14.3 5 4.9 11.1
[0212] The capsule can be made of materials well known in the art such as gelatin or hydroxypropylmethylcellulose. In one embodiment, the capsule is made of a material that dissolves in the gastric environment but does not dissolve in the oral or esophageal environment, which can prevent the system from being released prematurely before reaching the stomach.
[0213] In one embodiment, the system will be folded or compressed into a compact state to, for example, Figure 3 Once the capsule dissolves in the stomach, the system uses e.g. Figure 2 or Figure 2A The approach shown is for a configuration suitable for gastric retention. Preferred capsule sizes are 00 and 00el (a 00el-sized capsule has approximately the length of a 000 capsule and approximately the width of a 00 capsule), which then imposes constraints on the length and diameter of the folding system.
[0214] Once released from the container, the system adopts an uncompressed state having a size suitable for preventing the gastric retention system from passing through the pyloric sphincter. In one embodiment, the system has at least two vertical dimensions, each of which is at least 2 cm long; that is, the gastric retention system measures at least about 2 cm in length in at least two vertical directions. In another embodiment, when projected onto a plane, the perimeter of the system in the uncompressed state has two vertical dimensions, each of which is at least 2 cm long. The two vertical dimensions can independently have a length of about 2 cm to about 7 cm, about 2 cm to about 6 cm, about 2 cm to about 5 cm, about 2 cm to about 4 cm, about 2 cm to about 3 cm, about 3 cm to about 7 cm, about 3 cm to about 6 cm, about 3 cm to about 5 cm, about 3 cm to about 4 cm, about 4 cm to about 7 cm, about 4 cm to about 6 cm, about 4 cm to about 5 cm, or about 4 cm to about 4 cm. These dimensions prevent the gastric retention system from passing through the pyloric sphincter.
[0215] For star polymers having N arms (where N is greater than or equal to 3), the arms may have dimensions such that the system has at least two perpendicular dimensions, each with a length as described above. Figure 2A The system can be defined by triangles, such as Figure 2B As shown, where a triangle is described by the length of its base B and the height H, where B and H are perpendicular and contain the two length vertical dimensions as described above. These two vertical dimensions are selected as described above to promote retention of the gastric resident system.
[0216] The system is designed to eventually break apart in the stomach at the end of the desired residence time (residence period). Once the coupled polymer breaks apart, the remaining components of the system have a size that allows the system to pass through the pyloric sphincter, small intestine, and large intestine. Ultimately, the system is eliminated from the body by defecation or the system eventually dissolves completely in the small intestine and large intestine. Therefore, the coupled polymer is placed in the gastric resident system of the present invention so that at the end of the desired residence period, when the coupled polymer breaks apart or dissolves, the uncoupled components of the gastric resident system have a size suitable for passing through the pyloric sphincter and being eliminated from the digestive tract.
[0217] System polymer composition
[0218] The choice of various polymers used for the carrier polymer, coupling polymer and elastomer affects many properties of the system, such as the therapeutic agent elution rate (depending on the carrier polymer as well as other factors), the effective release period of the system, (residence period) (depending on the degradation of any polymer, mainly the coupling polymer), the uncoupling time of the system when it enters the intestine (mainly depending on the intestinal degradation rate of the coupling polymer as discussed herein) and the shelf life of the system in compressed form (mainly depending on the properties of the elastomer). Since the system will be administered to the gastrointestinal tract, all system components should be biocompatible with the gastrointestinal environment.
[0219] The rate at which the therapeutic agent is eluted from the carrier polymer-active agent component is affected by a variety of factors, including the composition and properties of the carrier polymer, which itself can be a mixture of several polymeric and non-polymeric components; the properties of the therapeutic agent, such as hydrophilicity / hydrophobicity, charge state, pKa, and hydrogen bonding ability; and the properties of the gastric environment. In the aqueous environment of the stomach, it is challenging to avoid burst release of the therapeutic agent (where burst release refers to a high initial delivery of the active drug component when the system is initially deployed in the stomach), especially for hydrophilic active agents, and to maintain sustained release of the active agent over a period of days to weeks.
[0220] The residence time of the system in the stomach is adjusted by the choice of coupling polymer. Despite the use of enteric coupling polymers, these systems will eventually break down in the stomach because the mechanical action and pH fluctuations of the stomach will eventually weaken the enteric coupling polymer. Coupling polymers that degrade in a time-dependent manner in the stomach can also be used to adjust the time until the system breaks up and thus adjust the residence time. Once the system breaks up, it enters the intestine and is then eliminated.
[0221] The elastomer used in the system affects the shelf life of the system. When the system is compressed, the elastomer is subjected to mechanical stress. In turn, the pressure causes polymer creep, which, if great enough, can prevent the system from returning to its uncompressed configuration when released from a capsule or other container; this in turn can cause the system to pass through the stomach prematurely. Polymer creep can also be temperature dependent, and thus the expected storage conditions of the system also need to be considered when selecting elastomers and other polymer components.
[0222] In some embodiments, system components and polymers should not swell or should have minimal swelling in the gastric environment. When in the gastric environment during residence, the components should swell no more than about 20%, no more than about 10%, or preferably no more than about 5%.
[0223] In some embodiments, system components and polymers can swell in the gastric environment.
[0224] Carrier polymers for carrier-polymer-active agent ingredients
[0225] The carrier polymer-active agent component comprises a therapeutic agent that is eluted from a gastric resident system in the gastric environment. The therapeutic agent is blended into a carrier polymer to form a carrier polymer-active agent mixture. The mixture can be formed into a desired shape for use as a carrier polymer-active agent component in a system, such as Figure 1 , Figure 2 and Figure 3 The rod-shaped (cylindrical member) of the system shown in FIG. Exemplary carrier polymers suitable for use in the present invention include, but are not limited to, hydrophilic cellulose derivatives (e.g., hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose), cellulose acetate phthalate, poly(vinyl pyrrolidone), ethylene / vinyl alcohol copolymers, poly(vinyl alcohol), carboxyvinyl polymers (carbomers), Acidic carboxyl polymers, polycarbophil, poly(ethylene oxide) (Polyox WSR), polysaccharides and their derivatives, polyalkylene oxides, polyethylene glycol, chitosan, alginate, pectin, gum arabic, tragacanth, guar gum, locust bean gum, vinyl pyrrolidone vinyl acetate copolymer, dextran, natural gum, agar, agarose, sodium alginate, carrageenan, fucoidan, furculan, laminarin, hypnea, eucheuma, gum arabic, gum ghatti, gum karaya, arbinoglactan, pullulan, gelatin, gellan, hyaluronic acid, pullulan, scleroglucan, xanthan gum, xyloglucan, maleic anhydride copolymer, ethylene maleic anhydride copolymer, poly(hydroxyethyl methacrylate), ammonium methacrylate copolymer (e.g., Eudragit RL or Eudragit RS), poly(ethyl acrylate-methyl methacrylate) (Eudragit NE), Eudragit E (cationic copolymer esters based on dimethylaminoethyl methacrylate and neutral methacrylate), poly(acrylic acid), poly(methacrylic acid), polylactones such as poly(caprolactone), polyanhydrides such as poly[bis-(p-carboxyphenoxy)-propionic anhydride], poly(terephthalic anhydride), polypeptides such as polylysine, polyglutamic acid, copolymers of poly(orthoesters) such as DETOSU with diols such as hexanediol, decanediol, cyclohexanedimethanol, ethylene glycol, polyethylene glycol, described in the U.S., incorporated herein by reference and described in the U.S. Poly(ortho)esters disclosed in Patent 4,304,767, starch, especially pregelatinized starch and starch-based polymers, carbomer, maltodextrin, amylomaltodextrins, dextran, poly(2-ethyl-2-oxazoline), poly(ethyleneimine), polyurethane, poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid) (PLGA), polyhydroxyalkanoates, polyhydroxybutyrates and copolymers, mixtures, blends and combinations thereof. Polycaprolactone (PCL) is a preferred carrier polymer.
[0226] Release enhancers and solubilizers for gastric resident systems
[0227] Other excipients may be added to the carrier polymer to modulate the release of the therapeutic agent. Such excipients may be added in an amount of about 1% to about 50%, about 1% to about 40%, about 1% to about 30%, about 1% to about 25%, about 1% to about 20%, about 1% to about 15%, about 5% to about 10%, about 5% or about 10% of the carrier polymer-active agent component. Examples of such excipients include Poloxamer 407 (available as Kolliphor P407, Sigma Cat#62035); Pluronic P407; Eudragit EPO (available from Evonik); Hydroxypropyl methylcellulose (available from Sigma, Cat#H3785); Kolliphor RH40 (available from Sigma, Cat#07076), polyvinyl caprolactam, polyvinyl acetate, polyethylene glycol, Aquaprenes such as Aquaprene 8020 (polydioxanone-polyethylene glycol polymer) and Soluplus (available from BASF; a copolymer of polyvinyl caprolactam, polyvinyl acetate and polyethylene glycol).
[0228] Excipients that function as solubilizers may be added. That is, solubilizer excipients aid in the dissolution of the therapeutic agent when the aqueous solution contacts the gastric resident system. Such solubilizers may be added in an amount of 1% to about 30%, about 1% to about 25%, about 5% to about 25%, about 5% to about 20%, or about 5% to about 15%.
[0229] Excipients may be added to promote release of the therapeutic agent from the carrier polymer. Examples include pore-forming materials that dissolve in a time-dependent manner and provide a pathway for aqueous solution to penetrate the carrier polymer-therapeutic agent matrix; and wicking materials that draw water into the carrier polymer-therapeutic agent matrix. Such release enhancers may be added in an amount of about 1% to about 30%, about 1% to about 25%, about 1% to about 20%, about 1% to about 15%, about 5% to about 10%, about 5%, or about 10%. For materials that are particularly difficult to release from the carrier polymer, a larger amount of release enhancer may be added, for example, about 1% to about 50% or about 1% to about 40%.
[0230] Dispersants and stabilizers (preservatives) are also useful and are discussed elsewhere herein.
[0231] Solubilizing excipients, release enhancing excipients, dispersing agents and stabilizers / preservatives suitable for use in the present invention are listed in Table 2.
[0232] Table 2
[0233]
[0234]
[0235] Method for preparing carrier polymer-active agent component
[0236] The blending temperature for incorporating the therapeutic agent into the polymer matrix is typically between about 80°C and about 120°C, although higher or lower temperatures may be used for polymers that blend best at temperatures outside this range. When free crystals of the therapeutic agent are used, a low blending temperature of about 80°C to about 100°C may be used so that the active agent particles or crystals melt. In some cases, melting of the therapeutic agent crystals during blending is acceptable when it helps disperse the active agent in the matrix and when the active agent does not recrystallize into an undesirable form.
[0237] A blending temperature below the degradation temperature of the therapeutic agent should be used so that less than about 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, or 0.005% of the drug is degraded during the blending or manufacturing process.
[0238] Hot melt extrusion can be used to prepare the carrier polymer-active agent component. A single shaft or preferably a dual shaft system can be used. As noted, in some embodiments, a carrier polymer should be used that melts at a temperature that will not melt the therapeutic agent particles blended into the polymer, because melting the therapeutic agent particles can greatly change the size distribution characteristics of the particles.
[0239] Plasticizers, such as triacetin, triethyl citrate, tributyl citrate, or poloxamer, may be added to the blend to reduce the temperature required for hot melt extrusion, thereby reducing any degradation of the therapeutic agent that may occur during hot melt extrusion. For extrudable materials, the melt viscosity should be from about 100 Pascal-seconds (Pa-s) to about 100,000 Pa-s, such as from about 100 Pa-s to about 1,000 Pa-s, from about 100 Pa-s to about 10,000 Pa-s, from about 100 Pa-s to about 50,000 Pa-s, from about 1,000 Pa-s to about 10,000 Pa-s, from about 1,000 Pa-s to about 50,000 Pa-s. -s, about 10,000 Pa-s to about 50,000 Pa-s, about 1,000 Pa-s to about 100,000 Pa-s or about 50,000 Pa-s to about 100,000 Pa-s; in some embodiments, the extrusion is carried out at a shear rate of about 10 / s to about 1,000 / s and a temperature of about 200°C or less, e.g., 150°C or less, 120°C or less, or below the melting temperature of the therapeutic agent.
[0240] Melting and melt casting can also be used to prepare the carrier polymer-active agent composition. The carrier polymer and the therapeutic agent and any other desired ingredients can be mixed with each other. The carrier polymer is melted (further at a temperature that does not melt the therapeutic agent particles) and the melt is mixed so that the active agent particles are evenly dispersed in the melt, poured into a mold and allowed to cool.
[0241] Solvent casting can also be used to prepare carrier polymer-active agent ingredients. The polymer is dissolved in a solvent and the therapeutic agent particles are added. A solvent that does not dissolve the active agent particles should be used to avoid changing the size characteristics of the particles. The solvent-carrier polymer-active agent particle mixture is then mixed to evenly distribute the particles, poured into a mold and the solvent evaporated.
[0242] Coupling polymer
[0243] Coupling polymers are used to connect one or more carrier polymer-active agent components with one or more carrier polymer-active agent components, connect one or more carrier polymer-active agent components with one or more elastomer components, or connect one or more elastomer components with one or more elastomer components. In some embodiments, enteric polymers are used as coupling polymers. In some embodiments, as coupling polymers, time-dependent polymers with pH tolerance are used, i.e., polymers with lower sensitivity to pH changes than enteric polymers. In some embodiments, enteric polymers and time-dependent polymers with lower sensitivity to changes in pH than enteric polymers are used as coupling polymers. Enteric polymers are relatively insoluble under acidic conditions, such as those encountered in the stomach, but soluble under weaker acidic to alkaline conditions encountered in the small intestine. Enteric polymers that dissolve at about pH 5 or above can be used as coupling polymers because the pH of the duodenum, the initial part of the small intestine, is in the range of about 5.4 to 6.1. If the gastric resident system passes the pyloric valve intact, the enteric coupling polymer will dissolve, and the components connected by the coupling polymer will decompose, thereby allowing the resident system to pass through the small intestine and the large intestine. If for any reason during treatment the gastric resident system must be rapidly removed, the patient may drink a mildly alkaline aqueous solution (eg, a bicarbonate solution) in order to induce immediate uncoupling of the gastric resident system.
[0244] By "a time-dependent polymer that is pH-resistant" (or equivalently, a "pH-resistant time-dependent polymer") is meant that under conditions in which the enteric polymer can degrade to the point where it no longer connects components to each other, the time-dependent polymer still has sufficient mechanical strength to connect components to each other. In some embodiments, the time-dependent polymer retains substantially the same ability to connect as after exposure to a solution of about pH 2 to about pH 3, i.e., about 100% of its connection strength, when exposed to a solution of about pH 7 to about pH 8, wherein the exposure time is about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, after exposure to a solution of about pH 7 to about pH 8, the time-dependent polymer retains at least about 90% of its connection strength as after exposure to a solution of about pH 2 to about pH 3, wherein the exposure time is about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, after exposure to a solution of about pH 7 to about pH 8, the time-dependent polymer retains at least about 75% of its connection strength as it has after exposure to a solution of about pH 2 to about pH 3, wherein the exposure time is about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, after exposure to a solution of about pH 7 to about pH 8, the time-dependent polymer retains at least about 60% of its connection strength as it has after exposure to a solution of about pH 2 to about pH 3, wherein the exposure time is about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, after exposure to a solution of about pH 7 to about pH 8, the time-dependent polymer retains at least about 50% of its connection strength as it has after exposure to a solution of about pH 2 to about pH 3, wherein the exposure time is about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, the time-dependent polymer retains at least about 25% of its connection strength after exposure to a solution of about pH 2 to about pH 3 after exposure to a solution of about pH 7 to about pH 8, wherein the exposure time is about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, the time-dependent polymer resists breakage after exposure to a solution of about pH 7 to about pH 8 at a bending force of about 0.2 Newtons (N), about 0.3N, about 0.4N, about 0.5N, about 0.75N, about 1N, about 1.5N, about 2N, about 2.5N, about 3N, about 4N, or about 5N, wherein the exposure time is about 1 hour, about 1 day, about 3 days, or about 1 week. The connection strength can be determined by any relevant test for testing coupling ability, such as the 4-point bend test (ASTM D790) described in Example 18.
[0245] Exemplary coupling polymers include, but are not limited to, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinyl acetate phthalate, polyvinyl acetate butyrate, vinyl acetate-maleic anhydride copolymer, styrene-maleic acid monoester copolymer, methyl methacrylate copolymer, methyl acrylate-methacrylic acid copolymer, methacrylate-methacrylic acid-octyl acrylate copolymer, and copolymers, mixtures, blends, and combinations thereof. Table 3 lists some enteric polymers that can be used in the present invention and their dissolution pH values. (See Mukherji, Gour and Clive G Wilson, "Enteric Coating for Colonic Delivery," Chapter 18 of Modified-Release Drug Delivery Technology (ed. Michael J. Rathbone, Jonathan Hadgraft, Michael S. Roberts), Drugs and the Pharmaceutical Sciences Volume 126, New York: Marcel Dekker, 2002). Preferably, an enteric polymer that dissolves at a pH of no more than about 5 or about 5.5 is used. Poly(methacrylic acid-co-ethyl acrylate) (sold under the trade name EUDRAGIT L 100-55; EUDRAGIT is a GmbH, Darmstadt, Germany) is a preferred enteric polymer. Cellulose acetate phthalate, cellulose acetate succinate and hydroxypropylmethylcellulose phthalate are also suitable enteric polymers.
[0246] In one embodiment, the enteric polymer for a gastric resident system dissolves at a pH above about 4. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH above about 5. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH above about 6. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH above about 7. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH above about 7.5. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH of about 4 to about 5. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH of about 4 to about 6. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH of about 4 to about 7. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH of about 4 to about 7.5. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH of about 5 to about 6. In another embodiment, the enteric polymer for a gastric resident system dissolves at a pH of about 5 to about 7. In another embodiment, the enteric polymer for use in a gastric retention system dissolves at a pH of about 5 to about 7.5. In another embodiment, the enteric polymer for use in a gastric retention system dissolves at a pH of about 6 to about 7. In another embodiment, the enteric polymer for use in a gastric retention system dissolves at a pH of about 6 to about 7.
[0247] Table 3
[0248] polymer Dissolution pH Cellulose acetate phthalate 6.0-6.4 Hydroxypropyl Methylcellulose Phthalate 50 4.8 Hydroxypropyl Methylcellulose Phthalate 55 5.2 Polyvinyl acetate phthalate 5.0 Methacrylic acid-methyl methacrylate copolymer (1:1) 6.0 Methacrylic acid-methyl methacrylate copolymer (2:1) 6.5-7.5 Methacrylic acid-ethyl acrylate copolymer (2:1) 5.5 shellac 7.0 Hydroxypropyl methylcellulose acetate succinate 7.0 Poly(methyl vinyl ether / maleic acid) monoethyl ester 4.5-5.0 Poly(methyl vinyl ether / maleic acid) n-butyl ester 5.4
[0249] Another preferred polymer for use as a coupling polymer is a polymer that degrades in a time-dependent manner in the gastric environment. The liquid plasticizer triacetin is released from the polymer formulation in a time-dependent manner over 7 days in simulated gastric fluid, while Plastoid B maintains its strength over 7 days in simulated gastric fluid. Therefore, a polymer that degrades in a time-dependent manner can be easily prepared by mixing Plastoid B and triacetin; the degradation time of the Plastoid B-triacetin mixture can be extended by increasing the amount of Plastoid B used in the mixture (i.e., using less triacetin in the mixture), while the degradation time can be reduced by reducing the amount of Plastoid B used in the mixture (i.e., using more triacetin in the mixture).
[0250] In some embodiments, carrier polymer-active agent composition is the elongated member of the fragments connected by enteric polymer.In some embodiments, carrier polymer-active agent composition is attached to the elastomer component of system by enteric polymer.In any of these embodiments, when enteric polymer is used for segment-segment connection and elongated member is connected to elastic component, the enteric polymer for segment-segment connection can be the enteric polymer identical with the enteric polymer for connecting elongated member to elastic component, or the enteric polymer for segment-segment connection can be the enteric polymer different from the enteric polymer for connecting elongated member ester elastic component by application.The enteric polymer for segment-segment connection can be all the same enteric polymer, or can be all different enteric polymers, or some enteric polymers in segment-segment connection can be the same, and some enteric polymers in segment-segment connection can be different.That is, the enteric polymer for each segment-segment connection and the enteric polymer for connecting elongated member to elastic component can be selected independently.
[0251] Elastomer
[0252] Elastomers (also called elastic polymers or stretch polymers) can be used as coupling polymers, and the gastric resident system is compressed into a container or capsule suitable for administration to the stomach by swallowing the compressed system, for example, by folding or compression. When the capsule dissolves in the stomach, the gastric resident system expands into a shape that prevents the system from passing through the patient's pyloric sphincter to reach the required residence time (residence period) of the system. Therefore, the elastomer must be able to be stored in a compressed configuration in the shape of a capsule to maintain a reasonable shelf life, and can expand to its original shape or approximate its original shape when released from the capsule. In one embodiment, the elastomer is, for example, those listed in Table 3. In another embodiment, the coupling polymer used in the system is also an elastomer. Figure 1 An example of a system is shown where the coupled polymer is also an elastomer, ie the rings are folded at the joints formed by the coupled polymers for packaging into, for example, a capsule.
[0253] In one embodiment, both the coupling polymer and the elastomer are enteric polymers that can more completely break up the system into the carrier polymer-active agent tablet if the system enters the intestine, or if the patient drinks a mildly alkaline solution to induce passage of the system.
[0254] Examples of elastomers that can be used include urethane-crosslinked polycaprolactone (see Example 10, Part B), poly(acryloyl 6-aminocaproic acid) (PA6ACA), poly(methacrylic acid-co-ethyl acrylate) (EUDRAGIT L100-55), and poly(acryloyl 6-aminocaproic acid)
[0255] A mixture of (PA6ACA) and poly(methacrylic acid-co-ethyl acrylate) (EUDRAGIT L 100-55) (see Example 11).
[0256] Flexible coupling polymers, i.e., elastomeric coupling polymers or elastomers, are used as the central polymer in the star or star-shaped design of the gastric retention system. A particularly preferred elastomer for use as the central elastomer of the star or star-shaped configuration is silicone rubber. Liquid silicone rubber (LSR) can be easily molded and cured into a desired shape. The Dow Corning QP-1 series, which contains cross-linked dimethyl and methyl-vinyl siloxane copolymers and reinforced silica, is an example of this type of silicone rubber polymer (see, e.g., Web site www.dowcorning.com / DataFiles / 090276fe8018ed07.pd f). the elongated member comprising the carrier polymer-active agent component segment may then be attached to the central silicone rubber elastomer; Figure 2C One embodiment of this configuration of the gastric retention system of the present invention is provided.Another elastomer that can be used as the central elastomer in the star-shaped design is a cross-linked polycaprolactone, such as the elastomer prepared in Example 10B.
[0257] System manufacturing / assembly
[0258] Embodiments of the gastric retention system of star or star-shaped design can be assembled by preparing the carrier polymer-active agent composition into "arms" in the shape of elongated members, wherein the arms are connected to the central elastic body. When the arms are prepared in the shape of cylinders, they contain a flat proximal end (one base of the cylinder, the first base), a distal end (the other base of the cylinder, the second base) and a curved outer surface enclosing the volume of the cylinder therebetween. The arms can also be made into triangular prisms, rectangular prisms or other shapes.
[0259] The central elastic body of the gastric retention system can be made into the shape of an "asterisk" (or star), e.g. Figure 2C Element 252 of one embodiment of a gastric retention system 250 is shown. Figure 2C In the embodiment of the present invention, central elastomer 252 is in the shape of an asterisk; the branches of the asterisk are connected to carrier polymer-active agent segment 254; segment 254 is connected to carrier polymer-active agent segment 256 via intestinal connector 257; segment 256 is connected to carrier polymer-active agent segment 258 via intestinal connector 259; and the assembly of 254-257-256-259-258 forms one arm of system 250. The elongated member (arm) is composed of a carrier polymer-active agent component, such as Figure 2C As shown in 254-257-256-259-258, the ends of each branch of the asterisk can then be connected by melt bonding, adhesives, solvent welding or other methods.
[0260] Example 10 describes the preparation of the carrier polymer-active agent ingredient "arms" (Part A) and the core elastomer (Part B).
[0261] The gastric retention system of the present invention can be manufactured by the following method, which comprises:
[0262] A: Formation of a flexible coupled polymeric component. In some embodiments, the flexible coupled polymeric component is star-shaped with a plurality of at least 3 branches (for making a star-shaped configuration).
[0263] B: Forming a plurality of at least 3 carrier polymer-active agent components as an elongated member comprising a proximal end and a distal end.
[0264] Note that forming step A and forming step B may be performed in any order or simultaneously.
[0265] C: Attaching the elongated member to the flexible coupling polymer component. When the elongated member is connected and in the absence of any external restraining force, the resulting assembly is a gastric retention system in its uncompressed form. The elongated member is connected to the flexible coupling polymer component so that the gastric retention system in its uncompressed form has at least two perpendicular dimensions, each of which is at least two centimeters, i.e., the gastric retention system measures at least about 2 cm in length in at least two perpendicular directions; or the perimeter of the gastric retention system in its uncompressed state when projected onto a plane has two perpendicular dimensions, each of which is at least 2 cm long. (More possible values for the length of the perpendicular dimensions are provided in the section describing the dimensions of the system.)
[0266] In order to place the gastric resident system into a capsule or another container for administration to a patient, another step may be performed comprising:
[0267] D: Compress the gastric resident system and insert the system into a container, such as a capsule, suitable for oral administration or administration through a gastric or feeding tube.
[0268] Step A, the formation of the flexible coupled polymer can be carried out by any method suitable for preparing a shaped polymer, for example by injection molding, gravity molding, compression molding, extrusion, hot melt extrusion or three-dimensional printing. The flexible coupled polymer can be formed into a ring, a donut, a sphere, an oblate ellipse (also known as an oblate spheroid, an ellipse or an oblate) or any other shape having at least one axis of rotational symmetry, such as a cube or a cuboid. Optionally, the shape of the flexible coupled polymer can have branches, protrusions or protrusions, in which the carrier polymer-active agent component as an elongated member can be connected. Optionally, the shape of the flexible coupled polymer can have a recess, a concave surface, a pit or a recess, in which the carrier polymer-active agent component as an elongated member can be connected.
[0269] Step B, a plurality of at least 3 carrier polymer-active agent components can also be formed by any method for preparing a shaped polymer, such as injection molding, gravity molding, compression molding, extrusion, hot melt extrusion or three-dimensional printing using a carrier polymer-active agent mixture. Prior to formation, the therapeutic agent is ground as described herein and then mixed with an appropriate carrier polymer and any desired release enhancer, solubilizer, dispersant, stabilizer and other components described herein. The elongated member can be formed in the shape of a solid rectangular prism, a solid triangular prism or a solid cylinder. In addition, as described herein, the elongated member can be formed by two, three or more sections, which are coupled by a coupling polymer, coupled by an enteric polymer, a time-dependent linker or by an enteric polymer and a time-dependent linker. The elongated members can be formed by joining the segments together using a butt joint (i.e., the end of one segment can be joined to the end of another segment by bonding, such as by adhering a film of enteric polymer between the two ends to adhere the segments together), or can be formed by melting the segments together or by joining the segments together using a joint joint (i.e., a thin film of enteric polymer can be wrapped around the ends of the two segments to join them together).
[0270] Step C, connecting the carrier polymer-active agent component elongated member to the flexible coupling polymer component can be performed by various methods, such as melt bonding, adhesives, solvent welding or any other method suitable for connecting polymers. If the flexible coupling polymer has branches, a clasp joint can be used to attach the carrier polymer-active agent component elongated member to the flexible coupling polymer component. The carrier polymer-active agent component elongated member attached to the flexible coupling polymer component can be formed using an enteric polymer. Once the carrier polymer-active agent component is attached to the flexible coupling polymer component, the gastric retention system will be in an uncompressed form without any external restraining force.
[0271] In a star-shaped configuration, melt bonding or heat fusion welding of the elongated member to the flexible coupling polymer can be achieved by providing small portions of carrier polymer (without therapeutic agent or excipient) at different locations on the central elastomer. Local heating of the ends of the elongated member to be connected to the flexible coupling polymer and the ends of the corresponding small portions of carrier polymer on the central elastomer, followed by connecting the elongated member to the small portions of carrier polymer and cooling the system provides a connection between the elongated member and the central elastomer.
[0272] As described in Example 10 below, a central elastomer having a small portion of carrier polymer can be prepared as follows:
[0273] providing an elongated member comprising a carrier polymer, neat or of a desired composition;
[0274] Placing the elongated member in a mold for preparing the central elastomer and adding a prepolymer or precursor component of the central elastomer to the mold, wherein the elongated member is in place in a form such that one end of the elongated member is bonded to the central elastomer after the prepolymer or precursor component is cured; in one embodiment, the mold is star-shaped having three, four, five, six, seven or eight arms, preferably three, four, five or six arms;
[0275] curing a prepolymer or precursor component of the central elastomer such that one end of the elongated member is bonded to the central elastomer;
[0276] The elongate members are cut to retain portions of the elongate members that are bonded sufficiently to be thermally welded to the central elastomer to a different elongate member comprising a carrier polymer and a therapeutic agent.
[0277] The different elongated members comprising the carrier polymer, therapeutic agent and any desired excipients and / or dispersants may then be thermally welded or melt joined to the central elastomer by using small portions of the elongated members comprising the carrier polymer that remain attached to the central elastomer after cutting.
[0278] In other embodiments, the portion of the elongated member bonded to the central elastomeric body is then thermally welded to the elongated member comprising the carrier polymer and the therapeutic agent to form an elongated thermally welded structure. Thermal welding can be performed at any temperature that provides a stable weld. In some embodiments, when the carrier polymer is polycaprolactone (e.g., M of polycaprolactone), the elongated thermally welded structure can be thermally welded to the elongated member. n When the thermal welding temperature is about 80 kDa, the thermal welding can be performed at about 90° C., about 93° C., about 95° C., about 100° C., about 110° C., about 120° C., about 130° C., about 140° C., about 150° C., about 160° C., about 170° C., about 180° C., about 90° C. to about 180° C., about 90° C. to about 170° C., about 140° C. to about 180° C., about 150° C. to about 170° C., or about 155° C. to about 165° C. After thermal welding, the thermally welded structure can be exposed to a room temperature environment for about 24 hours or a cooling environment of about 2° C. to about 12° C., about 5° C. to about 15° C., about 5° C. to about 10° C., or about 8° C. for about 24 hours.
[0279] The strength of the thermal weld formed between a carrier polymer not containing a therapeutic agent and an elongated member containing a carrier polymer, a therapeutic agent, and any desired excipients and / or dispersants was tested to ensure that the weld would not break under the compressive forces in the stomach. Example 34 describes a thermal weld. In this example, thermal welding at 160°C followed by cooling of the welded structure at 8°C for 24 hours provided a weld that resisted a bending force of about 100N without any measured weld breaking. When testing the strength of thermal welds between different polymer blends, the final assembled system can be tested for breaking strength. Alternatively, an elongated member containing a carrier polymer and not containing a therapeutic agent and an elongated member containing a carrier polymer, a therapeutic agent, and any desired excipients and / or dispersants can be welded together for ease of handling; omitting the central polymer test piece for such allows a single connected elongated member to be used for bending testing. After the heat welding and after the welded structure has cooled (at room temperature or reduced temperature, such as about 8° C.) for about 24 hours, a four-point bend test (such as ASTM D790 (used in Example 18)) can be used to evaluate the strength of the arm. In some embodiments, the heat weld can resist a bending force of about 10N without breaking. In some embodiments, the heat weld can resist a bending force of about 15N without breaking. In some embodiments, the heat weld can resist a bending force of about 20N without breaking. In some embodiments, the heat weld can resist a bending force of about 25N without breaking. In some embodiments, the heat weld can resist a bending force of about 30N without breaking. In some embodiments, the heat weld can resist a bending force of about 40N without breaking. In some embodiments, the heat weld can resist a bending force of about 50N without breaking. In some embodiments, the heat weld can resist a bending force of about 60N without breaking. In some embodiments, the heat weld can resist a bending force of about 70N without breaking. In some embodiments, the heat weld can resist a bending force of about 80N without breaking. In some embodiments, the thermal weld can resist a bending force of about 90 N without breaking. In some embodiments, the thermal weld can resist a bending force of about 100 N without breaking.
[0280] Step D, compressing the gastric resident system and inserting the system into a container, can be performed manually or by mechanical means, by compacting, folding or compressing the gastric resident system into its compacted configuration and inserting the system into an appropriately sized capsule or other container.
[0281] Determination of release rate
[0282] The properties of the solid state of the therapeutic agent blended with the carrier polymer also affect the release rate of the therapeutic agent from the gastric resident system. As described in Example 3 below, the release rate of the therapeutic agent from the system can be measured in vitro by placing the system in simulated gastric fluid (simulated gastric fluid or SGF). The release rate of the therapeutic agent from the system can be measured in vivo by administering the system to experimental animals, as described in Example 8A below; or by administering the system to human patients for in vivo determination, as described in Example 8B below.
[0283] The release rate of the therapeutic agent or a pharmaceutically acceptable salt thereof from the gastric retention system can be determined in a variety of environments, including 0.1N HCl aqueous solution, simulated gastric fluid, fasted simulated gastric fluid, fed simulated gastric fluid, animal stomach, pig stomach, dog stomach and human stomach.
[0284] Pharmacokinetics of gastric delivery of therapeutic agents via gastric resident systems
[0285] The gastric retention system of the present invention provides high bioavailability of the therapeutic agent that is higher than the bioavailability of conventional oral formulations of the therapeutic agent, as measured by AUC inf The system also provides for maintaining substantially constant plasma levels of the therapeutic agent.
[0286] The relative bioavailability of two different formulations, formulation A and formulation B, was calculated. REL Defined as:
[0287] F REL =100x(AUC A x dose B ) / (AUC B x dose A )
[0288] Where AUC A is the area under the curve of formulation A, AUC B is the area under the curve of preparation B, dose A is the dose of preparation A used, and the dose B is the dose of formulation B used. The area under the plasma concentration versus time curve (AUC) of the therapeutic agent is usually measured at the same time (t) after administration of each formulation to provide the relative bioavailability of the formulations at the same time point. inf It refers to the AUC measured or calculated over "infinite" time, that is, the time period from the time of initial administration to the end at which the plasma concentration of the therapeutic agent has dropped to negligible amounts.
[0289] In one embodiment, the substantially constant plasma levels provided by the gastric retention system of the invention can be obtained from daily administration of a conventional oral formulation (i.e., C of the therapeutic agent administered daily in the form of an immediate release formulation). min ) to a peak plasma level of the therapeutic agent administered daily in the form of a conventional oral formulation or below the peak plasma level (i.e., a C of the therapeutic agent administered daily in the form of an immediate release formulation). max In another embodiment, the substantially constant plasma level provided by the gastric retention system of the present invention may be the peak plasma level of the therapeutic agent when administered daily in the form of a conventional oral formulation (i.e., the C of the therapeutic agent administered daily in the form of an immediate release formulation). max ). The substantially constant plasma level provided by the gastric retention system of the present invention can be the average plasma level of the therapeutic agent when administered daily in the form of a conventional oral formulation (i.e., the C of the therapeutic agent administered daily in the form of an immediate release formulation). ave ) of about 75% to about 125% or about 50% to about 120% C ave The substantially constant plasma level provided by the gastric retention system of the present invention may be at the trough level of the plasma level of the therapeutic agent when administered daily in the form of a conventional oral formulation (i.e., the C of the therapeutic agent administered daily in the form of an immediate release formulation). min ) or above the trough level, such as about 100% to about 150% of C min or about 50% - about 150% C min .
[0290] The gastric retention system of the present invention can provide a bioavailability of the therapeutic agent released from the system that is at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the bioavailability provided by an immediate release form containing the same amount of the therapeutic agent. As shown above, according to the area under the plasma concentration-time curve (AUC i nf) Determine bioavailability.
[0291] Therapeutic agents for use in gastric resident systems
[0292] Therapeutic agents that can be administered through the gastrointestinal tract can be used in the gastric resident system of the present invention. Therapeutic agents include, but are not limited to, drugs, prodrugs, biologics, and any other substance that may be administered to produce a beneficial effect on a disease or injury. Therapeutic agents that can be used in the gastric resident system of the present invention include statins, such as rosuvastatin; nonsteroidal anti-inflammatory drugs (NSAIDs), such as meloxicam; selective serotonin reuptake inhibitors (SSRIs), such as escitalopram and citalopram; blood thinners, such as clopidogrel; steroids, such as prednisone; antipsychotics, such as aripiprazole and risperidone; analgesics, such as buprenorphine; opioid antagonists, such as naloxone; anti-asthmatics, such as montelukast; anti-dementia drugs, such as memantine; cardiac glycosides, such as digoxin; alpha blockers, such as tamsulosin; cholesterol absorption inhibitors, such as Ezetimibe; antigout therapeutic agents, such as colchicine; antihistamines, such as loratadine and cetirizine, opioids, such as loperamide; proton pump inhibitors, such as omeprazole; antiviral drugs, such as entecavir; antibiotics, such as doxycycline, ciprofloxacin and azithromycin; antimalarials; levothyroxine; substance abuse therapeutic agents, such as methadone and varenicline; contraceptives; stimulants, such as caffeine; and nutrients, such as folic acid, calcium, iodine, iron, zinc, thiamine, niacin, vitamin C, vitamin D, biotin, plant extracts, plant hormones and other vitamins or minerals. Biological agents that can be used as therapeutic agents in the gastric resident system of the present invention include proteins, polypeptides, polynucleotides and hormones. Exemplary classes of therapeutic agents include, but are not limited to, analgesics; anti-analgesics; anti-inflammatory drugs; antipyretics; antidepressants; anti-epileptic drugs; antipsychotics; neuroprotectants; antiproliferative drugs, such as anticancer drugs; antihistamines; antimigraine drugs; hormones; prostaglandins; antimicrobials, such as antibiotics, antifungals, antivirals, and antiparasitics; antimuscarinics; anxiolytics; antibacterials; immunosuppressants; sedatives; hypnotics; antipsychotics; bronchodilators; antiasthmatics; cardiovascular drugs; anesthetics; anticoagulants; enzyme inhibitors; steroids; steroids or nonsteroidal anti-inflammatory drugs; corticosteroids; dopaminergic drugs; electrolytes; gastrointestinal drugs; muscle relaxants; nutrients; vitamins; parasympathomimetics; stimulants; anorexia drugs; antinarcolepsy drugs; antimalarials, such as quinine, lumefantrine, chloroquine, amodiaquine, pyrimethamine, proguanil, chlorproguanil-dapsone, sulfonamides (such as sulfadoxine and sulfamethoxazole), mefloquine, atovaquone, primaquine, halofantrine, doxycycline, clindamycin, artemisinin and artemisinin derivatives (such as artemether, dihydroartemisinin, artemether and artesunate). The term "therapeutic agent" includes salts, solvates, polymorphs and cocrystals of the above substances. In certain embodiments, the therapeutic agent is selected from cetirizine, rosuvastatin, escitalopram, citalopram, risperidone, olanzapine, donezepil and ivermectin.In another embodiment, the therapeutic agent is a therapeutic agent for treating a neuropsychiatric disorder, such as a neuroleptic or anti-dementia drug, such as memantine.
[0293] In some embodiments of the invention disclosed herein, the treatment may not include an adamantane. In some embodiments of the invention disclosed herein, the treatment may not include any one or more of the following: memantine; amantadine; adapromine; nitromemantine; rimantadine; bromantane; neramexane; or tromantine; or a pharmaceutically acceptable salt of memantine, amantadine, adapromine, nitromemantine, rimantadine, bromantane, or tromantine. In some embodiments of the invention disclosed herein, the treatment may not include memantine. In some embodiments of the invention disclosed herein, the treatment may not include a salt of memantine or a pharmaceutically acceptable salt of memantine.
[0294] Crystalline and amorphous forms of therapeutic agents
[0295] The therapeutic agent can be used in the gastric retention system of the present invention in any suitable crystalline or amorphous form or in both crystalline and amorphous forms. That is, the therapeutic agent or drug particles contained in the gastric retention system can be used in crystalline form, amorphous form, or a mixture of crystalline form (single crystalline form or polymorphic form) and amorphous form, so as to provide a desired release rate or desired physical or chemical properties.
[0296] Class of therapeutic agents of interest
[0297] The gastric resident system is well suited for treating diseases and disorders that present difficulties for patient compliance, and thus, in some embodiments, the gastric resident system is used to treat diseases or disorders in which patient compliance with the medication regimen is problematic. Such diseases and disorders include neuropsychiatric diseases and disorders, dementia and other diseases and disorders that affect memory, Alzheimer's disease, psychosis, schizophrenia, and paranoia. Thus, therapeutic agents that may be used with the gastric resident system include, but are not limited to, anti-dementia drugs, anti-Alzheimer's disease drugs, and antipsychotic drugs.
[0298] Hydrophilic therapeutic agents
[0299] Exemplary hydrophilic therapeutic agents that can be used in the system include risperidone, cetirizine, memantine, and olanzapine.
[0300] Hydrophobic therapeutic agents
[0301] Exemplary hydrophobic therapeutic agents that can be used in the system include aripiprazole, ivermectin, rosuvastatin, citalopram, and escitalopram.
[0302] Physico-chemical class of the drug
[0303] Example 27 herein shows that the polycaprolactone (PCL) phase and the fasting simulated gastric fluid (FasSGF) phase (P PCL ) and between octanol and water (P OCT ) Partition coefficients of different therapeutic agents. Such partition coefficients can be used to guide the selection of excipients and dispersants for gastric retention systems containing those therapeutic agents. PCL (or log P PCL ) indicates that the therapeutic agent has a greater affinity for the PCL matrix. Therefore, the amount of the release enhancer, solubilizer, or release enhancer and solubilizer can be increased to promote the release of the therapeutic agent from the PCL matrix.
[0304] In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P of less than about 0 PCL The therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30% or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 30% of the carrier polymer-active agent component. In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P of less than about 1 PCL The therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30% or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 30% of the carrier polymer-active agent component. In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P of less than about 2 PCL The therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30% or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 30% of the carrier polymer-active agent component. In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P of less than about 5 PcLThe therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30% or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 30% of the carrier polymer-active agent component. In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P of less than about 10 PCL The therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30%, or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 30% of the carrier polymer-active agent component.
[0305] In some embodiments, in a gastric retention system, wherein the carrier polymer-active agent component may comprise a therapeutic agent having a solubility in 0.1 N HCl greater than about 1 mg / ml, the solubilizer may be used in an amount of about 1% to about 30%; or the release enhancer may be used in an amount of about 1% to about 30% or the solubilizer may be used in an amount of about 1% to about 30% and the release enhancer may be used in an amount of about 1% to about 30%; in other embodiments, with the proviso that the total amount of solubilizer and release enhancer added does not comprise more than about 30% of the carrier polymer-active agent component. In some embodiments, in a gastric retention system, wherein the carrier polymer-active agent component may comprise a therapeutic agent having a solubility in 0.1 N HCl greater than about 5 mg / ml, the solubilizer may be used in an amount of about 1% to about 30%; or the release enhancer may be used in an amount of about 1% to about 30%, or the solubilizer may be used in an amount of about 1% to about 30% and the release enhancer may be used in an amount of about 1% to about 30%; in other embodiments, with the proviso that the total amount of solubilizer and release enhancer added does not comprise more than about 30% of the carrier polymer-active agent component. In some embodiments, in a gastric retention system, wherein the carrier polymer-active agent component may comprise a therapeutic agent having a solubility in 0.1 N HCl greater than about 10 mg / ml, the solubilizer may be used in an amount of about 1% to about 30%; or the release enhancer may be used in an amount of about 1% to about 30%, or the solubilizer may be used in an amount of about 1% to about 30% and the release enhancer may be used in an amount of about 1% to about 30%; in other embodiments, with the proviso that the total amount of solubilizer and release enhancer added does not comprise more than about 30% of the carrier polymer-active agent component. In some embodiments, in a gastric retention system, wherein the carrier polymer-active agent component may comprise a therapeutic agent having a solubility in 0.1 N HCl greater than about 20 mg / ml, the solubilizer may be used in an amount of about 1% to about 30%; or the release enhancer may be used in an amount of about 1% to about 30%, or the solubilizer may be used in an amount of about 1% to about 30% and the release enhancer may be used in an amount of about 1% to about 30%; in other embodiments, with the proviso that the total amount of solubilizer and release enhancer added does not comprise more than about 30% of the carrier polymer-active agent component.
[0306] In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P of greater than about 10 PCLThe therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30%, or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 50% of the carrier polymer-active agent component. In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P higher than about 20 PCL The therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30%, or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 50% of the carrier polymer-active agent component. In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P higher than about 30 PCL The therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30%, or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 50% of the carrier polymer-active agent component. In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P higher than about 40 PCL The therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30%, or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 50% of the carrier polymer-active agent component. In some embodiments, in the gastric retention system, wherein the carrier polymer-active agent component comprises a P higher than about 50 PCL The therapeutic agent, the solubilizer can be used in an amount of about 1% to about 30%; or the release enhancer can be used in an amount of about 1% to about 30%, or the solubilizer can be used in an amount of about 1% to about 30% and the release enhancer can be used in an amount of about 1% to about 30%; in other embodiments, the total amount of the solubilizer and the release enhancer added does not contain more than about 50% of the carrier polymer-active agent component.
[0307] In some embodiments, in a gastric retention system, wherein the carrier polymer-active agent component comprises a therapeutic agent having a solubility of less than about 1 mg / ml in 0.1N HCl, the solubilizer may be used in an amount of about 1% to about 30%; or the release enhancer may be used in an amount of about 1% to about 30%, or the solubilizer may be used in an amount of about 1% to about 30% and the release enhancer may be used in an amount of about 1% to about 30%; in other embodiments, with the proviso that the total amount of solubilizer and release enhancer added does not comprise more than about 50% of the carrier polymer-active agent component. In some embodiments, in a gastric retention system, wherein the carrier polymer-active agent component comprises a therapeutic agent having a solubility of less than about 0.5 mg / ml in 0.1N HCl, the solubilizer may be used in an amount of about 1% to about 30%; or the release enhancer may be used in an amount of about 1% to about 30%, or the solubilizer may be used in an amount of about 1% to about 30% and the release enhancer may be used in an amount of about 1% to about 30%; in other embodiments, with the proviso that the total amount of solubilizer and release enhancer added does not comprise more than about 50% of the carrier polymer-active agent component. In some embodiments, in a gastric retention system, wherein the carrier polymer-active agent component comprises a therapeutic agent having a solubility of less than about 0.1 mg / ml in 0.1N HCl, the solubilizer may be used in an amount of about 1% to about 30%; or the release enhancer may be used in an amount of about 1% to about 30%, or the solubilizer may be used in an amount of about 1% to about 30% and the release enhancer may be used in an amount of about 1% to about 30%; in other embodiments, with the proviso that the total amount of solubilizer and release enhancer added does not comprise more than about 50% of the carrier polymer-active agent component. In some embodiments, in a gastric retention system, wherein the carrier polymer-active agent component comprises a therapeutic agent having a solubility of less than about 0.05 mg / ml in 0.1N HCl, the solubilizer may be used in an amount of about 1% to about 30%; or the release enhancer may be used in an amount of about 1% to about 30%, or the solubilizer may be used in an amount of about 1% to about 30% and the release enhancer may be used in an amount of about 1% to about 30%; in other embodiments, with the proviso that the total amount of solubilizer and release enhancer added does not comprise more than about 50% of the carrier polymer-active agent component.
[0308] Granulation
[0309] Granulation of the drug can be used to improve solubility, especially for hydrophobic drugs that are poorly soluble in water. The drug can be granulated with a solubilizing agent such as polyalkylene oxide (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG), PEG-PPG copolymer, PEG-PPG block copolymer), polyethoxylated castor oil, and a detergent solution. In some embodiments, wherein the carrier polymer-active agent component comprises a therapeutic agent having a solubility of less than about 1 mg / ml, 0.5 mg / ml, 0.1 mg / ml, or 0.05 mg / ml in 0.1N HCl, the therapeutic agent is granulated with one or more solubilizing agents such as one of the above-mentioned solubilizing agents (polyalkylene oxide (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG), PEG-PPG copolymer, PEG-PPG block copolymer), polyethoxylated castor oil, and a detergent) and then blended with the carrier polymer. In some embodiments, wherein the carrier polymer-active agent component comprises a P higher than about 10, about 20, about 30, about 40, or about 50. PCL The therapeutic agent is granulated with one or more solubilizing agents, such as one of the above-mentioned solubilizing agents (polyalkylene oxides (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG), PEG-PPG copolymers, PEG-PPG block copolymers), polyethoxylated castor oil, and detergents), and then blended with a carrier polymer.
[0310] Aripiprazole is a particularly poorly soluble drug, and in some embodiments, aripiprazole is granulated with one or more solubilizers and then blended with a carrier polymer. Aripiprazole is granulated with CAPROL 3GO, CAPTEX 355, CAPMUL MCM, Kolliphor P407, PVP, Kolliphor RH-40, SOLUPLUS, Kolliphor EL and / or SDS to increase solubility and release from gastric resident systems. Kolliphor EL and SDS are preferred solubilizers for aripiprazole.
[0311] Granulation of hydrophobic drugs is preferably used in conjunction with relatively small drug particle sizes, such as embodiments wherein the therapeutic agent particles are less than about 20 microns in diameter, embodiments wherein the therapeutic agent particles are less than about 10 microns in diameter, embodiments wherein the therapeutic agent particles are less than about 5 microns in diameter, embodiments wherein at least about 80% of the therapeutic agent particles are less than about 20 microns in diameter, embodiments wherein at least about 80% of the therapeutic agent particles are less than about 10 microns in diameter, embodiments wherein at least about 80% of the therapeutic agent particles are less than about 5 microns in diameter, embodiments wherein at least about 80% of the mass of the therapeutic agent particles have a size between about 1 micron and about 20 microns, and embodiments wherein at least about 80% of the mass of the therapeutic agent particles have a size between about 1 micron and about 20 microns. Embodiments wherein at least about 80% of the mass of the therapeutic agent particles have a size of about 1 micron to about 5 microns, embodiments wherein at least about 80% of the mass of the therapeutic agent particles have a size of about 2 microns to about 20 microns, embodiments wherein at least about 80% of the mass of the therapeutic agent particles have a size of about 2 microns to about 10 microns, embodiments wherein at least about 80% of the mass of the therapeutic agent particles have a size of about 2 microns to about 5 microns, embodiments wherein at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 20 microns, or embodiments wherein at least about 80% of the mass of the therapeutic agent particles have a size of about 5 microns to about 10 microns.
[0312] Low dose active agent
[0313] Drugs and additional therapeutic agents that are administered at relatively low doses, such as equal to or less than about 1 mg / day, about 0.5 mg / day, or about 0.1 mg / day, are also well suited for use in the gastric retention system of the present invention. Examples of such active agents that may be used in the gastric retention system include, but are not limited to, levothyroxine, low-dose birth control pills, and vitamins and other nutrients, such as vitamin A, vitamin D, vitamin K, folic acid, vitamin B12, and biotin.
[0314] Cetirizine
[0315] The hydrophilic drug cetirizine is a second-generation antihistamine (sgAH). Cetirizine is available under the trade name Cetirizine is available in different dosage forms. Typically, cetirizine is administered once daily in a dose of 5 mg or 10 mg. Extended release formulations are available as Zyrtec , which combines cetirizine hydrochloride and pseudoephedrine hydrochloride. However, this "extended release" combination is administered more frequently (once every 12 hours) than cetirizine alone, since the extended release is primarily pseudoephedrine.
[0316] Cetirizine is used to treat a variety of allergic diseases and histamine-mediated (histamine-induced) diseases. Cetirizine is used to treat allergic rhinitis, allergic conjunctivitis, dermatitis, acute urticaria, chronic urticaria, pollen-induced asthma, pruritus, anaphylaxis, angioedema, Kimura's disease, and angiolymphoid hyperplasia with eosinophilia (ALHE).
[0317] Cetirizine has been formulated as a racemic mixture of (S)-cetirizine and the dihydrochloride of (R)-cetirizine and is marketed under the trade name (ZYRTEC is a registered trademark of Johnson & Johnson Corporation, New Brunswick, New Jersey). The dihydrochloride salt has a melting point of 225°C (decomposition), while the free cetirizine crystals (non-salt form, present as zwitterions) melt at 110-115°C (U.S. Pat. No. 4,525,358). (R)-cetirizine, known as levocetirizine, is the more active enantiomer, and drugs comprising levocetirizine dihydrochloride are marketed under the trade name (XYZAL is a registered trademark of UCB Pharma, Brussels, Belgium). (S)-Cetirizine is known as dextrorotatory cetirizine.
[0318] The relatively low melting point of cetirizine crystals in the free (non-salt) form of about 110-115° C. presents particular challenges to formulating polymer matrices containing such crystals. Many polymers must be heated above 115° C. to soften and blend them with the drug, and / or to facilitate extrusion or shaping of the polymer. Therefore, formulating a mixture of free cetirizine crystals with a polymer requires judicious selection of polymers and blending conditions to ensure that the cetirizine contained in the polymer is in the desired form, which in turn will affect the release rate of the drug from the polymer-drug blend.
[0319] Cetirizine is also known to oxidize (Dyakonov et al., Pharm. Res. 27(7): 1318-24 (2010)), which is another challenge facing the development of extended release formulations. Therefore, cetirizine formulations must also resist oxidation or other degradation reactions during the extended release period.
[0320] In any of the embodiments described herein, wherein cetirizine is provided in a gastric-retention system, the cetirizine present in the gastric-retention system can be protected from oxidation such that less than about 5% of the cetirizine in the carrier polymer-drug component of the system is oxidized after being retained in the stomach for about 5 days.
[0321] In any of the embodiments recited herein, wherein cetirizine is provided in a gastric retention system, the gastric retention system can release about 5-15 mg of cetirizine in the stomach per day.
[0322] In any of the embodiments recited herein, wherein cetirizine is provided in a gastric resident system, the gastric resident system provides a bioavailability of cetirizine released from the system that is at least about 50% of the bioavailability provided by an immediate release form containing the same amount of cetirizine. The area under the plasma concentration-time curve (AUC inf ) to determine bioavailability.
[0323] In any of the embodiments recited herein, wherein cetirizine is provided in a gastric retention system, the gastric retention system may contain from about 40 mg to about 120 mg of cetirizine.
[0324] In one embodiment, the substantially constant plasma level of cetirizine provided by the gastric retention system of the present invention can be from a level at or above the trough level of cetirizine administered daily in the form of a conventional oral formulation (i.e., the C trough level of cetirizine administered daily in the form of an immediate release formulation). min ) to the peak plasma level of cetirizine administered daily in the form of a conventional oral formulation or below the high level (i.e., the C of cetirizine administered daily in the form of an immediate-release formulation) max In another embodiment, the substantially constant plasma level of cetirizine provided by the gastric retention system of the present invention may be the peak plasma level of cetirizine when administered daily in the form of a conventional oral formulation (i.e., the C of cetirizine administered daily in the form of an immediate release formulation). max ). The substantially constant plasma level of cetirizine provided by the gastric retention system of the present invention may be the average plasma level of cetirizine when administered daily in the form of a conventional oral formulation (i.e., the C of cetirizine administered daily in the form of an immediate-release formulation). ave ). The substantially constant plasma level of cetirizine provided by the gastric retention system of the present invention may be at or above the trough level of cetirizine administered daily in the form of a conventional oral formulation (i.e., the C trough level of cetirizine administered daily in the form of an immediate release formulation). min ), such as about 100% to about 150% C min .
[0325] The substantially constant plasma levels of cetirizine provided by the gastric retention system of the present invention may be from about 150 ng / ml to about 250 ng / ml in adults.
[0326] The gastric retention system of the present invention may release cetirizine at a rate of about 8.4 mg / day to about 11 mg / day or about 10 mg / day or about 0.35 mg / hour to about 0.45 mg / hour.
[0327] The gastric retention system of the present invention can provide a bioavailability of cetirizine released from the system that is at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the bioavailability provided by an immediate release form containing the same amount of cetirizine. As shown above, according to the area under the plasma concentration-time curve (AUC inf ) to determine bioavailability.
[0328] Rosuvastatin
[0329] The hydrophobic drug rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The active ingredient of rosuvastatin. HMG-CoA reductase converts HMG-CoA to mevalonic acid, which is a cholesterol precursor, and as a result of its mechanism of action, rosuvastatin is primarily indicated for the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood (e.g., cholesterol and / or triglycerides). Rosuvastatin was developed by Shionogi & Co., Ltd. and is described in particular in U.S. Patents RE37314 and 6,316,460.
[0330] Rosuvastatin and other statin HMG-CoA inhibitors are associated with adverse side effects, including myalgia. A rare side effect is severe myopathy and rhabdomyolysis - a condition in which damaged muscle breaks down rapidly, resulting in the production of compounds that are harmful to the kidneys and may lead to kidney damage and renal failure. Rosuvastatin has also been associated with an increased incidence of myalgia. While these complications can occur at any dose level, the risk increases with higher doses of the drug.
[0331] Rosuvastatin is typically administered orally once daily and has an elimination half-life of about 19 hours. The plasma concentration of the drug administered regularly will be at a maximum (C max ) and the minimum value before each regular application (C min ). Both in vitro and in vivo studies have shown that the major site of rosuvastatin uptake is the liver, which is the main target organ for treatments aimed at lowering cholesterol and triglycerides. Some adverse side effects, such as myopathy, are thought to be related to systemic drug exposure in serum in a dose-dependent manner. Therefore, an administration method that favors higher uptake in the liver with respect to systemic exposure may have a favorable risk-benefit profile.
[0332] Administration of rosuvastatin via the gastric resident system of the present invention allows relatively low, relatively constant levels of rosuvastatin to enter the portal circulation, as opposed to regular administration. Such low, sustained levels result in increased absorption of the drug in the liver (the target organ where the drug provides its therapeutic effect) and reduce the maximum amount of the drug in the systemic circulation (where the drug causes undesirable side effects).
[0333] In any of the embodiments set forth herein, rosuvastatin may be provided in the gastric retention system as rosuvastatin calcium, or may be provided in its free base (non-salt) form.
[0334] In any embodiment cited herein, wherein rosuvastatin is provided in a gastric resident system, the rosuvastatin present in the gastric resident system can be protected to resist degradation (e.g., acid degradation) so that less than about 5% of the rosuvastatin left in the system after about 24 hours of gastric resident period or effective release period is degraded. In some embodiments, less than about 5% of the rosuvastatin left in the system after about 48 hours of gastric resident period or effective release period is degraded. In some embodiments, less than about 5% of the rosuvastatin left in the system after about 72 hours of gastric resident period or effective release period is degraded. In some embodiments, less than about 5% of the rosuvastatin left in the system after about 96 hours of gastric resident period or effective release period is degraded. In some embodiments, less than about 5% of the rosuvastatin left in the system after about 5 days of gastric resident period or effective release period is degraded. In some embodiments, the rosuvastatin less than about 5% left in the system after about 1 week of gastric residence period or effective release period is degraded. In some embodiments, the rosuvastatin less than about 5% left in the system after about 2 weeks of gastric residence period or effective release period is degraded. In some embodiments, the rosuvastatin less than about 5% left in the system after about 3 weeks of gastric residence period or effective release period is degraded. In some embodiments, the rosuvastatin less than about 5% left in the system after about 4 weeks of gastric residence period or effective release period is degraded. In some embodiments, the rosuvastatin less than about 5% left in the system after about 1 month of gastric residence period or effective release period is degraded.
[0335] In any of the embodiments recited herein, wherein rosuvastatin is provided in a gastric resident system, the gastric resident system can release about 5 to about 40 mg of rosuvastatin per day in the stomach during its residence period or during its effective release period. In any of the embodiments recited herein, wherein rosuvastatin is provided in a gastric resident system, the gastric resident system can release about 5 to about 20 mg of rosuvastatin per day in the stomach during its residence period or during its effective release period.
[0336] In any of the embodiments recited herein, wherein rosuvastatin is provided in a gastric retention system, the gastric retention system reduces LDL cholesterol by about 90% to 150% of the reduction in LDL cholesterol of an immediate release formulation of approximately the same amount of rosuvastatin administered over the same time period, e.g., over a time period of about 1 week. The carrier polymer for the gastric retention system may comprise a polycaprolactone, e.g., a linear polycaprolactone having a number average molecular weight of about 45 kDa to about 55 kDa, about 60 kDa to about 100 kDa, about 75 kDa to about 85 kDa, or about 80 kDa.
[0337] In any of the embodiments recited herein, wherein rosuvastatin is provided in a gastric retention system, the gastric retention system comprises about 25 mg to about 300 mg of rosuvastatin.
[0338] In any of the embodiments described herein, wherein rosuvastatin is provided in a gastric retention system, the carrier polymer-drug component of the gastric retention system further comprises a buffer substance. The buffer substance may be one or more compounds selected from calcium carbonate, calcium lactate, calcium phosphate, sodium phosphate and sodium bicarbonate. The buffer substance is typically used in an amount of up to about 2% w / w.
[0339] In a further embodiment, the present invention includes a method of treating a patient with high cholesterol or triglyceride levels, comprising administering to the patient any embodiment of the gastric resident system disclosed herein, wherein the gastric resident system comprises rosuvastatin (in the form of the free base of rosuvastatin, the form of rosuvastatin calcium salt, or other pharmaceutically acceptable salt form). The gastric resident system can be administered to the patient at intervals, for example once a week. A novel gastric resident system can be administered to the patient at intervals of E days, wherein E days is the effective release period of the system; the administration can be performed once every E days throughout the desired treatment period.
[0340] When treating patients with rosuvastatin, myalgia is particularly worrying. In some embodiments, compared with the immediate release oral administration of rosuvastatin with approximately equivalent therapeutic effect, the use of a gastric retention device comprising a dispersant (e.g., silicon dioxide) to administer rosuvastatin can reduce the incidence of self-reported myalgia by at least 5%. In some embodiments, the use of a gastric retention device comprising a dispersant to administer rosuvastatin can reduce the incidence of self-reported myalgia by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% compared to the immediate release oral administration of rosuvastatin with approximately equivalent therapeutic effect. In some embodiments, the use of a gastric retention device comprising a dispersant to administer rosuvastatin can reduce the incidence of self-reported myalgia by about 5%-about 50% compared to the immediate release oral administration of rosuvastatin with approximately equivalent therapeutic effect. Administration of rosuvastatin using a gastric retention device comprising a dispersant can reduce the self-reported incidence of myalgia by about 5% to about 50% compared to immediate-release oral administration of rosuvastatin with approximately equivalent therapeutic efficacy. In some embodiments, administration of rosuvastatin using a gastric retention device comprising a dispersant can reduce the self-reported incidence of myalgia by about 10% to about 40% or about 15% to about 30% compared to immediate-release oral administration of rosuvastatin with approximately equivalent therapeutic efficacy.
[0341] Stabilizing drug plasma levels, especially limiting the initial burst phase and the burst release induced, is particularly challenging for rosuvastatin using a gastric resident system. Rosuvastatin is relatively hydrophobic and may be rapidly eluted from the gastric resident system after consuming high-fat food or alcoholic beverages because rosuvastatin is more soluble in water than ethanol. Consuming other hydrophobic substances, such as drugs used in vegetable oils, may also cause the sudden release of hydrophobic drugs from the gastric resident system. The burst of the drug is absorbed by the patient, causing the plasma level to rise suddenly. The burst release causes undesirable peak drug levels, and may also cause insufficient drug delivery during the remaining effective release time or residence time of the system. As described herein, the inclusion of a dispersant in the gastric resident system limits the sudden induced burst release of rosuvastatin caused by consuming hydrophobic substances (such as alcoholic beverages). The combination of a dispersant, rosuvastatin and a carrier polymer provides a more stable drug release than the combination of rosuvastatin and a carrier polymer without a dispersant. Milling as described herein may also ensure smaller drug particle size in the carrier polymer and thus greater surface area of rosuvastatin, thereby increasing drug exposure to the gastric environment and facilitating efficient drug elution.
[0342] In order to ensure the therapeutic efficacy of the lower systemic exposure level provided by the gastric release system comprising rosuvastatin, patients are monitored by regular lipid panel. Such lipid panel tests include the determination of total cholesterol, high-density lipoprotein (HDL) cholesterol (sometimes referred to as "good" cholesterol), low-density lipoprotein (LDL) cholesterol (sometimes referred to as "bad" cholesterol) and triglycerides. Other special tests can be used, such as LDL receptor density. Standard liver panel tests can also be used to monitor the normal liver function of patients, including the standard clinical chemistry tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), albumin, total protein, bilirubin, gamma-glutamyl transferase (GGT), L-lactate dehydrogenase (LD) and prothrombin time (PT).
[0343] In one embodiment, the gastric retention system of the present invention comprising rosuvastatin reduces LDL cholesterol by about 75%-150% of the reduction of LDL cholesterol by the immediate release formulation of rosuvastatin, wherein about the same amount of rosuvastatin is administered by each delivery method within the same time period. For example, the reduction of LDL cholesterol by the gastric retention system of the present invention with an effective release period or residence period of one week and containing 70 mg of rosuvastatin released at about 10 mg / day is about 75%-150% of the reduction of LDL cholesterol by the immediate release formulation of rosuvastatin administered at a dose of 10 mg / day within 7 days. The reduction of LDL cholesterol by the gastric retention system of the present invention with an effective release period or residence period of one week and containing 140 mg of rosuvastatin released at about 20 mg / day (administered rosuvastatin at a dose of 20 mg / day once a week for 4 consecutive weeks within 28 days) is about 75%-150% of the reduction of LDL cholesterol by the immediate release formulation (dosage 20 mg / day, 28 days). Approximately equal amounts can be 10 mg / day, 20 mg / day, 30 mg / day or 40 mg / day. The time period can be 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 4 weeks or 1 month. In a further embodiment, reducing LDL cholesterol by the gastric resident system of the present invention is to reduce LDL cholesterol by an immediate release formulation of rosuvastatin by at least about 50%, at least about 75%, at least about 90%, at least about 100%, at least about 125%, at least about 140%, at least about 150%, about 50%-150%, about 75%-150%, about 90%-about 150%, about 100%-150% or about 125%-150%, wherein approximately equal amounts of rosuvastatin are administered by each delivery method within the same time period.
[0344] Effective release period; duration of stay
[0345] The effective release period (or effective release time) of the gastric resident system is defined as the time during which the gastric resident system releases the therapeutically effective amount of the therapeutic agent in the gastric resident system. A preferred effective release period is 1 week or about 1 week; another preferred effective release period is 3 days or about 3 days. In one embodiment, the gastric resident system has an effective release period of about 24 hours or at most about 24 hours. In one embodiment, the gastric resident system has an effective release period of about 48 hours or at most about 48 hours. In one embodiment, the gastric resident system has an effective release period of about 72 hours or at most about 72 hours. In one embodiment, the gastric resident system has an effective release period of about 96 hours or at most about 96 hours. In one embodiment, the gastric resident system has an effective release period of about 5 days or at most about 5 days. In one embodiment, the gastric resident system has an effective release period of about 6 days or at most about 6 days. In one embodiment, the gastric resident system has an effective release period of about 7 days or at most about 7 days. In one embodiment, the gastric resident system has an effective release period of about 10 days or at most about 10 days. In one embodiment, the gastric resident system has an effective release period of about 14 days or at most about 14 days. In one embodiment, the gastric resident system has an effective release period of about 3 weeks or at most about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 4 weeks or at most about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 1 month or at most about 1 month.
[0346] In one embodiment, the gastric resident system has an effective release period of about 24 hours to about 7 days. In one embodiment, the gastric resident system has an effective release period of about 48 hours to about 7 days. In one embodiment, the gastric resident system has an effective release period of about 72 hours to about 7 days. In one embodiment, the gastric resident system has an effective release period of about 96 hours to about 7 days. In one embodiment, the gastric resident system has an effective release period of about 5 days to about 7 days. In one embodiment, the gastric resident system has an effective release period of about 6 days to about 7 days.
[0347] In one embodiment, the gastric resident system has an effective release period of about 24 hours to about 10 days. In one embodiment, the gastric resident system has an effective release period of about 48 hours to about 10 days. In one embodiment, the gastric resident system has an effective release period of about 72 hours to about 10 days. In one embodiment, the gastric resident system has an effective release period of about 96 hours to about 10 days. In one embodiment, the gastric resident system has an effective release period of about 5 days to about 10 days. In one embodiment, the gastric resident system has an effective release period of about 6 days to about 10 days. In one embodiment, the gastric resident system has an effective release period of about 7 days to about 10 days.
[0348] In one embodiment, the gastric resident system has an effective release period of about 24 hours to about 14 days. In one embodiment, the gastric resident system has an effective release period of about 48 hours to about 14 days. In one embodiment, the gastric resident system has an effective release period of about 72 hours to about 14 days. In one embodiment, the gastric resident system has an effective release period of about 96 hours to about 14 days. In one embodiment, the gastric resident system has an effective release period of about 5 days to about 14 days. In one embodiment, the gastric resident system has an effective release period of about 6 days to about 14 days. In one embodiment, the gastric resident system has an effective release period of about 7 days to about 14 days. In one embodiment, the gastric resident system has an effective release period of about 10 days to about 14 days.
[0349] In one embodiment, the gastric resident system has an effective release period of about 24 hours to about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 48 hours to about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 72 hours to about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 96 hours to about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 5 days to about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 6 days to about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 7 days to about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 10 days to about 3 weeks. In one embodiment, the gastric resident system has an effective release period of about 14 days to about 3 weeks.
[0350] In one embodiment, the gastric resident system has an effective release period of about 24 hours to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 48 hours to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 72 hours to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 96 hours to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 5 days to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 6 days to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 7 days to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 10 days to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 14 days to about 4 weeks. In one embodiment, the gastric resident system has an effective release period of about 3 weeks to about 4 weeks.
[0351] In one embodiment, the gastric resident system has an effective release period of about 24 hours to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 48 hours to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 72 hours to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 96 hours to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 5 days to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 6 days to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 7 days to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 10 days to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 14 days to about 1 month. In one embodiment, the gastric resident system has an effective release period of about 3 weeks to about 1 month.
[0352] The residence time (or residence period) of a gastric resident system is defined as the time between the application of the system to the stomach and the detachment of the system from the stomach. In one embodiment, the gastric resident system has a residence time (residence period) of about 24 hours or at most about 24 hours. In one embodiment, the gastric resident system has a residence time (residence period) of about 48 hours or at most about 48 hours. In one embodiment, the gastric resident system has a residence time (residence period) of about 72 hours or at most about 72 hours. In one embodiment, the gastric resident system has a residence time (residence period) of about 96 hours or at most about 96 hours. In one embodiment, the gastric resident system has a residence time (residence period) of about 5 days or at most about 5 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 6 days or at most about 6 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 7 days or at most about 7 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 10 days or at most about 10 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 14 days or at most about 14 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 3 weeks or at most about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 4 weeks or at most about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 1 month or at most about 1 month.
[0353] In one embodiment, the gastric resident system has a residence time (residence period) of about 24 hours to about 7 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 48 hours to about 7 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 72 hours to about 7 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 96 hours to about 7 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 5 days to about 7 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 6 days to about 7 days.
[0354] In one embodiment, the gastric resident system has a residence time (residence period) of about 24 hours to about 10 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 48 hours to about 10 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 72 hours to about 10 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 96 hours to about 10 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 5 days to about 10 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 6 days to about 10 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 7 days to about 10 days.
[0355] In one embodiment, the gastric resident system has a residence time (residence period) of about 24 hours to about 14 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 48 hours to about 14 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 72 hours to about 14 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 96 hours to about 14 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 5 days to about 14 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 6 days to about 14 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 7 days to about 14 days. In one embodiment, the gastric resident system has a residence time (residence period) of about 10 days to about 14 days.
[0356] In one embodiment, the gastric resident system has a residence time (residence period) of about 24 hours to about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 48 hours to about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 72 hours to about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 96 hours to about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 5 days to about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 6 days to about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 7 days to about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 10 days to about 3 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 14 days to about 3 weeks.
[0357] In one embodiment, the gastric resident system has a residence time (residence period) of about 24 hours to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 48 hours to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 72 hours to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 96 hours to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 5 days to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 6 days to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 7 days to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 10 days to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 14 days to about 4 weeks. In one embodiment, the gastric resident system has a residence time (residence period) of about 3 weeks to about 4 weeks.
[0358] In one embodiment, the gastric resident system has a residence time (residence period) of about 24 hours to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 48 hours to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 72 hours to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 96 hours to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 5 days to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 6 days to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 7 days to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 10 days to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 14 days to about 1 month. In one embodiment, the gastric resident system has a residence time (residence period) of about 3 weeks to about 1 month.
[0359] The gastric resident system releases a therapeutically effective amount of a therapeutic agent during at least part of the residence time or residence period. In one embodiment, the system releases a therapeutically effective amount of a therapeutic agent during at least about 25% of the residence period (i.e., the effective release period is at least about 25% of the residence period). In one embodiment, the system releases a therapeutically effective amount of a therapeutic agent during at least about 50% of the residence period (i.e., the effective release period is at least about 50% of the residence period). In one embodiment, the system releases a therapeutically effective amount of a therapeutic agent during at least about 60% of the residence period (i.e., the effective release period is at least about 60% of the residence period). In one embodiment, the system releases a therapeutically effective amount of a therapeutic agent during at least about 70% of the residence period (i.e., the effective release period is at least about 70% of the residence period). In one embodiment, the system releases a therapeutically effective amount of a therapeutic agent during at least about 75% of the residence period (i.e., the effective release period is at least about 75% of the residence period). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 80% of the residence period (i.e., the effective release period is at least about 80% of the residence period). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 85% of the residence period (i.e., the effective release period is at least about 85% of the residence period). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 90% of the residence period (i.e., the effective release period is at least about 90% of the residence period). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 95% of the residence period (i.e., the effective release period is at least about 95% of the residence period). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 98% of the residence period (i.e., the effective release period is at least about 98% of the residence period). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 99% of the residence period (i.e., the effective release period is at least about 99% of the residence period).
[0360] The gastric resident system releases a therapeutically effective amount of the therapeutic agent during at least a portion of the residence time or residence period. When the gastric resident system disintegrates and passes through the stomach into the small intestine, the components of the gastric resident system may stop releasing the therapeutically effective amount of the therapeutic agent, in which case the effective release period has expired. However, in some cases, the components of the gastric resident system may slowly release the therapeutically effective amount of the therapeutic agent. Therefore, the release period of the therapeutically effective amount of the therapeutic agent (effective release period) may last longer than the residence period in the stomach. In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 25% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 25% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 50% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 50% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 60% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 60% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 70% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 70% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 75% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 75% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 80% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 80% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 85% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 85% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 90% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 90% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 95% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 95% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 98% of the (residence period + about 24 hours) (i.e., the effective release period is at least about 98% of the (residence period + about 24 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent over at least about 99% of (dwelling period + about 24 hours) (ie, the effective release period is at least about 99% of (dwelling period + about 24 hours)).
[0361] In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 25% of (residence period + about 48 hours) (i.e., the effective release period is at least about 25% of (residence period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 50% of (residence period + about 48 hours) (i.e., the effective release period is at least about 50% of (residence period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 60% of (residence period + about 48 hours) (i.e., the effective release period is at least about 60% of (residence period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 70% of (residence period + about 48 hours) (i.e., the effective release period is at least about 70% of (residence period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 75% of the (residence period + about 48 hours) (i.e., the effective release period is at least about 75% of the (residence period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 80% of the (residence period + about 48 hours) (i.e., the effective release period is at least about 80% of the (residence period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 85% of the (residence period + about 48 hours) (i.e., the effective release period is at least about 85% of the (residence period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 90% of the (residence period + about 48 hours) (i.e., the effective release period is at least about 90% of the (residence period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 95% of the (dwelling period + about 48 hours) (i.e., the effective release period is at least about 95% of the (dwelling period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 98% of the (dwelling period + about 48 hours) (i.e., the effective release period is at least about 98% of the (dwelling period + about 48 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 99% of the (dwelling period + about 48 hours) (i.e., the effective release period is at least about 99% of the (dwelling period + about 48 hours)).
[0362] In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 25% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 25% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 50% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 50% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 60% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 60% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 70% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 70% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 75% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 75% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 80% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 80% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 85% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 85% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 90% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 90% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 95% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 95% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 98% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 98% of the (residence period + about 72 hours)). In one embodiment, the system releases a therapeutically effective amount of the therapeutic agent during at least about 99% of the (residence period + about 72 hours) (i.e., the effective release period is at least about 99% of the (residence period + about 72 hours)).
[0363] Radiometric Opacity
[0364] The system is optionally radiopaque so that they can be positioned by abdominal X-rays if necessary. In some embodiments, one or more materials used to construct the system are sufficiently radiopaque for X-ray visualization. In other embodiments, radiopaque substances are added to one or more materials of the system or coated on one or more materials of the system or placed on a small part of the system or added to a small part of the system. Examples of suitable radiopaque substances are barium sulfate, bismuth subcarbonate, bismuth oxychloride, and bismuth trioxide. Preferably, these materials should not be incorporated into the polymer used to construct the gastric resident system so as not to change the release of the therapeutic agent from the carrier polymer or other system polymers of the desired properties. Metals such as tungsten can also be used, using metal strips or metal tips on a small part of the system components.
[0365] Treatments using the gastric resident system
[0366] Gastric resident systems can be used to treat conditions that require administration of therapeutic agents over an extended period of time. For long-term administration of therapeutic agents that may need to be taken for months, years, or indefinitely, administration of a gastric resident system once a week, once every two weeks, or once a month can provide significant advantages in terms of patient compliance and convenience.
[0367] Once the gastric resident system is administered to a patient, the system provides sustained release of the therapeutic agent over an effective release period. After the gastric resident system, the system degrades and leaves the stomach. Therefore, for a system with an effective release period of one week, the patient will swallow (or administer to the stomach by other means) a new system once a week. Therefore, in one embodiment, a method of treating a patient with a gastric resident system of the present invention having an effective release period of several days E (wherein the Eth day is the effective release period in days) is provided, with an overall desired treatment time T-total (wherein T days is the desired period in days), the method comprising introducing a new gastric resident system into the patient's stomach every E days by oral administration or other means throughout the desired treatment period. The number of gastric resident systems administered to the patient will be divided by (T-total) by (E-days). For example, if the patient is expected to be treated for one year (T-total=365 days), and the effective release period of the system is 7 days (E-days=7 days), then about 52 gastric resident systems will be administered to the patient within 365 days, because a new system will be administered once every seven days.
[0368] Medicine boxes and products
[0369] Also provided herein is a kit for treating a patient with the gastric resident system of the present invention. The kit may contain, for example, a sufficient amount of the gastric resident system for regular administration to the patient over the desired total treatment time period. If the total treatment time in days is (T-total), and the gastric resident system has an effective release period of (E-days), the kit will contain a plurality of gastric resident systems, which is equal to ((T-total) divided by (E-days)) (approximately an integer), for administration once every E-day. The kit may contain, for example, several gastric resident systems in a container (wherein the container may be a capsule), and may optionally further contain printed or computer-readable instructions regarding the administration regimen, treatment period, or other information related to the use of the gastric resident system and / or the therapeutic agent contained in the gastric resident system. For example, if the total treatment period prescribed for the patient is 1 year and the gastric resident system has an effective release period of 1 week, the kit may contain 52 capsules, each capsule containing 1 gastric resident system, and instructions for swallowing 1 capsule once a week (e.g., every Saturday).
[0370] Also included in the present invention is an article of manufacture comprising a sufficient number of gastric retention systems for periodic administration to a patient over the desired total treatment time period, and optionally comprising instructions for dosing regimen, treatment period, or other information related to the use of the gastric retention system and / or the therapeutic agent contained in the gastric retention system. The article of manufacture can be supplied in suitable packaging, such as a dispenser, tray, or other packaging, which facilitates the patient to administer the gastric retention system at prescribed intervals.
[0371] Exemplary embodiments
[0372] The present invention is further described by the following embodiments. Each feature of the described embodiments may be combined with any other embodiments if suitable and practicable.
[0373] Embodiment 1: A gastric resident system for administration to a patient, comprising:
[0374] A plurality of carrier polymer-active agent components comprising:
[0375] i) a carrier polymer,
[0376] ii) a dispersant, and
[0377] iii) a therapeutic agent or a salt thereof,
[0378] wherein the plurality of carrier polymer-active agent components are connected to each other via one or more coupling polymer components, wherein at least one of the one or more coupling polymers is an elastomer;
[0379] wherein the gastric resident system is configured to have a compacted form in a container suitable for administration orally or via a feeding tube, and a non-compacted form when released from the container in the patient's stomach;
[0380] wherein the gastric resident system remains in the stomach for a period of at least about 24 hours; and
[0381] wherein the system releases a therapeutically effective amount of the therapeutic agent during at least a portion of the time period during which the system is retained in the stomach.
[0382] Embodiment 2: The gastric retention system of embodiment 1, wherein the dispersant comprises a compound selected from the group consisting of porous inorganic materials, polar inorganic materials, silica, hydrophilic-fumed silica, stearates, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethyl cellulose, hydrophobic colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium aluminum silicate, phospholipids, polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, fatty acids, sodium lauryl sulfate, non-toxic metal oxides, and aluminum oxide.
[0383] Embodiment 3: The gastric retention system of Embodiment 1, wherein the dispersing agent comprises silicon dioxide.
[0384] Embodiment 4: The gastric retention system of any one of Embodiments 1-3, wherein the therapeutic agent or salt thereof consists of particles dispersed in a carrier polymer.
[0385] Embodiment 5: The gastric retention system of Embodiment 4, wherein at least about 80% by mass of the therapeutic agent particles have a diameter of about 2 microns to about 50 microns.
[0386] Embodiment 6: The gastric retention system of any one of Embodiments 1-5, wherein the therapeutic agent or salt thereof is a hydrophilic therapeutic agent or salt thereof, and less than about 10% of the hydrophilic therapeutic agent contained therein is eluted within about the first 6 hours of exposure to gastric fluid.
[0387] Embodiment 7: The gastric retention system of any one of Embodiments 1-5, wherein the therapeutic agent or salt thereof is a hydrophilic therapeutic agent or salt thereof, and wherein the amount of hydrophilic therapeutic agent eluted from the system within about the first 6 hours of exposure to gastric fluid is about 50% or less of the amount of therapeutic agent eluted from a system without a dispersant.
[0388] Embodiment 8: The gastric retention system of embodiment 6 or embodiment 7, wherein the carrier polymer-active agent component comprises about 1% to about 30% of the hydrophilic therapeutic agent or a salt thereof, about 0.5% to about 2.5% of the dispersing agent, and about 67.5% to about 98.5% of the carrier polymer.
[0389] Embodiment 9: The gastric retention system of any one of Embodiments 6-8, wherein the aqueous therapeutic agent has a log P of less than or equal to about 0.5. In this embodiment, the logP is measured using a 1-octanol / water system.
[0390] Embodiment 10: The gastric retention system of any one of Embodiments 6-8, wherein the hydrophilic therapeutic agent has a solubility in water of at least about 1 mg / ml.
[0391] Embodiment 11: The gastric retention system of any one of Embodiments 1-5, wherein the therapeutic agent or salt thereof is a hydrophobic therapeutic agent or salt thereof.
[0392] Embodiment 12: The gastric retention system of embodiment 11, wherein the carrier polymer-active agent component comprises about 1% to about 30% of the hydrophobic therapeutic agent or a salt thereof, about 0.5% to about 2.5% of the dispersing agent, and about 67.5% to about 98.5% of the carrier polymer.
[0393] Embodiment 13: The gastric retention system of Embodiment 11 or Embodiment 12, wherein the hydrophobic therapeutic agent has a log P greater than or equal to about 1. In this embodiment, the log P is measured using a 1-octanol / water system.
[0394] Embodiment 14: The gastric retention system of Embodiment 11 or Embodiment 12, wherein the solubility of the hydrophobic therapeutic agent in water is less than about 1 mg / ml.
[0395] Embodiment 15: The gastric retention system of any one of Embodiments 1-14, wherein the carrier polymer comprises polycaprolactone.
[0396] Embodiment 16: The gastric retention system of Embodiment 15, wherein the polycaprolactone comprises a linear polycaprolactone having a number average molecular weight of about 45 kDa to about 55 kDa.
[0397] Embodiment 16A: The gastric retention system of Embodiment 15, wherein the polycaprolactone comprises a linear polycaprolactone having a number average molecular weight (M) of about 60 kilodaltons (kDa) to about 100 kDa; 75 kDa to 85 kDa; or about 80 kDa. n ).
[0398] Embodiment 17: The gastric retention system of any one of Embodiments 1-16, wherein a plurality of carrier polymer-active agent components are linked to each other via two or more coupling polymer components, wherein at least one of the two or more polymer components is an elastomer and another of the two or more coupling polymer components is an enteric polymer.
[0399] Embodiment 18: The gastric retention system of Embodiment 17, wherein each enteric polymer is independently selected from poly(methacrylic acid-co-ethyl acrylate), cellulose acetate phthalate, cellulose acetate succinate, and hydroxypropyl methylcellulose phthalate.
[0400] Embodiment 18A: The gastric retention system of Embodiment 17, wherein each enteric polymer is independently selected from poly(methacrylic acid-co-ethyl acrylate), cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate (HPMCAS).
[0401] Embodiment 19: The gastric resident system of any one of embodiments 1-18, wherein the gastric resident system is retained in the stomach for about 5 days to about 7 days.
[0402] Embodiment 20: A method for preparing a gastric retention system according to any one of embodiments 1 to 19, comprising:
[0403] forming a flexible coupled polymer component;
[0404] forming a plurality of at least three carrier polymer-active agent components as elongated members comprising a proximal end and a distal end; and
[0405] The elongated member is coupled to the flexible coupling polymer component.
[0406] Embodiment 21: The method of Embodiment 20, further comprising compacting the gastric retention system and inserting the system into a container suitable for oral administration or administration via a gastric or feeding tube.
[0407] Embodiment 22: The method of Embodiment 20 or Embodiment 21, wherein the carrier polymer-active agent component is formed by grinding the therapeutic agent or a salt thereof, and blending the ground therapeutic agent or a salt thereof, a dispersant, and a carrier polymer.
[0408] Embodiment 23: The method of Embodiment 22, wherein the therapeutic agent or its salt is ground together with a compound selected from the group consisting of silicon dioxide, calcium phosphate, powdered cellulose, colloidal silicon dioxide, hydrophobic colloidal silicon dioxide, magnesium oxide, magnesium trisilicate, talc, polyvinyl pyrrolidone, cellulose ethers, polyethylene glycol, polyvinyl alcohol, and surfactants.
[0409] Embodiment 24: The method of Embodiment 22 or Embodiment 23, wherein the therapeutic agent or salt thereof comprises particles, wherein at least about 80% by mass of the particles have a size of about 2 microns to about 50 microns in diameter.
[0410] Embodiment 25: The method of Embodiment 22, wherein the blending is performed by hot melt extrusion.
[0411] Embodiment 26: The method of any one of Embodiments 20-25, wherein the plurality of at least 3 carrier polymer-active agent components are formed as an elongated member, the method comprising forming the elongated member from at least 2 segments.
[0412] Embodiment 27: The method of Embodiment 26, wherein forming the elongated member from at least two segments comprises forming a loop linker between the segments.
[0413] Embodiment 28: The method of any one of Embodiments 20-27, wherein the flexible coupling polymer component is in the shape of an asterisk with a plurality of at least 3 branches.
[0414] Embodiment 29: The method of any one of Embodiments 20-28, wherein coupling the elongated member to the flexible coupling polymer component comprises attaching the elongated member to the flexible coupling polymer component.
[0415] Embodiment 30: The method of Embodiment 28, wherein attaching the elongated member to the asterisk-shaped flexible coupling polymer component comprises forming a ring linker between the elongated member and the branch of the flexible coupling polymer component.
[0416] Embodiment 31: A method of administering a therapeutic agent to a patient, comprising administering to the patient the gastric retention system of any one of Embodiments 1-19.
[0417] Embodiment 32: The method of Embodiment 31, wherein the gastric resident system has a gastric residence period of D days, and a new gastric resident system is administered to the patient every D days for a total desired treatment period.
[0418] Embodiment 33: The method of Embodiment 32, wherein the gastric residence period is 7 days.
[0419] Embodiment 34: A gastric resident system for administration to a patient, comprising:
[0420] A plurality of carrier polymer-active agent components comprising:
[0421] i) a carrier polymer; and
[0422] ii) a therapeutic agent or a pharmaceutically acceptable salt thereof,
[0423] wherein the carrier polymer-active agent components are connected to each other via one or more coupling polymer components, wherein at least one of the one or more coupling polymers is an elastomer;
[0424] wherein the gastric retention system is configured to have a compacted form in a container that is suitable for oral administration or administration via a feeding tube, and an uncompacted form when released from the container;
[0425] wherein the gastric resident system remains in the stomach for a period of at least about 24 hours to about 1 month; and wherein
[0426] The system releases a therapeutically effective amount of the therapeutic agent over at least a portion of the period in which the system is retained in the stomach; and the system releases less than about 20% of the therapeutic agent or a pharmaceutically acceptable salt thereof over a 6-hour period.
[0427] Embodiment 35: The gastric retention system of Embodiment 34, wherein the system releases about 30% to about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof within about 40% to 60% of the residence period.
[0428] Embodiment 36: The gastric retention system of Embodiment 34 or Embodiment 35, wherein the system releases about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof within about 90% of the residence period.
[0429] Embodiment 37: The gastric retention system of any one of Embodiments 34-36, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is measured in an aqueous environment selected from the group consisting of: 0.1N HCl aqueous solution, simulated gastric fluid, fasting simulated gastric fluid, fed simulated gastric fluid, animal stomach, pig stomach, dog stomach and human stomach.
[0430] Embodiment 38: The gastric retention system of any one of Embodiments 34-37, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is determined in 0.1 N HCl.
[0431] Embodiment 39: The gastric retention system of any one of Embodiments 34-37, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is determined in fasting simulated gastric fluid.
[0432] Embodiment 40: The gastric retention system of any one of Embodiments 34-37, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is determined in fed simulated gastric fluid.
[0433] Embodiment 41: The gastric retention system of any one of Embodiments 34-40, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof in a 40% ethanol / 60% 0.1N HCl aqueous solution is increased by no more than about 40% compared to the release in 0.1N HCl over the same time period, or in 40% ethanol / 60% simulated gastric fluid is increased by no more than about 40% compared to the release in simulated gastric fluid over the same time period, or in 40% ethanol / 60% fasted simulated gastric fluid is increased by no more than about 40% compared to the release in fasted simulated gastric fluid over the same time period, or in 40% ethanol / 60% fed simulated gastric fluid is increased by no more than about 40% compared to the release in fed simulated gastric fluid over the same time period.
[0434] Embodiment 42: The gastric retention system of any one of Embodiments 34-41, wherein: ii) the therapeutic agent or a pharmaceutically acceptable salt thereof comprises about 10% to about 35% of the carrier polymer-active agent component.
[0435] Embodiment 43: The gastric retention system of any one of Embodiments 34-42, wherein the therapeutic agent or a pharmaceutically acceptable salt thereof is selected from doxycycline, donepezil, ivermectin, risperidone, cetirizine and rosuvastatin.
[0436] Embodiment 44: The gastric retention system of any one of Embodiments 34-43, wherein the carrier polymer-active agent component further comprises iii) a release enhancer.
[0437] Embodiment 45: The gastric retention system of any one of Embodiments 34-44, wherein the release enhancing agent comprises from about 2% to about 30% of the carrier polymer-active agent component.
[0438] Embodiment 46: The gastric retention system of any one of Embodiments 34-45, wherein the release enhancing agent is selected from the group consisting of acrylate polymers, acrylic acid copolymers, polydioxanone-polyethylene glycol polymers, and polyvinylpyrrolidone.
[0439] Embodiment 47: The gastric retention system of any one of Embodiments 34-46, wherein the carrier polymer-active agent component further comprises iv) a dispersing agent.
[0440] Embodiment 48: The gastric retention system of any one of Embodiments 34-47, wherein the dispersion comprises from about 0.1% to about 4% of the carrier polymer-active agent component.
[0441] Embodiment 49: A gastric retention system according to any one of embodiments 34-48, wherein the dispersant is selected from porous inorganic materials, polar inorganic materials, non-toxic metal oxides, amphiphilic organic molecules, polysaccharides, cellulose, cellulose derivatives, fatty acids, detergents, silica, hydrophilic-fumed silica, hydrophobic colloidal silica, magnesium aluminum silicate, stearate, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, phospholipids, polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, sodium lauryl sulfate and alumina.
[0442] Embodiment 50: The gastric retention system of any one of Embodiments 34-48, wherein the dispersing agent comprises silicon dioxide.
[0443] Embodiment 51: The gastric retention system of any one of Embodiments 34-50, wherein the carrier polymer-active agent component further comprises: v) a solubilizer.
[0444] Embodiment 52: The gastric retention system of any one of Embodiments 34-51, wherein the solubilizing agent comprises from about 1% to about 10% of the carrier polymer-active agent ingredient.
[0445] Embodiment 53: The gastric retention system of any one of Embodiments 34-52, wherein the solubilizing agent is selected from the group consisting of polyalkylene oxides, polyethoxylated castor oils, and detergents.
[0446] Embodiment 54: The gastric retention system of any one of Embodiments 34-53, wherein the carrier polymer-active agent component further comprises: vi) a stabilizer.
[0447] Embodiment 55: The gastric retention system of any one of Embodiments 34-54, wherein the stabilizer comprises from about 0.1% to about 2% of the carrier polymer-active agent component.
[0448] Embodiment 56: The gastric retention system of any one of Embodiments 34-55, wherein the stabilizer is an antioxidant selected from the group consisting of antioxidants, tocopherol, α-tocopherol, ascorbic acid, ascorbate, carotene, butylated hydroxyanisole, butylated hydroxytoluene, fumaric acid, antimicrobial agents, buffer substances, calcium carbonate, calcium lactate, calcium phosphate, sodium phosphate and sodium bicarbonate.
[0449] Embodiment 57: The gastric retention system of any one of Embodiments 34-56, wherein the carrier polymer comprises a polylactone.
[0450] Embodiment 58: The gastric retention system of Embodiment 57, wherein the polylactone comprises polycaprolactone.
[0451] Embodiment 59: The gastric retention system of Embodiment 58, wherein the polycaprolactone has an average M of about 60,000-100,000. n .
[0452] Embodiment 60: The gastric retention system of embodiment 58, wherein the polycaprolactone has an average M of about 75,000-85,000. n .
[0453] Embodiment 61: The gastric retention system of Embodiment 58, wherein the polycaprolactone has an average M of about 80,000. n .
[0454] Embodiment 62: The gastric retention system of any one of Embodiments 34-61, wherein the solubilizer, if present, comprises no more than about 5% of the carrier polymer-active agent component; and if one or more of a solubilizer, a release enhancer, a dispersant, or a stabilizer is present, the total combined amount of any solubilizer, release enhancer, dispersant, and stabilizer present comprises no more than about 30% of the carrier polymer-active agent component.
[0455] Embodiment 63: An extended release formulation of a therapeutic agent, comprising: i) a polylactone; wherein ii) the therapeutic agent is selected from doxycycline, donepezil, ivermectin, risperidone, rosuvastatin, cetirizine, or a pharmaceutically acceptable salt thereof.
[0456] Embodiment 64: The formulation of Embodiment 63, wherein the polylactone comprises polycaprolactone.
[0457] Embodiment 65: The formulation of Embodiment 63, wherein the polycaprolactone has an average M of about 60,000-100,000. n .
[0458] Embodiment 66: The formulation of Embodiment 63, wherein the polycaprolactone has an average M of about 75,000-85,000. n .
[0459] Embodiment 67: The formulation of Embodiment 63, wherein the polycaprolactone has an average M of about 80,000. n .
[0460] Embodiment 68: The formulation of any one of Embodiments 63-67, further comprising: iii) a release enhancer.
[0461] Embodiment 69: The formulation of Embodiment 68, wherein the release enhancing agent comprises about 2%-30% of the formulation.
[0462] Embodiment 70: The formulation of Embodiment 68 or Embodiment 69, wherein the release enhancer is selected from the group consisting of acrylate polymers, acrylate copolymers, polydioxanone-polyethylene glycol polymers, and polyvinylpyrrolidone.
[0463] Embodiment 71: The formulation of Embodiment 68 or Embodiment 69, wherein the release enhancing agent comprises polyvinylpyrrolidone and the polyvinylpyrrolidone comprises about 2% to about 8% of the formulation.
[0464] Embodiment 72: The formulation of Embodiment 68 or Embodiment 69, wherein the release enhancing agent comprises an acrylate polymer or an acrylic acid copolymer and the acrylate polymer or acrylate copolymer comprises about 5% to about 30% of the formulation.
[0465] Embodiment 73: The formulation of embodiment 70 or embodiment 72, wherein the acrylate polymer or acrylate copolymer comprises a copolymer of ethyl acrylate, methyl methacrylate and trimethylammonioethyl methacrylate, optionally in a molar ratio of about 1:2:0.1, about 1:2:0.2, or about 1:2:0.1 to about 1:2:0.2; or the acrylate polymer or acrylate copolymer comprises a copolymer of dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate, optionally in a molar ratio of about 2:1:1 to about 1:1:1.
[0466] Embodiment 74: The formulation of any one of Embodiments 63-73, further comprising: iv) a dispersant.
[0467] Embodiment 75: The formulation of Embodiment 74, wherein the dispersant comprises about 0.1% to about 4% of the formulation.
[0468] Embodiment 76: The formulation of embodiment 74 or embodiment 75, wherein the dispersant is selected from porous inorganic materials, polar inorganic materials, non-toxic metal oxides, amphiphilic organic molecules, polysaccharides, cellulose, cellulose derivatives, fatty acids, detergents, silica, hydrophilic-fumed silica, hydrophobic colloidal silica, magnesium aluminum silicate, stearate, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, phospholipids, polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, sodium lauryl sulfate and alumina.
[0469] Embodiment 77: The formulation of Embodiment 74 or Embodiment 75, wherein the dispersant comprises silicon dioxide.
[0470] Embodiment 78: The formulation of Embodiment 77, wherein the silica comprises hydrophilic fumed silica.
[0471] Embodiment 79: The formulation of any one of Embodiments 63-78, wherein the formulation further comprises: v) a solubilizer.
[0472] Embodiment 80: The formulation of Embodiment 79, wherein the solubilizing agent comprises about 0.2% to about 10% of the formulation.
[0473] Embodiment 81: The formulation of Embodiment 79 or Embodiment 80, wherein the solubilizing agent is selected from the group consisting of polyalkylene oxides, polyethoxylated castor oils, and detergents.
[0474] Embodiment 82: The formulation of any one of Embodiments 79-81, wherein the solubilizing agent comprises a polyalkylene glycol.
[0475] Embodiment 83: The formulation of any one of Embodiments 79-82, wherein the solubilizing agent is selected from polyethylene glycol (PEG), polypropylene glycol (PPG), and a block copolymer of PEG and PPG.
[0476] Embodiment 84: The formulation of any one of Embodiments 79-83, wherein the solubilizing agent is a block copolymer of PEG and PPG, optionally having the formula H-(OCH2CH2) x -(O-CH(CH3)CH2) y -(OCH2CH2) z -OH, wherein x and z are about 101, and y is about 56.
[0477] Embodiment 85: The formulation of any one of Embodiments 63-84, wherein the formulation further comprises: vi) a stabilizer.
[0478] Embodiment 86: The formulation of Embodiment 85, wherein the stabilizer comprises about 0.1% to about 2% of the formulation.
[0479] Embodiment 87: The formulation of Embodiment 85 or Embodiment 86, wherein the stabilizer comprises one or more compounds selected from antioxidants, tocopherol, alpha-tocopherol, ascorbic acid, ascorbate, carotene, butylated hydroxyanisole, butylated hydroxytoluene, fumaric acid, antimicrobial agents, buffer substances, calcium carbonate, calcium lactate, calcium phosphate, sodium phosphate and sodium bicarbonate.
[0480] Embodiment 88: The formulation of Embodiment 85 or Embodiment 86, wherein the stabilizer comprises alpha-tocopherol.
[0481] Embodiment 89: The formulation of any one of Embodiments 63-88, wherein the therapeutic agent or a pharmaceutically acceptable salt thereof comprises about 15% to about 35% of the formulation.
[0482] Embodiment 90: The formulation of any of Embodiments 63-89, wherein if a solubilizer is present, the solubilizer comprises no more than about 5% of the carrier polymer-active agent component; and if one or more of a solubilizer, a release enhancer, a dispersant, or a stabilizer is present, the total combined amount of any solubilizer, release enhancer, dispersant, and stabilizer present comprises no more than about 30% of the carrier polymer-active agent component.
[0483] Embodiment 91: The formulation of any one of Embodiments 63-90, wherein the therapeutic agent is doxycycline or a pharmaceutically acceptable salt thereof.
[0484] Embodiment 92: The formulation of any one of Embodiments 63-90, wherein the therapeutic agent is donepezil or a pharmaceutically acceptable salt thereof.
[0485] Embodiment 93: The formulation of any one of Embodiments 63-90, wherein the therapeutic agent is ivermectin or a pharmaceutically acceptable salt thereof.
[0486] Embodiment 94: The formulation of any one of Embodiments 63-90, wherein the therapeutic agent is risperidone or a pharmaceutically acceptable salt thereof.
[0487] Embodiment 95: The formulation of any one of Embodiments 63-90, wherein the therapeutic agent is rosuvastatin or a pharmaceutically acceptable salt thereof.
[0488] Embodiment 96: The formulation of any one of Embodiments 63-90, wherein the therapeutic agent is cetirizine or a pharmaceutically acceptable salt thereof.
[0489] Embodiment 97: The formulation of any one of Embodiments 63-96, wherein the formulation meets any one, any two, or any three of the following criteria:
[0490] The formulation releases less than about 20% of the therapeutic agent or a pharmaceutically acceptable salt thereof in an aqueous environment over a period of 6 hours; the formulation releases about 30% to about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof in an aqueous environment over a period of about 3 days; and the formulation releases greater than about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof in an aqueous environment over a period of about 7 days.
[0491] Embodiment 98: The gastric retention system of Embodiment 97, wherein the aqueous environment is selected from the group consisting of: 0.1N HCl, simulated gastric fluid, fasting simulated gastric fluid, fed simulated gastric fluid, animal stomach, pig stomach, dog stomach and human stomach.
[0492] Embodiment 99: The gastric retention system of Embodiment 97, wherein the aqueous environment is 0.1N HCl.
[0493] Embodiment 100: The gastric retention system of Embodiment 97, wherein the aqueous environment is fasting simulated gastric fluid.
[0494] Embodiment 101: The gastric retention system of Embodiment 97, wherein the aqueous environment is fed simulated gastric fluid.
[0495] Embodiment 102: A gastric retention system for administering a therapeutic agent or a pharmaceutically acceptable salt thereof to a patient, comprising a plurality of carrier polymer-active agent components comprising the formulation of any one of Embodiments 63-96;
[0496] wherein the carrier polymer-active agent components are connected to each other via one or more coupling polymer components, wherein at least one of the one or more polymer components is an elastomer;
[0497] wherein the gastric retention system is configured to have a compacted form in a container that is suitable for administration orally or via a feeding tube, and an uncompacted form when released from the container;
[0498] wherein the gastric retention system remains in the stomach for a residence period of at least about 24 hours to about 1 month; and wherein:
[0499] The system releases a therapeutically effective amount of the therapeutic agent over an effective release period that is less than or equal to the residence period in which the system remains in the stomach; and the system releases less than about 20% of the therapeutic agent or a pharmaceutically acceptable salt thereof over a 6 hour period.
[0500] Embodiment 103: The gastric retention system of Embodiment 102, wherein the system releases about 30% to about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof within a period of about 40% to 60% of the effective release period.
[0501] Embodiment 104: The gastric retention system of Embodiment 102 or Embodiment 103, wherein the system releases about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof within about 90% of the effective release period.
[0502] Embodiment 105: The gastric retention system of any one of Embodiments 102-104, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is measured in an aqueous environment selected from the group consisting of: 0.1N HCl aqueous solution, simulated gastric fluid, fasting simulated gastric fluid, fed simulated gastric fluid, animal stomach, pig stomach, dog stomach and human stomach.
[0503] Embodiment 106: The gastric retention system of any one of Embodiments 102-104, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is determined in 0.1 N HCl.
[0504] Embodiment 107: The gastric retention system of any one of Embodiments 102-104, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is determined in fasting simulated gastric fluid.
[0505] Embodiment 108: The gastric retention system of any one of Embodiments 102-104, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is determined in fed simulated gastric fluid.
[0506] Embodiment 109: The gastric retention system of any one of Embodiments 102-108, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof in a 40% ethanol / 60% 0.1N HCl aqueous solution is increased by no more than about 40% compared to the release in 0.1N HCl over the same time period, or in 40% ethanol / 60% simulated gastric fluid is increased by no more than about 40% compared to the release in simulated gastric fluid over the same time period, or in 40% ethanol / 60% fasted simulated gastric fluid is increased by no more than about 40% compared to the release in fasted simulated gastric fluid over the same time period, or in 40% ethanol / 60% fed simulated gastric fluid is increased by no more than about 40% compared to the release in fed simulated gastric fluid over the same time period.
[0507] Embodiment 110: The gastric retention system of any one of Embodiments 102-108, wherein less than about 20% of the therapeutic agent is released from the system after about 2 hours in 40% ethanol / 60% 0.1 N HCl.
[0508] Embodiment 111: An elongated member formed from a material comprising the formulation of any of Embodiments 63-96.
[0509] Embodiment 112: A gastric retention system comprising at least one elongated member of embodiment 111.
[0510] Embodiment 113: The gastric retention system of any of embodiments 1-19, 34-62, or 98-101, comprising at least one elongate member of embodiment 111.
[0511] Embodiment 114: A gastric retention system for administration to a patient's stomach, comprising: a plurality of carrier polymer-drug ingredients comprising a carrier polymer and cetirizine or a salt thereof, wherein the plurality of carrier polymer-drug ingredients are connected to each other by a coupling polymer, wherein the gastric retention system is configured to have a compacted form in a container suitable for administration orally or by a feeding tube; and an uncompacted form when released from the container in the patient's stomach; wherein the gastric retention system remains in the stomach for at least about 24 hours; and wherein the system releases a therapeutically effective amount of cetirizine over the period in which the system remains in the stomach.
[0512] Embodiment 115: The gastric retention system of Embodiment 114, wherein cetirizine is in the form of cetirizine hydrochloride.
[0513] Embodiment 116: The gastric retention system of Embodiment 114, wherein cetirizine is in non-salt form.
[0514] Embodiment 117: The gastric retention system of any one of Embodiments 114-116, wherein the carrier polymer is polycaprolactone.
[0515] Embodiment 118: The gastric retention system of any one of Embodiments 114-117, wherein the coupling polymer is an enteric polymer.
[0516] Embodiment 119: The gastric retention system of Embodiment 118, wherein the coupling polymer is an enteric polymer that dissolves at a pH of about 5 or above.
[0517] Embodiment 120: The gastric retention system of Embodiment 118, wherein the enteric polymer dissolves at a pH of about 5 to about 7.
[0518] Embodiment 121: The gastric retention system of any one of Embodiments 114-120, wherein the coupling polymer is poly(methacrylic acid-co-ethyl acrylate).
[0519] Embodiment 122: The gastric resident system of any one of Embodiments 114-121, wherein the system remains in the stomach for at least about 5 days.
[0520] Embodiment 123: The gastric retention system of any one of Embodiments 114-122, wherein after about 5 days of retention in the stomach, less than about 5% of the cetirizine present in the system is oxidized.
[0521] Embodiment 124: The gastric retention system of any one of Embodiments 114-123, wherein the system releases about 5-15 mg of cetirizine per day in the stomach.
[0522] Embodiment 125: The gastric retention system of any one of Embodiments 114-124, wherein the bioavailability of cetirizine released from the system is at least about 50% of the bioavailability provided by an immediate release form comprising the same amount of cetirizine, wherein the bioavailability is determined based on the area under the plasma concentration-time curve (AUCinf).
[0523] Embodiment 126: The gastric retention system of any one of Embodiments 114-125, wherein the system comprises about 40 mg to about 120 mg of cetirizine.
[0524] Embodiment 127: The gastric retention system of any one of Embodiments 114-126, wherein the system is in its uncompacted form when released from the container.
[0525] Embodiment 128: The gastric retention system of any one of Embodiments 114-127, wherein the container is a capsule.
[0526] Embodiment 129: The gastric retention system of any one of Embodiments 114-128, wherein the gastric retention system further comprises a radiopaque material.
[0527] Embodiment 130: The gastric retention system of any one of Embodiments 114-129, wherein the carrier polymer-drug component further comprises an antioxidant.
[0528] Embodiment 131: A method of treating a patient suffering from an allergic reaction, comprising administering to the patient a gastric retention system according to any one of Embodiments 114-130.
[0529] Embodiment 132: The method of Embodiment 131, wherein the allergic reaction is allergic rhinitis.
[0530] Embodiment 133: The method of Embodiment 131, wherein the allergic reaction is dermatitis.
[0531] Embodiment 134: The method of Embodiment 131, wherein the allergic reaction is acute urticaria or chronic urticaria.
[0532] Embodiment 135: The method of any one of Embodiments 131-134, wherein the gastric retention system is administered to the patient once a week.
[0533] Embodiment 136: The method of any one of Embodiments 131-134, wherein the gastric retention system has a gastric retention period of D days, and a new gastric retention system is administered to the patient every D days for the total desired treatment period.
[0534] Embodiment 137: A gastric retention system for administration to a patient, comprising a plurality of carrier polymer-drug components, comprising: i) a carrier polymer, ii) a dispersant, and iii) cetirizine or a salt thereof, wherein the plurality of carrier polymer-drug components are connected to each other by one or more coupling polymer components, wherein at least one of the one or more polymer components is an elastomer; wherein the gastric retention system is configured to be in a compacted form in a container suitable for administration orally or by a feeding tube; and in an uncompacted form when released from the container in the patient's stomach; wherein the gastric retention system is retained in the stomach for a period of at least about 24 hours; and wherein the system releases a therapeutically effective amount of the drug during at least a portion of the period in which the system is retained in the stomach.
[0535] Embodiment 138: The gastric retention system of embodiment 137, wherein the dispersant comprises a compound selected from the following: porous inorganic materials, polar inorganic materials, silica, hydrophilic-fumed silica, stearate, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethyl cellulose, hydrophobic colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium aluminum silicate, phospholipids, polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, fatty acids, sodium lauryl sulfate, non-toxic metal oxides and aluminum oxide.
[0536] Embodiment 139: The gastric retention system of Embodiment 137, wherein the dispersing agent comprises silicon dioxide.
[0537] Embodiment 140: The gastric retention system of any one of Embodiments 137-139, wherein cetirizine or a salt thereof consists of particles dispersed in a carrier polymer.
[0538] Embodiment 141: The gastric retention system of Embodiment 140, wherein at least about 80% of the cetirizine or cetirizine salt particles have a diameter of about 2 microns to about 50 microns.
[0539] Embodiment 142: The gastric retention system of any one of Embodiments 137-141, wherein less than about 10% of the cetirizine or a salt thereof contained in the system elutes within about the first 6 hours of exposure to gastric fluid.
[0540] Embodiment 143: The gastric retention system of any one of Embodiments 137-141, wherein the amount of cetirizine or a salt thereof eluted from the system within about the first 6 hours of exposure to gastric fluid is about 50% or less of the amount of cetirizine eluted from a system without a dispersant.
[0541] Embodiment 144: The gastric retention system of Embodiment 142 or Embodiment 143, wherein the carrier polymer-drug component comprises about 1% to about 30% of cetirizine or a salt thereof, about 0.5% to about 2.5% of a dispersant, and about 67.5% to about 98.5% of a carrier polymer.
[0542] Embodiment 145: The gastric retention system of any one of Embodiments 137-144, wherein the carrier polymer comprises polycaprolactone.
[0543] Embodiment 146: The gastric retention system of Embodiment 145, wherein the polycaprolactone comprises a linear polycaprolactone having a number average molecular weight range of about 45 kDa to about 55 kDa.
[0544] Embodiment 147: The gastric retention system of any one of Embodiments 137-146, wherein a plurality of carrier polymer-drug components are linked to each other via two or more coupling polymer components, wherein at least one of the two or more coupling polymer components is an elastomer, and at least another of the two or more coupling polymer components is an enteric polymer.
[0545] Embodiment 148: The gastric retention system of Embodiment 147, wherein the enteric polymer is selected from the group consisting of poly(methacrylic acid-co-ethyl acrylate), cellulose acetate phthalate, cellulose acetate succinate, and hydroxypropyl methylcellulose phthalate.
[0546] Embodiment 149: The gastric resident system of any one of Embodiments 136-148, wherein the gastric resident system is retained in the stomach for about 5 days to about 7 days.
[0547] Embodiment 150: A gastric retention system for administration to a patient's stomach, comprising cetirizine or a salt thereof, wherein a plurality of carrier polymer-drug components are connected to each other by coupling polymer components; wherein the gastric retention system is configured to be in a compacted form in a container suitable for administration orally or by a feeding tube; and in an uncompacted form when released from the container in the stomach; wherein the gastric retention system is retained in the stomach for a period of at least about 24 hours; and wherein the system releases a therapeutically effective amount of cetirizine over the period in which the system is retained in the stomach.
[0548] Embodiment 151: The gastric retention system of Embodiment 150, wherein cetirizine is in the form of cetirizine hydrochloride.
[0549] Embodiment 152: The gastric retention system of Embodiment 150, wherein cetirizine is in non-salt form.
[0550] Embodiment 153: The gastric retention system of any one of Embodiments 150-152, wherein the carrier polymer is polycaprolactone.
[0551] Embodiment 154: The gastric retention system of any one of Embodiments 150-153, wherein the coupling polymer is an enteric polymer.
[0552] Embodiment 155: The gastric retention system of Embodiment 154, wherein the coupling polymer is an enteric polymer that dissolves at a pH of about 5 or above.
[0553] Embodiment 156: The gastric retention system of Embodiment 154, wherein the enteric polymer dissolves at a pH of about 5 to about 7.
[0554] Embodiment 157: The gastric retention system of any one of Embodiments 150-156, wherein the coupling polymer is poly(methacrylic acid-co-ethyl acrylate).
[0555] Embodiment 158: The gastric resident system of any one of Embodiments 150-157, wherein the system remains in the stomach for at least about 5 days.
[0556] Embodiment 159: The gastric retention system of any one of Embodiments 150-158, wherein less than about 5% of the cetirizine present in the system is oxidized after about 5 days of retention in the stomach.
[0557] Embodiment 160: The gastric retention system of any one of Embodiments 150-159, wherein the system releases about 5-15 mg of cetirizine per day in the stomach.
[0558] Embodiment 161: The gastric retention system of any one of Embodiments 150-160, wherein the bioavailability of cetirizine released from the system is at least about 50% of the bioavailability provided by an immediate release form comprising the same amount of cetirizine, wherein the bioavailability is determined based on the area under the plasma concentration-time curve (AUCinf).
[0559] Embodiment 162: The gastric retention system of any one of Embodiments 150-161, wherein the system comprises about 40 mg to about 120 mg of cetirizine.
[0560] Embodiment 163: The gastric retention system of any one of Embodiments 150-162, wherein the system assumes its uncompacted form when released from the container.
[0561] Embodiment 164: The gastric retention system of any one of Embodiments 150-163, wherein the container is a capsule.
[0562] Embodiment 165: The gastric retention system of any one of Embodiments 150-164, wherein the gastric retention system further comprises a radiopaque material.
[0563] Embodiment 166: The gastric retention system of any one of Embodiments 150-165, wherein the carrier polymer-drug component further comprises an antioxidant.
[0564] Embodiment 167: A method of treating a patient suffering from an allergic reaction, comprising administering to the patient a gastric retention system according to any one of Embodiments 137-166.
[0565] Embodiment 168: The method of Embodiment 167, wherein the allergic reaction is allergic rhinitis.
[0566] Embodiment 169: The method of Embodiment 167, wherein the allergic reaction is dermatitis.
[0567] Embodiment 170: The method of Embodiment 167, wherein the allergic reaction is acute urticaria or chronic urticaria.
[0568] Embodiment 171: The method of any one of Embodiments 167-170, wherein the gastric retention system is administered to the patient once a week.
[0569] Embodiment 172: The method of any one of Embodiments 167-170, wherein the gastric retention system has a gastric retention period of D days, and a new gastric retention system is administered to the patient every D days for the total desired treatment period.
[0570] Embodiment 173: A method for preparing a gastric retention system according to any one of embodiments 137-166, comprising forming a coupled polymer component; forming a plurality of at least 3 carrier polymer-drug components, which are elongated members comprising a proximal end and a distal end, wherein the drug is cetirizine or a salt thereof; and attaching the elongated members to the coupled polymer component.
[0571] Embodiment 174: The method of Embodiment 173, further comprising compacting the gastric retention system and inserting the system into a container suitable for oral administration or administration via a gastric or feeding tube.
[0572] Embodiment 175: The method of Embodiment 173 or Embodiment 174, wherein the carrier polymer-drug ingredient is formed by grinding cetirizine or a salt thereof and blending the ground cetirizine or a salt thereof, the dispersant and a carrier polymer.
[0573] Embodiment 176: The method of Embodiment 175, wherein the blending is performed by hot melt extrusion.
[0574] Embodiment 177: The method of any one of Embodiments 173-176, wherein forming a plurality of at least 3 carrier polymer-drug component as an elongated member comprises forming the elongated member from at least two segments.
[0575] Embodiment 178: The method of Embodiment 177, wherein forming the elongated member from at least two segments comprises forming a ring joint between the segments.
[0576] Embodiment 179: The method of any one of Embodiments 173-178, wherein the coupled polymer component is in the shape of an asterisk with at least 3 branches.
[0577] Embodiment 180: The method of any one of Embodiments 173-179, wherein attaching the elongated member to the coupled polymer component comprises attaching the elongated member to the coupled polymer component.
[0578] Embodiment 181: The method of Embodiment 179, wherein attaching the elongated member to the asterisk-shaped coupled polymer component comprises forming a ring linker between the elongated member and the branch of the coupled polymer component.
[0579] Embodiment 182: A gastric retention system for administration to a patient's stomach, comprising a plurality of carrier polymer-drug ingredients, comprising a carrier polymer and rosuvastatin or a salt thereof, wherein the plurality of carrier polymer-drug ingredients are connected to each other by a coupling polymer; wherein the gastric retention system is configured to have a compacted form in a container suitable for oral administration or through a feeding tube; and an uncompacted form when released from the container in the patient's stomach; wherein the gastric retention system is retained in the stomach for at least about 24 hours; and wherein the system releases a therapeutically effective amount of rosuvastatin over the period in which the system is retained in the stomach.
[0580] Embodiment 183: The gastric retention system of Embodiment 182, wherein the rosuvastatin is in the form of rosuvastatin calcium.
[0581] Embodiment 284: The gastric retention system of Embodiment 182 or Embodiment 183, wherein the carrier polymer is polycaprolactone.
[0582] Embodiment 185: The gastric retention system of any one of Embodiments 182-185, wherein the coupling polymer is an enteric polymer.
[0583] Embodiment 186: The gastric retention system of Embodiment 185, wherein the coupling polymer is an enteric polymer that dissolves at a pH of about 5 or above.
[0584] Embodiment 187: The gastric retention system of Embodiment 185, wherein the enteric polymer dissolves at a pH of about 5 to about 7.
[0585] Embodiment 188: The gastric retention system of any one of Embodiments 182-187, wherein the coupling polymer is poly(methacrylic acid-co-ethyl acrylate).
[0586] Embodiment 189: The gastric resident system of any one of Embodiments 182-188, wherein the system remains in the stomach for at least about 5 days.
[0587] Embodiment 190: The gastric retention system of any one of Embodiments 182-189, wherein less than about 5% of the rosuvastatin present in the system is degraded after being retained in the system for about 5 days.
[0588] Embodiment 191: The gastric retention system of any one of Embodiments 182-190, wherein the system releases about 5-40 mg of rosuvastatin per day in the stomach.
[0589] Embodiment 192: The gastric retention system of any one of Embodiments 182-191, wherein the system reduces LDL cholesterol by about 90%-150% of the reduction in LDL cholesterol achieved by an approximately equivalent amount of an immediate release formulation of rosuvastatin administered over about the same time period.
[0590] Embodiment 193: The gastric retention system of Embodiment 192, wherein the time period is about 1 week.
[0591] Embodiment 194: The gastric retention system of any one of Embodiments 182-193, wherein the system comprises about 25 mg to about 300 mg of rosuvastatin.
[0592] Embodiment 195: The gastric retention system of any one of Embodiments 182-194, wherein the system assumes its uncompacted form when released from the container.
[0593] Embodiment 196: The gastric retention system of any one of Embodiments 182-195, wherein the container is a capsule.
[0594] Embodiment 197: The gastric retention system of any one of Embodiments 182-196, wherein the gastric retention system further comprises a radiopaque material.
[0595] Embodiment 198: The gastric retention system of any one of Embodiments 182-197, wherein the carrier polymer-drug component further comprises a buffer substance.
[0596] Embodiment 199: A method of treating a patient having high cholesterol or triglyceride levels comprising administering to the patient a gastric retention system according to any one of Embodiments 182-198.
[0597] Embodiment 200: The method of Embodiment 199, wherein the gastric retention system is administered to the patient once a week.
[0598] Embodiment 201: The method of Embodiment 199, wherein the gastric retention system has a gastric retention period of D days, and a new gastric retention system is administered to the patient every D days for the total desired treatment period.
[0599] Embodiment 202: A gastric retention system for administration to a patient, comprising a plurality of carrier polymer-drug components, comprising: i) a carrier polymer, ii) a dispersant and iii) rosuvastatin or a salt thereof, wherein the plurality of carrier polymer-drug components are connected to each other by one or more coupling polymer components, wherein at least one of the one or more coupling polymer components is an elastomer; wherein the gastric retention system is configured to be in a compacted form in a container suitable for administration orally or by a feeding tube; and in an uncompacted form when released from the container in the patient's stomach; wherein the gastric retention system is retained in the stomach for a period of at least about 24 hours; and wherein the system releases a therapeutically effective amount of the drug during at least a portion of the period in which the system is retained in the stomach.
[0600] Embodiment 203: The gastric retention system of embodiment 202, wherein the dispersant comprises a compound selected from the following: porous inorganic material, polar inorganic material, silica, hydrophilic-fumed silica, stearate, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethyl cellulose, hydrophobic colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium aluminum silicate, phospholipids, polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, fatty acid, sodium lauryl sulfate, non-toxic metal oxide and aluminum oxide.
[0601] Embodiment 204: The gastric retention system of Embodiment 202, wherein the dispersing agent comprises silicon dioxide.
[0602] Embodiment 205: The gastric retention system of any one of Embodiments 202-204, wherein rosuvastatin or a salt thereof consists of particles dispersed in a carrier polymer.
[0603] Embodiment 206: The gastric retention system of Embodiment 205, wherein at least about 80% of the rosuvastatin or rosuvastatin salt particles have a diameter of about 2 microns to about 50 microns.
[0604] Embodiment 207: The gastric retention system of any one of Embodiments 202-206, wherein less than about 10% of the rosuvastatin or a salt thereof contained in the system elutes within about the first 6 hours of exposure to gastric fluid.
[0605] Embodiment 208: The gastric retention system of any one of Embodiments 202-207, wherein the amount of rosuvastatin or a salt thereof eluted from the system within about the first 6 hours of exposure to gastric fluid is about 50% or less of the amount of rosuvastatin eluted from a system without a dispersant.
[0606] Embodiment 209: The gastric retention system of embodiment 207 or embodiment 208, wherein the carrier polymer-drug component comprises about 1% to about 30% rosuvastatin or a salt thereof, about 0.5% to about 2.5% dispersant and about 67.5% to about 98.5% carrier polymer.
[0607] Embodiment 210: The gastric retention system of any one of Embodiments 202-209, wherein the carrier polymer comprises polycaprolactone.
[0608] Embodiment 211: The gastric retention system of Embodiment 210, wherein the polycaprolactone comprises a linear polycaprolactone having a number average molecular weight of about 45 kDa to about 55 kDa.
[0609] Embodiment 212: The gastric retention system of any one of Embodiments 202-221, wherein a plurality of carrier polymer-drug components are connected to each other via two or more coupling polymer components, wherein at least one of the two or more coupling polymer components is an elastomer, and at least another of the two or more coupling polymers is an enteric polymer.
[0610] Embodiment 213: The gastric retention system of Embodiment 212, wherein the enteric polymer is selected from the group consisting of poly(methacrylic acid-co-ethyl acrylate), cellulose acetate phthalate, cellulose acetate succinate, and hydroxypropyl methylcellulose phthalate.
[0611] Embodiment 214: The gastric retention system of any one of Embodiments 202-213, wherein the gastric retention system is retained in the stomach for about 5 days to about 7 days.
[0612] Embodiment 215: A gastric retention system for administration to the stomach of a patient, comprising a plurality of carrier polymer-drug components, comprising a carrier polymer and rosuvastatin or a salt thereof, wherein the plurality of carrier polymer-drug components are connected to each other by a coupling polymer component; wherein the gastric retention system is configured to have a compacted form in a container, which is suitable for administration orally or by a feeding tube; and an uncompacted form when released from the container in the patient's stomach; wherein the gastric retention system is retained in the stomach for a period of at least about 24 hours; and wherein the system releases a therapeutically effective amount of rosuvastatin during the period in which the system is retained in the stomach.
[0613] Embodiment 216: The gastric retention system of Embodiment 215, wherein the rosuvastatin is in the form of rosuvastatin calcium.
[0614] Embodiment 217: The gastric retention system of Embodiment 215 or Embodiment 216, wherein the carrier polymer comprises polycaprolactone.
[0615] Embodiment 218: The gastric retention system of any one of Embodiments 215-217, wherein the coupling polymer is an enteric polymer.
[0616] Embodiment 219: The gastric retention system of Embodiment 218, wherein the coupling polymer is an enteric polymer that dissolves at a pH of about 5 or above.
[0617] Embodiment 220: The gastric retention system of Embodiment 218, wherein the enteric polymer dissolves at a pH of about 5 to about 7.
[0618] Embodiment 221: The gastric retention system of any one of Embodiments 215-220, wherein the coupling polymer is poly(methacrylic acid-co-ethyl acrylate).
[0619] Embodiment 222: The gastric resident system of any one of Embodiments 215-221, wherein the system remains in the stomach for at least about 5 days.
[0620] Embodiment 223: The gastric retention system of any one of Embodiments 215-222, wherein less than about 5% of the rosuvastatin present in the system is degraded after about 5 days of residence in the stomach.
[0621] Embodiment 224: The gastric retention system of any one of Embodiments 215-223, wherein the system releases about 5-40 mg of rosuvastatin per day in the stomach.
[0622] Embodiment 225: The gastric retention system of any one of Embodiments 215-224, wherein the system reduces LDL cholesterol by about 90%-150% of the reduction in LDL cholesterol achieved by an approximately equivalent amount of an immediate release formulation of rosuvastatin administered over about the same time period.
[0623] Embodiment 226: The gastric retention system of Embodiment 225, wherein the time period is about 1 week.
[0624] Embodiment 227: The gastric retention system of any one of Embodiments 215-226, wherein the system comprises about 25 mg to about 300 mg of rosuvastatin.
[0625] Embodiment 228: The gastric retention system of any one of Embodiments 215-227, wherein the system assumes its uncompacted form when released from the container.
[0626] Embodiment 229: The gastric retention system of any one of Embodiments 215-228, wherein the container is a capsule.
[0627] Embodiment 230: The gastric retention system of any one of Embodiments 215-229, wherein the gastric retention system further comprises a radiopaque material.
[0628] Embodiment 231: The gastric retention system of any one of Embodiments 215-230, wherein the carrier polymer-drug component further comprises a buffer substance.
[0629] Embodiment 232: A method of treating a patient suffering from high cholesterol or triglyceride levels comprising administering to the patient a gastric retention system according to any one of Embodiments 1-30.
[0630] Embodiment 233: The method of Embodiment 232, wherein the gastric retention system is administered to the patient once a week.
[0631] Embodiment 234: The method of Embodiment 232, wherein the gastric retention system has a gastric retention period of D days, and a new gastric retention system is administered to the patient every D days for the total desired treatment period.
[0632] Embodiment 235: A method for preparing a gastric retention system according to any one of embodiments 182-231, comprising forming a coupled polymer component; forming a plurality of at least 3 carrier polymer-drug components, which are elongated members comprising a proximal end and a distal end, wherein the drug is rosuvastatin or a salt thereof; and attaching the elongated members to the coupled polymer component.
[0633] Embodiment 236: The method of Embodiment 235, further comprising compacting the gastric retention system and inserting the system into a container suitable for oral administration or administration via a gastric or feeding tube.
[0634] Embodiment 237: The method of Embodiment 235 or Embodiment 236, wherein the carrier polymer-drug ingredient is formed by milling rosuvastatin or a salt thereof and blending the milled rosuvastatin or a salt thereof, a dispersant and a carrier polymer.
[0635] Embodiment 238: The method of Embodiment 237, wherein the blending is performed by hot melt extrusion.
[0636] Embodiment 239: The method of any one of Embodiments 235-238, wherein forming a plurality of at least 3 carrier polymer-drug components as elongated members comprises forming the elongated members from at least two segments.
[0637] Embodiment 240: The method of Embodiment 239, wherein forming the elongated member from at least two segments comprises forming a ring joint between the segments.
[0638] Embodiment 241: The method of any of Embodiments 235-240, wherein the coupled polymer is in the shape of an asterisk with a plurality of at least 3 branches.
[0639] Embodiment 242: The method of any of Embodiments 235-241, wherein attaching the elongated member to the coupling polymer component comprises attaching the elongated member to the coupling polymer component.
[0640] Embodiment 243: The method of Embodiment 241, wherein attaching the elongated member to the asterisk-shaped coupled polymer component comprises forming a ring linker between the elongated member and the branch of the coupled polymer component. Example
[0641] The invention is further illustrated by the following non-limiting examples.
[0642] Example 1
[0643] preparation
[0644] Weigh the cetirizine hydrochloride powder and blend it with the hydrophilic excipient polymer dry powder in a glass vial. Add polycaprolactone (PCL) beads and heat the vial to 90°C in an oven for 10-20 min or until the PCL is completely melted. Then transfer the vial to a dry heating block at 90°C where the components are thoroughly mixed using a spatula. The mixture is then transferred to the desired mold and returned to a 90°C oven for 20-30 min for gravity molding. The mold is then removed from the oven and allowed to cool to room temperature.
[0645] Example 2
[0646] Liquid chromatography / mass spectrometry analysis
[0647] Drug concentrations in media for in vitro release experiments were determined using an Agilent 1100 series HPLC with an Agilent Eclipse XDB C18 column or a Waters Acquity UPLC with a XevoQToF LC / MS. Samples were run on an Agilent system using a gradient of 5%-95% acetonitrile in water over 10 min or an isocratic method in 40% acetonitrile: water over 10 min or on a Waters system using a Waters Acuity C18 column with a gradient of 5%-95% (acetonitrile containing 0.1% formic acid): (water containing 0.1% formic acid) over 3 min. A standard curve for determining cetirizine concentrations was developed by integrating UV absorption traces. The column eluate can be sent to a spectrometer for further analysis.
[0648] Example 3
[0649] In vitro release in simulated gastric fluid
[0650] Formulations of 25% cetirizine, 5-20% other excipients and the balance PCL were prepared as described in Example 1. The formulations were gravity molded into rod-shaped tablets.
[0651] Fasted simulated gastric fluid (FaSSGF, also referred to as SGF) was prepared according to the vendor's instructions (Biorelevant.com, London, United Kingdom). A NaCl / HCl solution was prepared by dissolving 2.0 g NaCl in approximately 0.9 L of purified water. The pH was adjusted to 1.6 with HCl. The volume was brought to 1.0 L with purified water at room temperature. FaSSGF (also referred to herein as SGF) was prepared by adding 0.060 g FaSSIF, FeSSIF, and FaSSGF powders to approximately 0.5 L of HCl / NaCl solution and the volume was brought to 1.0 L with HCl / NaCl solution at room temperature.
[0652] The polymer-active agent sheet was immersed in 20 mL of FaSSGF in a glass vial with a small stirring bar. The vial was heated to 37°C in a dry heating block and stirred at a rate of ~200 rpm. At each time point, the release medium was sampled for LCMS or HPLC analysis according to Example 2, and the entire volume of the release medium was replaced with fresh FaSSGF.
[0653] Cetirizine burst release, the percentage of drug load released from the formulation within the first 6 hours of incubation in SGF is shown in Figure 5 for the formulations of cetirizine in polycaprolactone (PCL) containing different amounts of Pluronic P407 as a polymer excipient. Panel A shows the release after 3 hours in SGF, while Panel B of Figure 5 shows the release after 6 hours in SGF. Cetirizine is an extremely hydrophilic drug and is rapidly released from the PCL formulation in SGF. Reducing the amount of the hydrophilic excipient polymer (in this case Pluronic P407) in the formulation reduces the release rate of cetirizine from the formulation.
[0654] Example 4
[0655] In vitro release variability testing in different solvents
[0656] Preparations were prepared as described and molded into 200-mg discs. The disc was immersed in 10 mL FaSSGF, heated to 37 ° C in a dry heating block, and stirred at a speed of ~200 rpm for 24 h. After 24 h, FaSSGF was removed and 10 mL warm (50 ° C) water, 40% ethanol or fresh FaSSGF (control) was added to the vial. After another 1 hour, the release medium was sampled and analyzed by LCMS or HPLC to determine the concentration of cetirizine and calculated compared to the control formulation (which was incubated in 10 mL FaSSGF at 37 ° C for 1 h) within a 1 hour time range of total drug release.
[0657] Example 5
[0658] Testing of in vitro therapeutic stability in different solutions and under thermal conditions
[0659] Cetirizine was subjected to various forced degradation conditions in solution and PCL formulations. A 50 mg formulation tablet (25% cetirizine, 5% Pluronic P407, 70% PCL) was immersed in 30% H2O2 at 37°C. At the specified time point, the formulation was removed from the peroxide solution, and the remaining drug was extracted and analyzed by HPLC. Figure 4 shows the results of the analysis. The first trace (A) shows the complete cetirizine extracted from the formulation before any exposure to peroxide. The second trace (B) shows cetirizine without any polymer formulation, which was degraded by dissolving in 30% H2O2 at 37°C for 20 hours. The remaining traces show cetirizine extracted from the formulation after the specified time in 30% H2O2 at 37°C (trace C, 4 hours; trace D, 8 hours; trace E, 20 hours). The decrease in peak size from trace C to E is due to the elution of the drug in the carrier polymer matrix. Traces C, D, and E indicate that the cetirizine remaining in the PCL formulation (ie, drug that was not eluted during this time period) was protected from oxidative degrada...
Claims
1. A gastric resident system for administration to a patient, comprising: A plurality of carrier polymer-active agent components comprising: i) a carrier polymer; and ii) a therapeutic agent or a pharmaceutically acceptable salt thereof, wherein the carrier polymer-active agent components are connected to each other via one or more coupling polymer components, wherein at least one of the one or more coupling polymer components is an elastomer; wherein the gastric retention system is configured to have a compacted form in a container that is suitable for administration orally or via a feeding tube, and an uncompacted form when released from the container; wherein the gastric resident system remains in the stomach for a residence period of at least about 24 hours to about 1 month; and in: The system releases a therapeutically effective amount of the therapeutic agent over an effective release period; and The system releases less than about 20% of the therapeutic agent or a pharmaceutically acceptable salt thereof over a 6 hour period.
2. The gastric retention system of claim 1, wherein the system releases about 30% to about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof within about 40% to 60% of the effective release period.
3. The gastric retention system of claim 1 or claim 2, wherein the system releases about 70% of the therapeutic agent or a pharmaceutically acceptable salt thereof within about 90% of the effective release period.
4. The gastric retention system of any one of claims 1-3, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is measured in an aqueous environment selected from the group consisting of 0.1N HCl aqueous solution, simulated gastric fluid, fasting simulated gastric fluid, fed simulated gastric fluid, animal stomach, pig stomach, dog stomach, and human stomach.
5. The gastric retention system of any one of claims 1-4, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is measured in 0.1 N HCl.
6. The gastric retention system of any one of claims 1 to 4, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is measured in fasting simulated gastric fluid.
7. The gastric retention system of any one of claims 1 to 4, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof is measured in fed simulated gastric fluid.
8. The gastric retention system of any one of claims 1-7, wherein the release of the therapeutic agent or a pharmaceutically acceptable salt thereof in a 40% ethanol / 60% 0.1 N HCl aqueous solution is increased by no more than about 40% compared to the release in 0.1 N HCl over the same time period, or in 40% ethanol / 60% simulated gastric fluid is increased by no more than about 40% compared to the release in simulated gastric fluid over the same time period, or in 40% ethanol / 60% fasted simulated gastric fluid is increased by no more than about 40% compared to the release in fasted simulated gastric fluid over the same time period, or in 40% ethanol / 60% fed simulated gastric fluid is increased by no more than about 40% compared to the release in fed simulated gastric fluid over the same time period.
9. The gastric retention system of any one of claims 1 to 8, wherein: ii) the therapeutic agent or a pharmaceutically acceptable salt thereof comprises from about 10% to about 35% of the carrier polymer-active agent component.
10. The gastric retention system of any one of claims 1 to 9, wherein the therapeutic agent or a pharmaceutically acceptable salt thereof is selected from the group consisting of doxycycline, donepezil, ivermectin, risperidone, cetirizine and rosuvastatin.
Citation Information
Patent Citations
Apparatus for Concealing Household Objects
US20150035423A1
Polymers of di- (and higher functionality) ketene acetals and polyols
US4304767A
2-[4-(Diphenylmethyl)-1-piperazinyl]-acetic acids and their amides
US4525358A
Pharmaceutical compositions
US6316460B1
